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In this study, vascular prostanoid EP-receptors were characterised in the human 
puhnonary artery and the guinea-pig aorta, while neuronal IP-receptors were 
investigated in the rat colon. 
PGE2 and its analogues, sulprostone and SC46275, contracted isolated rings of 
human puhnonary artery and guinea-pig aorta at low concentrations (> 5, > 0.5 
and > 0.1 nM respectively). The contractile actions of sulprostone were not 
blocked by the TP-receptor antagonists, EP169 (200 nM) or GR32191 (200 
nM), and the EPi-receptor antagonist, AH6809 (5 [iM). The relative 
contractile potencies for PGE analogues in the human puknonary artery were 
SC46275 > sulprostone > misoprostol = gemeprost > PGE2 > GR63799 > 17-
phenyl-0)-trinor PGE2 > 11-deoxy PGEi, while those in the guinea-pig aorta 
ranked as SC46275 > sulprostone > misoprostol > gemeprost > 17-phenyl-0)-
trinor PGE2 > PGE2 > GR63799. This suggests that EP3-recept0rs are present 
in both vascular preparations. 
Further experiments were performed on the guinea-pig aorta to investigate the 
potential mechanism(s) of EP3-recept0r-mediated contractions. In the absence 
of extracellular Ca2+, high doses of phenylephrine produced a phasic response, 
which was abolished by the sarcoplasmic reticulum Ca2+ pump inhibitor 
cyclopiazonic acid (CPA，10 i^M); this phasic effect is due to release of Ca2+ 
from intemal stores. In contrast, although removal of extracellular calcium 
markedly reduced the contractile response to single high doses of sulprostone 
(300 nM), the residual contraction was not phasic, and this raises the possibility 
that EP3 agonists do not release intemal calcium. Cadmium chloride (500 ^M) 
markedly suppressed the contractile effect of sulprostone, emphasising the 
large contribution of Ca^+ influx to EP3 contractions. However, the L-type 
Ca2+ channel blocker nifedipine only produced a partial inhibition in 
preparations showing a high sensitivity to sulprostone. Contractions to 
sulprostone were potentiated in normal Krebs-Henseleit solution containing 
CPA (10 |iM). This may be due to CPA eliminating the Ca2+-buffering 
activity of the sarcoplasmic reticulum, resulting in a greater proportion of the 
inflowing Ca2+ reaching the contractile apparatus. 
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The selective IP-receptor agonist cicaprost potently inhibited spontaneous 
contractions of the rat isolated colon (IC50 = 2.8 - 6 nM). These inhibitory 
actions of cicaprost were virtually abolished by the neuronal Na+ channel 
blockers saxitoxin and tetrodotoxin, but not affected by phentolamine, 
propranolol and atropine; this indicates that cicaprost releases inhibitory 
transmitters from non-adrenergic non-choUnergic (NANC) enteric neurones. 
One of the transmitters is likely to be nitric oxide (NO), as evidenced by the 
finding that the nitric oxide synthase inhibitor N®-nitro-L-arginine methyl ester 
(L-NAME) partially but specifically inhibited cicaprost action. The second 
transmitter mechanism was apamin-sensitive; ATP, adenosine, VIP or pituitary 
adenylate cyclase-activating peptides (PACAP) appeared not to be transmitter 
candidates. Nicotine also inhibited the contractility of rat colon by stimulating 
the release of NO and an apamin-sensitive transmitter from enteric neurones; 
however, the action of cicaprost was not dependent on the integrity of nicotine 
cholinergic synapses since desensitisation with nicotine did not affect cicaprost 
inhibition. 
Two non-prostanoid prostacyclin mimetics BMY42393 and BMY45778 were 
also studied on the rat colon, but only the latter produced a small degree of 
inhibition (7 -15%) up to 10 p,M. However, they all behaved as full agonists at 
IP-receptors in human pulmonary artery (i.e. complete relaxation could be 
produced). Furthermore, BMY45778 antagonised cicaprost action in rat colon; 
the blocking effect developed slowly, and the pA2 value estimated when the 
colon was exposed to this compound for 70 min was 6.8. Thus, the different 
biological profiles of the structurally-diverse prostacyclin mimetics on these 
two tissues suggest that neuronal IP-receptors in rat colon are different from 
vascular BP-receptors. 
In conclusion, the constrictor actions of PGE analogues on the guinea-pig aorta 
are mediated via EP3-recept0rs and are associated with Ca2+ influx; IP-receptor 
agonists inhibit the contractility of rat colon through release of NO and an 
apamin-sensitive transmitter from enteric neurones; neuronal IP-receptors are 
different from vascular IP-receptors, on the basis of their interactions with non-
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The name "prostaglandin" was first proposed by von Euler (1936) for the 
substance in the male accessory genital glands, which has vasodepressor and 
intestinal muscle stimulating actions; it was obvious to Goldblatt (1933) and 
also to von Euler (1936) that the active principle was different from other 
endogenous agents such as histamine and acetylcholine. Later studies by 
Bergstrom and colleagues at the Karolinska Institute in Sweden established the 
structures of PGEi and PGFi in 1962. Since then, prostaglandin research has 
proven to be one of the most rapidly growing areas in the biological sciences 
(see Anggard and Flower, 1993 for an overview). The discovery of 
thromboxane A2 and prostacyclin meant that the term "prostaglandin" was too 
restrictive, and the term "prostanoid", which covers all cyclo-oxygenase 
products and their synthetic analogues, has gradually come into general use. In 
this Introduction, the emphasis will be on the nature of prostanoid receptors, 
while a brief description of the formation and metabolism of prostanoids is also 
included. 
Prostanoid Biochemistry 
Formation ofthe natural prostanoids 
The naturally occurring prostanoids are formed by the action of the cyclo-
oxygenase enzyme (COX) on particular polyunsaturated fatty acids, followed 
by further enzymatic attack or spontaneous chemical reaction. The most 
important fatty acid is arachidonic acid (all-cis 5,8,1 l,14-eicosatetraenoic acid) 
which gives rise to the "2-series" prostanoids (e.g. PGE2, PGF2a). The "1-
series" and "3-series" prostanoids are usually formed in much smaller amounts 
from 8,11,14-eicosatrienoic acid (y-homolinolenic acid) and 5,8,11,14,17-
, eicosapentaenoic acid (EPA) respectively. Interest in the 1-series prostanoids 
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stems from both scientific and commercial considerations; Evening Primrose 
Oil which contains large amounts of y-homolinolenic acid is an over-the-
counter preparation which is recommended for a variety of aihnents, including 
eczema, pre-menstrual syndrome, breast tendemess and joint aches and pains. 
The 3-series fatty acids are contained in higher amounts in the cell membranes 
and lipid stores of fish and other marine animals compared to freshwater and 
land animals. As a consequence of this, a number of fish-eating populations, 
notably Greenland Eskimos, have high concentrations of EPA in their 
phospholipids, and this may explain the resistance of such populations to 
atherosclerotic and thrombotic diseases. 
Prostanoids are not stored, but are synthesised de novo and released in 
response to a wide variety of stimuli ranging from activation of hormone 
receptors to simple mechanical trauma. They are formed in three stages (Smith, 
1989): (a) release of arachidonic acid from precursor glycerophospholipids, (b) 
oxygenation of free arachidonic acid by prostaglandin endoperoxide G/H 
synthase (cyclo-oxygenase), and (c) metabolism of PGH2 to specific 
biologically active end products PGE2, PGD2, PGF2a, PGI2 (prostacyclin), or 
TXA2 (thromboxane A2), which are illustrated in Figure 1. 
Prostanoid formation requires free, unesterified arachidonic acid. Therefore, 
since cytoplasmic levels of this fatty acid are very low, liberation of substrate is 
a necessary first step. This is usually achieved by activation of phospholipase 
A2 (PLA2), which cleaves fatty acids from the 2-position of the 
glycerophospholipids, phosphatidylcholine and phosphatidylethanolamine. 
Arachidonate release happens relatively quickly (i.e. 5 - 60 s), and is typically 
accompanied by turnover of inositol-containing phospholipids. In fact, some of 
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Figure 1.1 Biosynthetic pathways for prostanoid formation. 
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sequential hydrolysis of phosphoinositides by phospholipase C and 
diacylglycerylipase. 
As shown in Figure 1，the generation of the endoperoxide intermediates PGG2 
and PGH2 is the pivotal point in the formation of prostanoids. The sequential 
formation of PGG2 and PGH2 is catalysed by the enzyme prostaglandin 
endoperoxide synthase, an integral membrane protein found in greatest 
abundance in the endoplasmic reticulum of prostanoid-forming cells. The 
enzyme is composed of two subunits and exhibits two distinct catalytic 
activities. The cyclo-oxygenase portion catalyses the insertion of two 
molecules of oxygen into arachidonic acid to give the 15-hydroperoxy 
compound PGG2, and the peroxidase portion then reduces the hydroperoxy 
group to hydroxy group, giving PGH2. The cyclo-oxygenase, but not the 
hydroperoxidase activity, is specifically inhibited by aspirin and related 
nonsteroidal anti-inflammatory drugs. Upon exposure to aspirin, the enzyme is 
0-acetylated at a serine residue located 70 amino acids from the C-terminus; 
acetylation leads to irreversible cyclo-oxygenase inhibition, and thus, new 
enzyme synthesis is required before more prostanoid can be produced. 
Indomethacin also causes irreversible inactivation of the cyclo-oxygenase 
activity but apparently without covalent modification of the enzyme. Recently, 
it has been shown that cyclo-oxygenase exists in two isoforms, COX-1 
(constitutive) and COX-2 (inducible). It has been suggested that the anti-
inflammatory actions of aspirin and related drugs are due to the inhibition of 
COX-2, whereas the unwanted side-effects (such as irritation of the stomach 
lining and toxic effects on the kidney) are due to the inhibition of the 
constitutive enzyme, COX-1; the search for better anti-inflammatory drugs 




The endoperoxides PGG2 and PGH2 are unstable in aqueous media and 
decompose {tm = 4-5 min at 37 ^C) to a mixture of PGD2, PGE2, PGF2a, 12-
L-hydroxy-5,8,10-heptadecatrienoic acid and malondialdehyde. However, 
formation of PGD2, PGE2, PGF2a, PGI2 and TXA2 is normally catalysed by 
specific enzymes. Different types of prostanoid-forming cells tend to form 
different prostanoids; generally, only one of the prostanoids is the major 
product in one type of cell. For example, smooth muscle cells and endothelial 
cells from large arteries form primarily PGI2, which is catalysed by 
prostacyclin synthase, and blood platelets form mainly TXA2, which is 
catalysed by thromboxane synthase. 
Metabolism ofprostanoids 
In general, metabolism leads to a reduction or abolition of the biological effects 
of the prostanoid, whilst at the same time facilitating renal clearance by 
increasing the number of polar functional groups in the molecule. Metabolism 
can occur in a number of tissues, particularly in the lung, the liver and the 
kidney. 
The earliest work on the metabolic transformation of prostaglandins was 
performed by Anggkd and Samuelsson. They showed that both PGE and PGF 
compounds undergo rapid dehydrogenation at carbon-15 catalysed by 15-
hydroxy-prostaglandin dehydrogenase (see Anggard and Flower, 1993 for 
review). The resulting 15-keto metabolites are usually much less potent than 
the parent prostaglandin. 
In addition to dehydrogenation (oxidation) of the 15-hydroxyl function， 
three other basic enzymatic pathways are also involved in the metabolism 
of the prostanoids: reduction of the 13,14 double bond; 6-oxidation of the 
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Figure 1.2 Main metabolic pathways for PGE2, PGF2a and PGD2 in man. 
Main urinary metabolites are indicated by MUM. Enzyme activities 
involved are 15-OH-dehydrogenase (1), 13,14-reductase (2)，6-oxidation 
(3)，co-oxidation (4), 9-ketoprostaglandin reductase (5) and 11-
ketoprostaglandin reductase (6) (After Anggard and Flower, 1993; Hanss 
and Taylor, 1993). 
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Figure 1.3 Main metabolic pathways for PGI2 and TXA2. PGI2 is rapidly 
converted to 6-keto-PGFia and TXA2 to TXB2, from which the main urinary 
metabolites are derived. TXB2 is excreted either unchanged or following a 
single step of P-oxidation (3) to din0r-TXB2. Much of the TXB2 is also 
dehydrogenated (5) to ll-dehydr0-TXB2 which is then further transformed by 
15-OH-dehydrogenase (1), 13,14-reductase (2), p-oxidation (3) and co-
oxidation (4). A substantial part of 6-keto-PGFia is excreted as dinor-6-keto-
PGFia (After Anggard and Flower, 1993). 
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a(C-l to C-7) side chain; and cytochrome P450-mediated oxidation of the 0) 
(C-13 to C-20) side chain and the associated oxidations to the co-aldehyde and 
co-acid (Figure 1.2). In some cases, these reactions are catalysed by enzymes 
which are not necessarily specific to the prostanoids, and aknost certainly play 
a wider role in metabolic processes than in the control of prostanoid levels 
alone. 
Both PGI2 and TXA2 are unstable and quickly non-enzymatically hydrolysed 
to stable but biologically inactive products, 6-keto-PGFia and TXB2 
respectively. However, further metabolism of 6-keto-PGFia and TXB2 may 
follow the general metabolism pathways as described above (Figure 1.3). 
The metabolic transformation of prostaglandins does not always represent a 
biological inactivation. For example, PGE2 can be converted to PGF2a by 9-
ketoprostaglandin reductase, and PGD2 is metabolised via a specific 11-
ketoreductase to form 9a,lip-PGP2. 9a, l ip-PGp2 has marked biological 
activity, but it appears to possess relatively more FP-receptor agonist activity 
than PGD2 while the parent and the metabolite have similar potency at TP-
receptors (Giles etal., 1991). 
Prostanoid Receptors 
Prostanoids, like other local hormones, produce their effects by interacting with 
specific receptors on cell membranes. The earliest evidence for the existence of 
more than one type of prostanoid receptor came from the work of Pickles in 
1967. He demonstrated that a range of different prostanoids, both natural and 
synthetic, showed different patterns of activity on a variety of isolated smooth 
muscle preparations. During 1970s, Jones and his colleagues made distinctions 
between PGD, PGF and thromboxane receptors by using natural prostaglandins 
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as well as the compounds obtained from simple chemical modifications to 
PGD2 and PGF2a (Jones, 1976; 1978; Welbum and Jones, 1978). However, a 
comprehensive receptor classification was not proposed until 1982. Kennedy 
and his co-workers classified the prostanoid receptors into DP, EP, FP, JP and 
TP, which are specific for each of the five naturally-occurring prostanoids, 
PGD2, PGE2, PGF2a, PGI2 and TXA2 respectively (Kennedy et al” 1982). 
This classification scheme covered the early observations of Jones and 
colleagues using pharmacological techniques and was supported by those of 
Andersen and co-workers who used both pharmacological and ligand-binding 
techniques (see Coleman et al., 1990 for review). Further support is also being 
provided from the emerging molecular biology of the prostanoid receptors. All 
the prostanoid receptors belong to the superfamily of G protein-coupled 
rhodopsin-type receptors with seven hydrophobic domains which span the 
plasma membrane. There is some conservation of amino acid sequence in 
several regions, with the seventh transmembrane domain being the most 
conserved region for all the prostanoid receptors but different from that of 
other rhodopsin-type receptors. The basic classification scheme of prostanoid 
receptors is shown in Figure 1.4. In the following section, the properties of 
individual prostanoid receptors including biological actions, distribution, 
ligand binding, signal transduction, molecular biology, and selective agonists 
and antagonists will be discussed. Relevant information on signal transducing 
systems, selective agonists and antagonists and molecular biology has been 
summarised in Tables 1.1，1.2,1.3 and 1.4. 
DP-receptors 
A. Biological actions and distribution 
DP-receptors are largely distributed in blood platelets, vascular smooth muscle 
and nervous tissue, including the CNS. There are also examples of DP-
10 
Prostanoid Receptors 
DP EP FP n> TP 
I I I I 
EPi EP2 EP3 EP4 
Figure 1.4 A tree showing the classification scheme of prostanoid receptors. 
receptors in gastro-intestinal, uterine and airway smooth muscle in some 
animal species (see Coleman et aL, 1994b). 
PGD2 is a potent inhibitor of the aggregation of blood platelets obtained from 
man, sheep and horse, but not from dog, rabbit and rat (Whittle et aL, 1978; 
Macintyre and Armstrong, 1987); this presumably reflects the absence of 
specific DP-receptors in the latter species. PGD2 also produces systemic 
vasodilation and vasoconstriction, pulmonary constriction and 
bronchoconstriction, and again these actions are also dependent on the species. 
Although some of these actions of PGD2 are undoubtedly mediated through 
cross-reaction with TP- or FP-receptors (Giles et aL, 1991; Eglen and Whiting, 
1988), the systemic vasodilator and vasoconstrictor actions are probably 
mediated by specific DP-receptors. Thus in the sheep PGD2 is a highly potent, 
directly acting vasoconstrictor; this action is not blocked by TP-receptor 
antagonists and PGF2a is about 50 times less potent (Jones, 1978). Further 
study of this system, which appears to be also present in pig, dog and rabbit 
peripheral vascular beds, has been hampered by the inability to obtain 
contractile effects of PGD2 in corresponding isolated arterial ring preparations 
(Jones, personal communication). In other situations PGD2 is a potent 
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Table 1.1 Signal transducing systems for prostanoid receptors 
Receptor Transducing systems* References 
DP t cAMP via Gs Ito et al” 1990 
Hirata et aL, 1994 
T Ca2+ influx Okuda-Ashitaka et al” 1993 
EPi T Ca2+ influx Creese et al, 1981 
Watabe et al, 1993 
T PI turnover (via ？) Li et al” 1994 
EP2 T cAMP via Gs Sonnenburg et al.，1990; 
Honda et al, 1993 
EP3 >t- cAMP via Gi Sonnenburg et al，1990; 
Negishi etaL,l993 
个 PI turnover via Gq Me et al” 1994 
T Ca2+ influx? Goureau et al, 1992 
FP t PI turnover via Gq Baum & Rosberg, 1987 
Ito et al., 1994 
n> T cAMP via Gs Hashimoto et al” 1990 
WiUiams etaL,l994 
Nakagawa et al.，1994 
T intraceUular Ca2+ (via Watanabe et al，1991 
Ca2+ influx or L1sP3) Oka et al” 1993 
TP T IP turnover via Gq Pollock et al，1984; 
Shenker etal, 1991 
T Ca2+ mobilisation (not Nakano et al” 1988 
via InsP3) Arita et al” 1989 
T Ca2+ influx Loutzenhiser et al., 1981 
* Bold faced type indicates good evidence for this transducing system. 
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Table 1.2 Properties of cloned and expressed prostanoid receptors 
Receptor Origin of J^^^ = i d Mol. w t References 
cDNA library residues (estimated) 
DP mouse ？ 357 40,012 Hirata^“/.，1994 
EPi mouse kidney 405 42,966 Watabe et al, 1993 
HEC 402 41,855 Funk et al” 1993 
EP2 MMC 513 56.157 Honda etaL, 1993 
human lung 488 53,115 Bastien et al” 1994 
human placenta 358 Regan et al.，1994 
EP3 MMC 365 40,077 Sugimoto et aL, 1992 
Negishi^r aL, 1993 
We etaL, 1994 
FP mouse ovary 366 40,077 Sugimoto et aL’ 1994 
rat astrocytes 366 40,077 Kitanaka et aL，1994 
BCL 362 40,983 Sakamoto^r^/., 1994 
human uterus 359 40,060 Abramoitz et aL, 1994 
n> human lung 386 40,961 Boie et al, 1994 
HMLC 386 40,956 Katsuyama^fa/., 1994 
MMC 417 44,722 Namba et al.，1994 
TP human placenta 343 37,429 Hirata et al” 1991 
mouse lung 341 Namba et aL, 1992 
HEC = human erythroleukemia cell; MMC = mouse mastocytoma cell; BCL = 
bovine corpus luteum; HMLC = human megakaryocytic leukaemia cell. 
Receptors were expressed either in CHO or in COS cells. 
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vasodilator; for example, it relaxes the rabbit jugular vein, partly through 
activation of DP-receptors (Giles et al., 1989). In parenchymal liver cells PGD2 
increases the activity of phosphorylase, the regulatory enzyme in 
glycogenolysis, leading to the stimulation of glucose production (Casteleijn et 
a/” 1988), while in mast cells it acts as a negative feedback regulator for 
histamine secretion (Holgate et al., 1980). 
PGD2 has been also shown to play important roles in the central nervous 
system. Such roles include a possible relation to sleep induction (Ueno et al” 
1983; Onoe et al” 1988)，regulation of body temperature (Forstermann et al., 
1983), modulation of olfactory function by suppressing the inhibitory synaptic 
inputs from granule cells to mitral cells (Watanabe et aL, 1986), inhibition of 
luteinizing hormone secretion through the mediation of serotonin (Koh et al, 
1988)，alterations in nociception (Horiguchi etaL，1986) and potentiation of 
calcitonin gene-related peptide-like substance release from the dorsal hom of 
the rat spinal cord (Andreeva and Rang,1993). PGD2 was initially reported to 
inhibit cell proliferation and DNA synthesis in various cell lines, but this 
inhibition by PGD2 has been explained by the action of Ai2-PGJ2, the ultimate 
metabolite of PGD2 and not by PGD2 itself. This action appears to be 
independent of cAMP since Ai2-PGJ2 is virtually inactive in raising 
intracellular cAMP levels (Narumiya and Fukushima,1985). It is Ukely that the 
chemically reactive enone system in Ai2-PGJ2 may interact with a crucial 
component of the genetic apparatus; a similar argument has been proposed for 
the anti-proliferative effects of PGA2, the dehydration product of PGE2 (Sasaki 
and Fukushima, 1994). However, it has been reported in fibroblasts that PGD2 
itself suppresses the expression of c-myc mRNA and then inhibits DNA 





Specific binding sites for PGD2 have been identified in human platelet 
membranes; the rank order of binding affinity is: D2 > h > Ei > F2a > E2 
(Cooper and Ahem, 1979). The DP-receptor agonist BW 245C has high 
affinity for PGD2 specific binding sites in human platelets but has no affinity 
for PGI2 binding sites in the same cells (Town et aL, 1983). Binding sites for 
[^H]PGD2 have also been identified in rat brain synaptic membranes (Shimizu 
et aL, 1982) and in different regions of human brain CWatanabe et aL, 1985). 
The specific binding in human brain is of high affinity with a K<j of 30 nM; the 
high binding activity is observed in the hypothalamus, amygdala and 
hippocampus followed by cerebellar nuclei, thalamus, nucleus accumbens and 
the cerebral cortex. 
Signal transduction 
In human platelets, DP-receptors couple positively to adenylate cyclase via Gs, 
and it is through this mechanism that PGD2 inhibits aggregation (Schafer et al., 
1979; Whittle etal” 1978). In mast cells (Holgate etal” 1980), adipocytes 
(Kather and Zimmer, 1983), keratinocytes CWlUdnson and Orenberg, 1979) and 
neuroblastoma NlE-115 cells (Shimizu etal” 1979), PGD2 also increases the 
cAMP level. Furthermore, the elevation in cAMP by PGD2 in EBTr cells, a 
fibroblastic cell line derived from bovine embryonic trachea, can be 
competitively antagonised by AH6809 (Ito et al., 1990). This action is 
mediated via DP-receptors since these cells specifically respond to PGD2 
among the natural prostaglandins (Sugama etal., 1989) and AH6809 has 
blocking activity at DP-receptors. Although PGD2 has also been reported to 
stimulate phosphoinositide metabolism and Ca2+ mobilisation in Swiss 3T3 
cells (Ito et aL, 1990), this may be mediated through FP- as opposed to DP-
receptors (Woodward and Lawrence, 1994). However, in freshly isolated 
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nonchromaffin cells from bovine adrenal medulla a DP-receptor-mediated 
increase in intracelluar Ca2+ has been found (Okuda-Ashitaka etaL, 1993). 
This action is due to an increase in Ca^+ influx via cAMP, since removal of 
extracellular Ca2+ markedly reduces the Ca^+ response and the time-course of 
cAMP production stimulated by PGD2 coincides with that of the intracellular 
Ca2+ increase. 
Molecular biology 
The amino acid sequence deduced from a cDNA fragment for a mouse DP-
receptor has a high degree of similarity with the mouse IP- and EP2-recept0rs 
(Hirata et aL, 1994). The receptor expressed in Chinese hamster ovary cells 
shows a single class of binding sites for [3H]PGD2 with a K^ of 40 nM. This 
binding is displaced by unlabeled ligands in the following order: PGD2 > BW 
245C > BW A868C > STA2; PGE2, PGF2a and iloprost show little 
displacement activity at concentrations up to 10 |xM. PGD2 and BW 245C also 
induce a concentration-dependent increase in cAMP levels in Chinese hamster 
ovary cells expressing the receptor. 
EP-receptors 
Since the existence of putative PGE receptors was first demonstrated in 1972 
by Kuehl and Humes, EP receptors have been reported in various mammalian 
tissues. PGE2 has a wide spectrum of physiological and pharmacological 
actions, including contraction and relaxation of smooth muscle, inhibition and 
enhancement of neurotransmitter release, inhibition of lipolysis, inhibition of 
gastric acid secretion, inhibition of immunoglobulin expression, 
immunoregulation, etc. It is now clear that these diverse biological activities 
are due to the activation of different subtypes of EP receptors. Four subtypes 
have been proposed: EPi, EP2, EP3 and EP4. However, the nomenclature of 
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subtypes of EP receptors is somewhat confusing; some researchers (for 
example, Negishi et al., 1993a) have mistaken PGEi-induced activity for that 
mediated via EPi-receptors and PGE2-induced activity for that mediated via 
EP2 receptors. 
EPi-receptors 
A. Distribution and biological actions 
EPi-receptors are mainly distributed in the smooth muscle of the trachea, the 
gastrointestinal tract, the uterus and the bladder from the guinea pig, and also 
in some of these same tissues from rat and hamster, where they mediate smooth 
muscle contraction (see Coleman et al., 1994b). EPi-receptors have also been 
demonstrated in dog gastric fundus (see Coleman et aL, 1994b), bovine iris 
sphincter (Dong and Jones, 1982), human myometrium (Senior et al, 1991)， 
and pig cerebral vessels (Li et al, 1994). It is documented that PGE2 induces 
hyperthermia and this effect has been recently identified to be mediated, at 




Little information concerning ligand-binding studies on native EPi-receptors is 
available. However, specific binding of [^H]PGE2 to membranes prepared 
from pig brain microvessels has been reported (Li et aL, 1994). Specifically 
bound [^H]PGE2 to brain microvessels is displaced by the EPi-receptor 
antagonist AH6809 by 80-90%, but only by 30-35% by the EP3-recept0r 
agonist MB28767, with the EP2-recept0r agonist butaprost being completely 
ineffective. Interestingly, the density of this receptor in the tissues from 
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newbom pig is less than 50% of that in the tissues from adults, but K^ values 
are similar (6 - 6.8 nM). 
Signal transduction 
The contraction of guinea pig trachea induced by PGE2 is absolutely dependent 
on extracellular Ca2+ (Creese and Denborough, 1981), indicating that the EPi-
receptor is coupled to Ca2+ influx. On the other hand, the EPi-receptor also 
mediates intracellular Ca2+ mobilisation in some cells. For example, PGE2 and 
sulprostone both stimulate Ca2+ mobilisation from intracellular stores in the 
rabbit cortical collecting tubule cells, and AH6809 causes about 50% inhibition 
of this response (for reviews, see Coleman et al., 1994b; Hebert, 1994), thus, 
the EPi-receptors are, at least partly, involved. It appears that the mechanism is 
independent of phospholipase C, since PGE2 does not affect InsP3 formation in 
this system. However, PGE2 and 17-phenyl-co-trinor PGE2 are able to stimulate 
InsP3 production in pig brain microvessels and the stimulation is ahnost 
completely blocked by AH6809 (Li et al, 1994). 
Several investigations on signal transducing mechanisms for EP-receptors have 
been conducted in osteoblasMike cell lines, such as MC3T3-E1, UMR-106 and 
MDCK. Both Ca2+ influx and intracellular Ca2+ mobilisation have been 
observed. PGE2 stimulates Ca2+ influx in MC3T3-E1 cells, which is insensitive 
to the L-type Ca2+ channel blocker nifedipine but is suppressed by the protein 
kinase C activator phorbol ester (Tokuda et aL，1992)，indicating that protein 
kinase C acts as a negative regulator. In MDCK (Aboolian et aL, 1989) and 
UMR-106 (Yamaguchi et al” 1988) cells, PGE2 induces both cAMP 
production and phosphatidylinositol turnover, suggesting the involvement of 
multiple signal transducing pathways. However, the subtypes of EP-receptors 
have not been identified in all these studies. The responses might be mediated 
via EPi-receptors or any of the other EP-receptors. 
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Molecular biology 
The mouse EPi-receptor contains two potential phosphorylation sites for 
cAMP-dependent protein kinase in the first and third intracellular loops, and 
one potential phosphorylation site for protein kinase C in the third intracellular 
loop, suggesting that these protein kinase are involved in the regulation of this 
receptor's function. [^H]PGE2 had a K^ value of 21 nM for the EPi-receptor 
expressed in Chinese hamster ovary cells (Watabe etal” 1993), and PGE2, 
sulprostone, iloprost, and 17-phenyl-co-trinor PGE2, were approximately 
equipotent displacers, which is in agreement with their functional potencies at 
EPi-receptors. The binding specificity order among other PGs is: PGE2 > 
iloprost > PGEi > PGF2a > U46619 > PGD2; 11-deoxy PGEi and butaprost 
exhibited weak or negligible binding activity. However, the EPi-receptor 
antagonist AH6809 was virtually ineffective in displacing bound pH]PGE2, 
which is not consistent with the effectiveness of AH6809 in functional studies 
on other tissues. PGE2 induced a rapid increase in intracellular Ca2+ 
concentration within 10 seconds and then the level decreased quickly but 
remained above the basal level for more than 3 min (Watabe et al, 1993). This 
increase appears to be due to Ca2+ influx through receptor-operated Ca2+ 
channels since it is completely abolished by the removal of extracellular Ca2+ 
and PGE2 neither significantly stimulates phosphoinositide metabolism nor 
alters the intracellular cAMP level in this system (Watabe et al” 1993). 
With the human EPi-receptors expressed in COS cells (Funk et al, 1993)， 
pH]PGE2 had an affinity of 1 nM K^; the rank order of potency for 
prostaglandins in competition for pH]PGE2 specific binding was PGE2 > 
PGEi > PGF2a > PGD2. AH6809 and SC19220 were more potent displacers 
than the EP2 receptor agonist butaprost, with potencies consistent with their 
affinity values for EPi-receptors determined in functional studies. It has also 
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been found that the human EPi-receptor, when expressed in Xenopus oocytes, 
induces the elevation of intracellular Ca2+ (Funk et al” 1993). 
EP2-recept0rs 
A. Distribution and biological actions 
EP2-recept0rs are widely distributed in smooth muscle, epithelial cells, mast 
cells, basophils, thymocytes, sensory afferent nerves (see Coleman et al., 
1994b). Tissues which strongly express the EP2-recept0r are ileum and thymus 
and those which significantly express this receptor are lung, spleen, heart and 
uterus (Honda et aZ.,1993). EP2-recept0r mRNA in mouse kidney is 
specifically localised to the glomeruli (Sugimoto etal., 1994). It has been 
documented that EP2-recept0rs are involved in the relaxation of trachea 
(Gardiner, 1986) and ileum circular muscles of guinea pig (Coleman et al, 
1990), dilatation of various blood vessels (Coleman et al” 1990), and 
stimulation of sodium and water reabsorption in the kidney tubule (see Hebert, 
1994 for review). In the guinea pig ileum myenteric plexus preparation, E 
series prostanoids potently enhance parasympathetic neurotransmission 
through an increase in the release of acetylcholine (Ehrenpreis et al., 1973). 
This neuronal PGE effect appears to be mediated through EP2-recept0rs, since 
the contractile action of butaprost on the guinea-pig ileum is abolished by 
morphine (Lawrence et aL, 1992). EP2-recept0rs are not present in brain 
synaptosomes from newbom pigs, but do exist in some tissues from the adult 
animal (Li et al., 1993). 
B. Properties 
Binding sites 
In brain synaptosomes from the newborn pig, only an EP3-recept0r can be 
detected by radioligand binding, cAMP and InsP3 assays, but both EP2-and 
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EPs-receptors are present in the adult with a K^ of 11 nM for pH]PGE2 
binding to the synaptosomes ¢^ et aL, 1993). It has been suggested that the 
low EP-receptor densities in this tissue are caused by the high levels of 
prostaglandins present, and indeed the receptors can be up-regulated by 
inhibiting prostaglandin synthesis (Li et al., 1995). 
Signal transduction 
The earliest evidence that EP2-recept0rs couple with a G-protein to stimulate 
adenylate cyclase, resulting in elevation of intracellular cAMP, came from the 
work of Simon et aL (1980) and Hardcastle et al. (1982) (see Coleman et al., 
1994b for review). The existence of this transducing mechanism has been 
supported and extended in different tissues. On duodenal epithelial cells EP2-
receptor agonists increase adenylate cyclase activity (Reimer et aL, 1992); 
cAMP generation in comeal endothelial cells is positively linked with the 
activation of EP2-recept0rs (Jumblatt and Peterson, 1991). The evidence for a 
direct link between EP2-recept0rs and Gs was observed in rabbit cortical 
collecting tubule (RCCT) cells (Sonnenburg et aL, 1990). PGE2 can either 
increase or decrease the formation of intracellular cAMP in freshly isolated 
RCCT cells, depending upon its concentration; but it only has the cAMP 
stimulatory effect in cultured RCCT cells and sulprostone, which is a very 
weak EP2 agonist, has no effect. Correspondingly, there are high and low 
affinity PGE2-binding sites in the isolated RCCT cells; but the cultured RCCT 
cells contain only one class of binding sites. Furthermore, binding to the single 
class of sites is inhibited by guanine nucleotide derivatives. 
Molecular biology 
In contrast to the EPi- and EP3-recept0rs, the mouse EP2-recept0r possesses a 
long C-terminal tail (153 amino acid residues) (Honda et aL, 1993), and this 
tail contains many serine and threonine residues as potential receptor kinase 
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phosphorylation sites. Furthermore, this receptor has four potential 
phosphorylation sites for cAMP-dependent protein kinase in the third 
intracellular loop and C-terminal tail. These phosphorylation sites may be 
involved in cAMP-mediated heterologous and agonist-induced homologous 
desensitisation. The EP2-recept0rs specifically bound [3H]PGE2 with a K<i of 
11.2 nM. The binding specificity order among prostaglandins is as follows: 
PGE2 = PGEi » iloprost > PGF2a ^ PGD2. PGE2 strongly stimulates 
adenylate cyclase activity, but does not change phosphoinositide metabolism in 
cells expressing the EP2-recept0r. The transducing mechanism for the 
expressed receptor appear to be the same as that of the native receptor. 
Two fragments of cDNA for EP2-recept0rs have been isolated from human 
lung (An et al” 1993; Bastien et al., 1994) and human placenta (Regan et al., 
1994). However, butaprost, a selective EP2-recept0r agonist, has been shown to 
be active in competition with binding of pH]PGE2 only at the latter (Regan et 
al” 1994). Moreover, butaprost and AH13205 are also active in stimulating the 
formation of cAMP in these cells. Thus, the existence of more than one EP2-
receptor appears possible since one receptor site displays high affinity for 
butaprost and the other does not. This is supported by pharmacological 
evidence showing that butaprost is a much weaker agonist at the rabbitjugular 
vein EP2-recept0r than at the EP2-recept0r of the cat trachea (Lawrence and 
Jones, 1992). 
EP3-recept0rs 
A. Distribution and biological actions 
EP3-recept0rs are widely distributed. They are present in gastrointestinal and 
uterine smooth muscle, on neurones, in gastric mucosal cells, in renal medulla 
and in human platelets. Tissues which highly express EP3-recept0rs are kidney 
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and uterus, followed by stomach, thymus, spleen, lung and brain (Sugimoto et 
al, 1992). PGE2 has diverse actions on these tissues via the activation 0fEP3-
receptors; it contracts smooth muscle, and inhibits neurotransmitter release in 
peripheral autonomic nerves (Coleman et al，1990) and in brain (Exner and 
Schlicker, 1995), lipolysis in adipocytes, gastric acid secretion, and water 
reabsoq)tion in kidney. In the case of the EP3-recept0r-mediated inhibition of 
autonomic neurotransmission, the guinea-pig vas deferens is the "gold 
standard" preparation since it is very sensitive and specifically contains this 
subtype of EP-receptor. Although the chick ileum has also been used to 
evaluate EP3-recept0r agonists, its value has been challenged since the 
contraction of this preparation is mediated by at least two EP-receptor subtypes 
(Lawrence and Jones, 1992). In human platelets, EP3-recept0rs do not mediate 
aggregation on their own, but potentiate aggregation induced by other 
aggregatory agents (Matthews and Jones, 1993). PGE2-induced hyperalgesia 
has been reported to be mediated via more than one type of EP receptors 
(Khasar et al” 1995) and the EP3-recept0r being one of them (Kumazawa et 
al” 1993; Oka etaL, 1994). 
B. Properties 
Binding sites 
In tissues containing EP3-recept0rs, [^H]PGE2 has been shown to have high 
affinity for its binding sites (Kd < 10 nM); the EP3-recept0r agonist 
sulprostone potently inhibits PGE2 binding (Schillinger et al, 1979). The 
relative binding affinities of sulprostone and AY23626, a less potent EP3-
receptor agonist, are compatible with their relative agonist potencies in 
functional tests at EP3-recept0rs. There is a fairly precise correlation between 
binding affinities of a diverse range of prostanoids for the high-affinity PGE 
binding sites (EP3-recept0rs) and their abilities to inhibit pepsinogen secretion 
in pig gastric mucosa (Sewing and Beinbom, 1990). 
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Signal transduction 
The EP3-recept0r may couple to different signal transducing systems, including 
inhibition of adenylate cyclase with resulting in a decrease in intracellular 
cAMP and stimulation of phosphoinositide metabolism. PGE2 at low 
concentrations (0.1 - 100 nM) inhibits vasopressin-induced cAMP 
accumulation, but at high concentrations (0.1 - 10 i^M) stimulates cAMP 
accumulation (Sonnenburg and Smith, 1988), perhaps resulting in dual 
regulation of water reabsorption in the rabbit cortical collecting tubules. From 
the sensitivity of this tissue to sulprostone, these actions are believed to be 
mediated by EP3-and EP2-recept0rs respectively (Sonnenburg etal” 1990). 
The activity of the renal EP3-recept0r is blocked by pertussis toxin, indicating 
that the receptor is coupled to a Gi protein (Sonnenburg et al., 1990); 
furthermore, the EP3-recept0r associated with pertussis toxin-sensitive Gi has 
been partially purified from canine renal outer medulla (Watanabe et aL, 1986). 
Thus, renal EP3-recept0rs appear to be coupled to Gi and involved in the 
inhibition of cAMP formation. A similar signal transducing mechanism has 
been suggested for the activation of EP3-like receptors in human platelets 
(Matthews & Jones, 1993)，where sulprostone inhibits adenylate cyclase in the 
presence of a TP-receptor antagonist (GR32191, 0.5 i^M) and an EPi-receptor 
antagonist (AH6809,10 i^M). 
However, in bovine adrenal chromaffin cells, PGE2 activates voltage-
independent Ca2+ channels through a diffusible second messenger, possibly 
InsP3 (Ito et al” 1991; Mochizuki-Oda et al” 1991). Furthermore, an ionic 
channel (K+ or Ca2+) modulatory mechanism has been proposed for the 
contractile effect of PGE2 (predominantly via EP3-recept0rs) in the rat uterine 
smooth muscle; the EP receptor is coupled to a pertussis toxin-sensitive G 




The EP3-recept0r, expressed using a cDNA from mouse mastocytoma cells 
(Sugimoto et aL, 1992)，is the most compact of the EP-receptor subtypes, with 
the cytoplasmic loops being short. [3H]PGE2 specifically bonds to this receptor 
with a Kd of 2.9 nM; the rank order of binding affinities is PGE2 = PGEi > 
iloprost > PGF20c > PGD2, with the EP3 agonists, MB28767, GR63799X and 
sulprostone also showing potent binding. The EP3-recept0r expressed in 
Chinese hamster ovary cells negatively couples to adenylate cyclase via a 
pertussis toxin-sensitive G protein (Negishi etal., 1993). When reconstituted 
with various pertussis toxin-sensitive G proteins, the EP3-recept0r is 
functionally coupled to these proteins with a selectivity order: Gii = G|2 > Gi3 
> Go. In addition to this inhibition of adenylate cyclase, however, the Gi 
coupled to EP3-recept0rs has also been reported to stimulate phospholipase C, 
leading to Ca2+ mobilisation from intemal stores and influx from the 
extracellular medium in the same cells as above (Lie et aL, 1994). 
Three isoforms of the murine EP3-recept0rs (EP3a, EP3p and EP3y) have been 
identified. They arise through alternative splicing of C-terminal tail (Sugimoto 
et aL, 1993; Me et aL, 1993). These isoforms display identical agonist binding 
properties, indicating that the C-terminal tail does not contribute to agonist 
binding. However, they are functionally different. EP3a and EP3p are coupled 
exclusively to inhibition of adenylate cyclase, but EP3a causes the inhibition 
more efficiently than EP3p, with its IC50 being three orders lower than that of 
EP3p. A similar difference in agonist potency was also observed for agonist-
induced stimulation of GTPase activity. GTPyS increases the PGE2 binding 
affinity of EP3a, while it decreases that of the EP3p. The opposite responses to 
GTP^S of the two isoforms may be correlated with their different efficiencies 
as to Gi activity. On the other hand, E P s y is coupled to both G s and Gi, causing 
the inhibition of adenylate cyclase at low concentration of PGE2 and 
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stimulation at high concentration. Thus, the C-terminai tail of the EP2-recept0r 
plays an important role not only in the efficiency of G protein activation but 
also in the specificity of G protein coupling. EP3a and EP3p also show different 
sensitivities to agonist-induced desensitisation. EP3a-recept0rs undergo short 
and long term desensitisation, whereas EP3p-recept0rs are not desensitised 
either in the short or long term. 
cDNAs for the four bovine EP3 receptor isoforms (EP3A, EP3B, EP3c and 
EP3D) have also been isolated from bovine adrenal medulla (Namba et aL, 
1993). EP3A is coupled to adenylate cyclase inhibition; EP3B and EP3c to 
adenylate cyclase stimulation; EP3D to stimulation and inhibition of adenylate 
cyclase and stimulation of phosphoinositide metabolism in a pertussis toxin-
insensitive manner. The arginine residue in the seventh transmembrane domain 
of EP3D has been found to be important in signal transduction for adenylate 
cyclase stimulation and Ca^+ mobilisation but not for adenylate cyclase 
inhibition since the receptor selectively losses the ability to couple with cAMP 
production and Ca2+ mobilisation when the arginine is mutated to glutamine 
(Negishi et al., 1995). In addition, the homologous splice variants on EP3 
mRNA are also present in human and rabbit (Adam et aL, 1994; Breyer et aL, 
1993). These isoforms show alternative splicing at the position identical with 
that found in the bovine variants. The diversity of the cellular responses to 
PGE2 is mainly based on the existence of functionally different EP-receptor 
subtypes and isoforms produced through alternative splicing. 
EP4-recept0rs 
As described in the Section on EP2-recept0rs, there is an atypical EP-receptor 
which mediates the relaxation of smooth muscle and at which butaprost has 
only a low potency/affinity. In the rabbit jugular vein, butaprost is about 600 
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times less potent than 16,16-dimethyl PGE2 and 11-deoxy PGEi (Lawrence & 
Jones, 1992)，whereas they are of similar potency on the cat trachea (EP2 
preparation). Recently, EP4-recept0rs have been identified in piglet saphenous 
vein, where prostanoids induce relaxation via an EP receptor but at which 
selective agonists for EPi-, EP2-, and EP3-recept0rs are weak or inactive 
(Coleman et al., 1994a). This receptor is blocked by the TP-receptor 
antagonists, AH22921 and AH23848; their pA2 values are 5.3 and 5.4 
respectively, being at least 2 log units less than those for TP-receptors. 
Furthermore, AH23848 has no antagonist activity at other EP-receptors. Thus, 
the atypical relaxant EP-receptors in rabbitjugular vein (Lawrence and Jones, 
1992), rat trachea (Lydford and Mckechnie,1994), hamster uterus (Yeardley et 
al., 1992) and fetal rabbit ductus arteriosus (Smith et al, 1994) could possibly 
be listed here as EP4-recept0rs. 
FP-receptors 
A. Distribution and biological actions 
FP receptors are present in a variety of different tissues from a range of 
different species, such as corpus luteum, airway smooth muscle, myometrium 
(in humans and some rodents, but not guinea pig), vascular smooth muscle and 
iris sphincter muscle. The distinguishing action of PGF2a is induction of 
luteolysis (Dukes et al” 1974; Horton and Poyser, 1976). The corpus luteum is 
formed in the ovary following ovulation, and if pregnancy occurs it has a role 
in maintaining the pregnancy through the secretion of progesterone. If 
pregnancy does not occur, the corpus luteum undergoes regression. PGF2a 
induces luteolysis by inhibiting luteinizing hormone-induced cAMP 
accumulation, as well as inhibiting progesterone production. However, in 
women PGF2a and its analogues proved to be ineffective luteolytics while they 
are highly effective in many other animal species. 
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FP-receptors mediate smooth muscle contraction, causing bronchoconstriction 
(Wasseraian, 1975)，vasoconstriction or potentiation of vasoconstriction 
induced by adrenoceptor agonists (Rapoport, 1993), and contraction of 
myometrium (Senior et al, 1992)and iris sphincter muscle (Dong & Jones， 
1982). Since the iris sphincter muscle from both cat and dog appears to contain 
a homogeneous FP_receptor population, it is very useful in the determination of 
FP agonist and antagonist potencies. The presence of FP-receptors in ocular 
tissue has had important pharmacological consequences because PGF20t and its 
analogues have proven to be effective in lowering intraocular pressure in 
various species, including man, and are being developed as anti-glaucoma 
drugs (Coleman et al, 1990). 
B. Properties 
Binding sites 
The specific binding of [^H]PGF2a has been demonstrated in a variety of 
tissues and the corpus luteum shows the highest activity. The affinities for 
[^H]PGF2a binding to membranes of corpora lutea from various species are 
less than 10 nM and the binding is selectively displaced by unlabeled PGF2a 
and by fluprostenol, a potent and selective FP-receptor agonist (Kimball and 
Lauderdale, 1975; Kimball and Wyngarden, 1977; Lin and Rao，1978; Wright 
et al” 1979). The receptor from bovine corpus luteum has been solubilized 
with Triton-X 100 and partially purified, and its molecular mass estimated to 
be 107 kDa by Sepharose 6B column chromatography (Kylden and 
Hammarstrom,1980). In brain microvessels of pigs the density of FP receptors 
increases with age, without change in Kd (10 - 13 nM) QJi et al” 1994). In the 
human myometrium, specific PGF2a binding sites have also been suggested 
(Giannopoulos et al, 1985), but the affinity of pH]PGF2a is lower than for 
PGEi and PGE2. 
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Signal transduction 
PGP2a-induced luteolysis can be mimicked by phorbol 12-myristate 13-acetate 
and A23187 and is thus believed to be mediated by protein kinase C activation, 
resulting from PGF2a-stimulated phosphoinositide metabolism (Baum and 
Rosberg, 1987). In rat myometrium, FP-receptor-mediated contraction is 
associated with a phospholipase C pathway, which is insensitive to pertussis 
toxin, and the putative G protein involved in this mechanism might be Gq 
(Goureau et al” 1992). The interaction of FP-receptors with a member of the 
Gq protein family to activate phospholipase C, leading ultimately to an InsP3-
mediated mobilisation of Ca2+ from intracellular pools, has also been 
suggested in murine fibroblasts (Nakao et aL, 1993; Quarles et al, 1993). 
However, there also appears to be a secondary phase of Ca2+ elevation in 
PGF20rtreated murine fibroblasts that is likely to be due to extracellular Ca^+ 
entry (Nakao et al” 1993). The removal of extracellular Ca^+ also modestly 
reduces FP-receptor-mediated Ca^+ signals in Swiss 3T3 cells (Woodward & 
Lawrence, 1994). 
Molecular biology 
The mouse FP-receptors expressed in COS cells bind [3H]PGp2a with a K^ of 
1.32 nM, and this [^HJPGFia binding is displaced by unlabeled PGs in the 
order of PGF2a = 9a,nP-PGF2 > PGFia > PGD2 > STA2 > PGE2 > iloprost 
(Sugimoto et aL, 1994). PGF2a induces formation of InsP3 in a concentration-
dependent manner in COS cells transfected with a cDNA for either the mouse 
FP-receptor (Sugimoto et aL, 1994) or the bovine FP-receptor (Sakamoto et 
“/•，1994), which is consistent with the signal transducing mechanism operating 
in rat myometrium and mouse fibroblasts. The direct link between FP-receptors 
and Gq has been demonstrated in FP-receptor cDNA-transfected Chinese 
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hamster ovary cells, where Gq a antibody, applied intracellularly, blocks 
PGP2a-induced responses (Ito et al, 1994). 
[3H]PGF2a specifically binds to the membranes prepared from COS cells 
expressing human FP-receptors with a K<j of 1 nM; unlabeled prostaglandins 
compete for [3H]PGP2a specific binding with a rank order of potency: PGF2a = 
fluprostenol > PGD2 > PGE2 > U46619 > iloprost (Abramovitz et al, 1994). 
Functionally, the human FP-receptor is coupled to the Ca^+ signalling pathway 
since either PGF2a or fluprostenol causes an elevation in intracellular Ca2+. 
However, the mechanism underlying the increase in Ca2+ is not clear. 
IP-receptors 
A. Distribution and biological actions 
ff receptors are primarily distributed in blood platelets and vascular smooth 
muscle, where prostacyclin plays an important inhibitory role in local control 
of vascular tone and platelet aggregation (Moncada, 1982). However, it has 
also been found that PGI2 has biological actions in other tissues and cells. 
PGI2 is potent lipolytic agent and antagonises the antilipolytic effect of PGE2 
in adipocytes (Chatzipanteli et al, 1992); it suppresses activation of white 
blood cell, including human monocytes/macrophages (Wise et al” 1991) and 
rat neutrophils (Wise and Jones, 1994). 
Although PGI2 shows inhibitory effects in most cases, it does induce excitatory 
responses in some tissues, particularly in the nervous system. In sensory nerves 
prostacyclin activates "cardiopulmonary receptors" in the large pulmonary 
vessels of the dog to elicit vagal bradycardia (Nganele and Hintze,1987), and 
cicaprost potentiates sensory discharge from the arthritic ankle joint of the rat 
following depression with either acetylsalicylic acid or paracetamol (McQueen 
et al, 1991). In a spinal cord/functionally-attached tail preparation from the 
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neonate rat, cicaprost also enhances responses of peripheral nociceptors to 
thermal and chemical stimuli (Rueff and Dray, 1993). In terms of motor 
actions，cicaprost elicits contraction of the longitudinal muscle of the guinea-
pig ileum by releasing both acetylcholine (Gaion and Trento, 1983) and a 
substance P-Uke transmitter (Jones and Lawrence, 1993) from enteric nerves. A 
relevant phenomenon has been observed in the rabbit iris sphincter muscle, 
where PGEi enhances the release of substance P from the trigeminal nerve 
terminals (Ueda et al” 1985). ff receptors might be involved in this neuronal 
effect since PGEi generally acts at the same receptor as PGI2 does. 
In addition, PGI2 has cytoprotective effects against tissue injury in acute 
myocardial ischemia, hypoxic perfusion of isolated liver, gaIactosamine-treated 
liver, and vascular endothelial cells (Sakai et al” 1990). The cytoprotective 
effect of PGI2 has been suggested to be unrelated to its antiplatelet or 
vasodilator activities. 
Under the present classification scheme of prostanoid receptors, IP-receptors 
are not subclassified. The attempt to develop a compound that distinguishes 
platelet IP-receptors from vascular IP-receptors has not been successful. 
However, heterogeneity of platelet IP-receptors has been suggested. Firstly, 
IP-receptors on human, pig, and horse platelets have been reported to be 
similar in nature, but distinct from those on rabbit and rat platelets on the basis 
of agonist potency ranking (Armstrong et al, 1989). Thus, for inhibition of 
aggregation and production of cAMP, iloprost and cicaprost always have 
similar potencies, whereas 6a-carba PGI2 is much more potent than EP 157, a 
prostaglandin endoperoxide analogue with prostacyclin activity, on rabbit and 
rat platelets compared with human, pig and horse platelets. Secondly, using 
similar methods, platelets from cynomolgus monkeys are found to be 3-fold 
more sensitive to octimibate, a non-prostanoid prostacyclin mimetic than those 
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from humans (Merritt et al., 1991a), while rat, cat and cow platelets are 50， 
100, and 250 fold less sensitive than human platelets; the sensitivity of these 
different species to iloprost varies over a range of only 10-fold with no obvious 
difference between primates and non-primates. These species differences may 
reflect the existence of receptor subtypes. 
B. Properties 
Binding sites 
Early binding studies using [^HJPGh and [3H]PGEi were performed on blood 
platelets. PGI2 and PGEi are believed to interact at the same receptor on 
platelets (Miller and Gorman, 1979). Binding studies with either [3H]PGh 
(Siegl et al., 1979) or [3H]PGEi (Schafer et al, 1979) have demonstrated the 
existence of two classes of PGI2/PGE1 receptors on platelets: a high-affinity 
class of receptors with a K<i value in the nanomolar range and a low-affinity 
class with a K^ value in the micromolar range. PGI2 and PGEi interact at the 
same receptor via interaction with the high-affinity sites. It is likely that there is 
considerable receptor reserve for PGI2 action since the interaction of the 
agonist with the receptor produces a sixty-fold amplification from binding to 
intracellular response (Jaschonek et al, 1987). 
More recently, [3H]iloprost has been used as radioligand. It has the distinct 
advantage over prostacyclin of being chemically stable. Using this ligand, 
binding studies have been performed on human platelets (Lombroso et al, 
1984), bovine coronary artery (Town et al., 1982), mouse mastocytoma P-815 
cells (Hashimoto et al, 1990) and neuronal hybrid cells (Hall and Strange, 
1984). [3H]PGl2 and [3H]iloprost have high affinities for binding to IP-
receptors with a K4 of less than 10 nM; the rank order of competitive potency 
is iloprost = PGI2 > PGEi » PGE2, 6-keto-PGFia, PGF2a, and PGD2. In 
addition, PGI2 specific binding sites have also been found on the myometrium 
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and vascular smooth muscle of nonpregnant human uterus, but not on the 
endometrium or vascular endothelium, using the technique of quantitative 
light microscopic autoradiographic analysis (Chegini and Rao,1988). 
Autoradiography using [^H]iloprost has also confirmed that IP-receptors are 
present in the nervous system although the relationship between the 
distribution and biological functions remains unclear (Matsumura et al., 1995). 
A stable PGI2 analogue, 19-(3-azidophenyl)-15-epi-20-noriso-carbacyclin 
(APNIC), has been used as a photoaffinity probe; direct photoaffinity labelling 
of BP-receptor was performed with this agent in mastocytoma cells, and the 
molecular mass of the IP-receptor estimated as approximately 43 kDa (Ito et 
al., 1992). However, Leigh et al (1984) estimated the molecular weight of the 
PGI2 receptor complex to be 83 kDa, using membranes prepared from the 
NCB-20 cell line and the technique of radiation inactivation. The PGI2yPGE1 
receptor purified from platelet membranes has a molecular weight of 190 kDa, 
with two subunits of 85 kDa and 95 kDa (Dutta-Roy and Sinha, 1987). The 
receptor has a high-affinity site with a Kd value of 9.8 nM and a low-affinity 
site with a K^ value of 700 nM for [3H]PGEi, values similar to those reported 
for the intact receptor. 
Signal transduction 
ff-receptors appear to couple with Gs to stimulate adenylate cyclase; the rise in 
cAMP resulting from the activation of adenylate cyclase produces a decrease in 
intracellular Ca2+ (see Halushka et al” 1989 for review; Hashimoto et aL, 
1990). Normally, if a receptor is coupled to a G protein, agonist binding to this 
receptor should be decreased in the presence of guanine nucleotides, due to the 
conversion of high agonist affinity receptor-G protein complexes to 
"uncoupled" receptors, which have a lower affinity for agonists. This property 
has been demonstrated by experiments examining the effect of guanine 
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nucleotides on [^H]iloprost binding to membranes from NG108-15 cells and 
human platelets (Keen etal., 1991). Recent desensitisation experiments also 
support the idea that the IP-receptor is coupled to Gs in these cells; iloprost 
pretreatment induces two distinct phases of desensitisation of IP-receptor-
activated adenylate cyclase, with the initial desensitisation being partly due to 
the loss of the a subunit of Gs (Williams and KeUy, 1994). All the inhibitory 
effects of prostacyclin on platelets can be explained by lowering of 
intraceUular Ca2+. However, on vascular smooth muscle the relaxant effect of 
PGI2 could be due in part to the hyperpolarisation from its K+ channel opening 
effect through the influence of cAMP-PK system (Siegel et aL, 1992), and not 
directly to a decrease in intracellular Ca2+. 
On the other hand, cAMP may cause a rise in intracellular Ca2+ rather than a 
fall. For example, in rat cardiomyocytes, PGI2 elicits increases in contraction 
frequency through the activation of adenylate cyclase and subsequent opening 
of nifedipine-sensitive Ca2+ channels (Church et aL, 1994). Furthermore, 
besides cAMP generation, other signal transduction systems have also been 
reported to be involved in the activation of IP-receptors. In megakaryoblastic 
leukaemia cells (MEG-Ols) expressing IP-receptors, iloprost induces cAMP 
production and Ca^+ influx (Watanabe et aL, 1991). One argument arising is 
that the increase in intracellular Ca2+ might not be due to the activation of IP-
receptors since PGE2 can also cause Ca^+ influx and iloprost has EPi-receptor 
agonist activity. However, PGE2 and PGI2 elevate intracellular Ca^+ in a 
different manner: the former is pertussis toxin-sensitive and the latter 
insensitive, which indicates that the effect of iloprost is not mediated via an 
EP-receptor. Another example has been reported in cultured interleukin 3-
dependent mast cells, the BNu-2cl3 cell line (Oka et aL, 1993). Iloprost 
induces the accumulation of intracellular cAMP and InsP3, and an increase in 
intracellular Ca^+. Two distinct Ca2+ mobilising pathways might be involved: 
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Ca2+ release from InsP3-sensitive intracellular stores and receptor-operated 
InsP3-insensitive Ca2+ channels in these BNu-2cl3 cells. The authors have 
proposed that two ff-receptor subtypes exist in BNu-2cl3 cells; one couples to 
stimulation of adenylate cyclase, while the other couples to 
phosphatidylinositol hydrolysis. However, the selectivity of iloprost is again 
questionable in this study (see Section on selective agonists for the best 
standard JP agonist). 
Molecular biology 
With the human IP-receptor expressed in mammalian COS cells (Boie et al” 
1994), [^H]iloprost binding is inhibited by various PGI analogues and other 
prostanoids in the order: i loprost» carbacyclin » PGE2 > PGF2a = PGD2 = 
U46619, which agrees with the previous characterisation of the receptor in 
platelets and other sources. A two-site model for [^H]iloprost specific binding 
to the human IP-receptor has been suggested by Scatchard analysis. The high 
affinity and low affinity equilibrium dissociation constants are 1 and 44 nM 
respectively; both binding sites are saturable. Furthermore, this receptor has 
been shown to couple to elevation in intracellular cAMP in Xenopus oocytes. 
Northern blotting analysis on human tissues reveals that ff-receptor mRNA is 
abundantly expressed in the aorta, lung, atrium, ventricle, and kidney 
(Nakagawa et al, 1994); its abundant gene expression in the human 
cardiovascular system is consistent with its significance in this system. 
Multiple signal transduction pathways have been demonstrated for the 
activation of both human IP-receptors (Katsuyama et al.’ 1994) and the mouse 
IP-receptors (Namba et al, 1994) expressed in Chinese hamster ovary cells. 
They are coupled to the stimulation of adenylate cyclase and 
phosphatidylinositol turnover at low and high concentrations of iloprost 
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respectively; the EC50 for the former is 0.1 nM and that for the latter is 100 nM 
(Namba etal., 1994). 
TP-receptors 
A. Distribution of biological actions 
Prostaglandin H2 is the precursor for thromboxane A2. Both are labile and have 
half-lives of approximately 5 min and 30 sec, respectively under physiological 
conditions. Since they share the same pharmacological properties in virtually 
every tissue in which they have been studied, they presumably share a 
common receptor. Thus, some researchers prefer the name of TXA2/PGH2 
receptor (Halushka et al, 1989). Here the name of TP is used for this receptor 
in order to comply with the nomenclature of prostanoid receptor in the 
Receptor and Ion Channel Nomenclature Supplementary Issue of Trends in 
Pharmacological Sciences (Watson & Girdlestone, 1995). 
Like IP-receptors, TP-receptors are widely distributed in vascular smooth 
muscle and platelets, where they mediate vasoconstriction and platelet 
aggregation. Studies of platelet TP-receptors have shown significant species 
differences. Of those species studied, the guinea pig platelet TP-receptor 
(Halushka et al, 1986) appears to most closely resemble the human, whereas 
the dog, rat, and rabbit receptors differ considerably from the human and each 
other (Narumiya et al., 1986). Vascular TP-receptors do not appear to be 
highly different although quantitative differences have been found among the 
species or vessels. Of the various blood vessels that have been studied, the 
canine saphenous vein appears to be one of the most sensitive to TP agonists 
(Jones et al, 1982). Besides platelets and smooth muscle (vascular and 
airway), some other tissues have also been found to contain TP-receptors, such 
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as monocytes (Allan and Halushka，1994), mesangial cells (Scharschmidt et 
aL, 1986) and epithelium of the gastrointestinal tract (Bunce and Spraggs, 
1987). 
There has been some controversy regarding the existence of TP-receptor 
subtypes (Halushka et aL, 1989). The differences may not simply reflect 
species variants since the platelet and vascular TP receptors appear different 
irrespective of species. The canine and human saphenous vein TP-receptors are 
similar but the human platelet and vascular receptors are significantly different 
(Mais et al” 1985a; 1985b; 1988). It has been suggested that it is difficult to 
distinguish TP subtypes on the basis of agonist potencies but the different 




Several [^ H]- or [i25i]_iabelled agonists and antagonists for TP-receptors have 
been used for radioligand binding studies. Most of the studies have been 
conducted in either washed human platelets or platelet membranes, while the 
platelets from other sources and vascular and bronchial smooth muscle have 
also been used. The K<j values for the ligands have differed, but the Bmax 
values reported for the most of the ligands have been in the range of 1500 to 
2500 sites/platelet (Halushka et al, 1989). Using subcellular fractionation and 
radioligand binding studies, the receptor has been localised to the plasma 
membrane/dense tubular system in the platelet (Saussy et al, 1988). The 
binding studies with [3H]GR32191 (a selective TP-receptor antagonist, see 
Section on selective agonists and antagonists) indicate that GR32191 interacts 
with a single site on human platelets but the interaction of this drug with the 
receptor is characterised by a slow dissociation which is directly related to 
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contact time (Armstrong et al” 1993). This characteristic makes it difficult to 
estimate a true Kd value for this compound, and it may explain its long 
duration of action following administration to man. 
The human TP-receptor has been purified from human platelets using a stable 
TP antagonist S-145. The molecular weight of the purified receptor is 57 kDa 
and it maximally binds 19.2 nmol of pH]S-145/mg protein with a K^ of 29.8 
nMOLJshikubi etaL, 1989). 
Signal transduction 
The signal transduction systems have been studied most extensively in 
platelets and also in vascular smooth muscle. TP-receptor-mediated platelet 
activation is complex and consists of at least two main responses: shape change 
and aggregation/secretion of granule contents; other functional effects include 
adhesion to a suitable surface. It has been suggested that two different signal 
pathways are involved in platelet shape change and aggregation. The former 
involves mobilisation of Ca2+ from intracellular stores via an InsP3-
independent process since S-145, a drug only initiating platelet shape change, 
causes an increase in the cytosolic Ca2+ concentration, which is independent of 
extracellular Ca2+ and does not change the InsP3 level (Nakano et al., 1988; 
Arita et al” 1989). Platelet aggregation involves activation of phospholipase C 
and the subsequent formation of InsP3 and diacylglycerol (DAG) (Pollock et 
al, 1984; see Halushka et al” 1989 for review); InsP3 may be responsible for 
the increase in intracellular free Ca^+ concentration; endogenous synthesis of 
TXA2 induced by InsP3 may further elevate intracellular free Ca2+ (Authi et 
a/” 1987). These responses are mediated via G proteins, which are not sensitive 
to either cholera or pertussis toxins, indicating that the proteins are not Gs or Gi 
(Halushka et al, 1989). Further study with a specific antibody against the 
carboxyl-terminal peptide of Gqa has identified that the G protein coupled to 
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the TP-receptor in human platelets is a member of the Gq family (Shenker et 
al” 1991). 
A similar pattem of signal transduction associated with TP-receptor-mediated 
contraction has been demonstrated in vascular smooth muscle (see Coleman et 
al., 1994b for review): the TP receptor is coupled to the activation of 
phosphoUpase C via a G protein, causing an increase in InsP3 and mobilisation 
of intraceUular Ca2+. 
In addition, a totally different signal transduction pathway for TP-receptor has 
been reported on equine monocyte: the receptor couples to production of 
cAMP (Simmons et al” 1993). The authors explained that this TP-receptor was 
different from that in platelet and vasculature. 
Molecular biology 
The human and mouse TP-receptors expressed in cultured COS cells 
specifically bind the selective TP-receptor ligand [3H]S-145 with a Kd of 1.2 
and 3.3 nM respectively (see Narumiya et al” 1993 for review); this binding is 
displaced by various TP analogues in the order of S-145 > ONO-3708 > STA2 
> U46619. Other prostaglandins such as PGD2 also displace the binding, but 
their potencies are at least two orders of magnitudes less than those of TP 
analogues. When expressed in Xenopus oocytes, the TP-receptors are coupled 
to PI turnover and Ca2+ mobilisation. 
Selective agonists and antagonists 
Information on some selective prostanoid agonists and antagonists is 
summarised in Tables 1.3 and 1.4. Some compounds in the tables may not 
strictly fall within the usual definition of "selective agonist" or "selective 
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antagonist" because of their limited selectivities, but practically they have 
proven very useful. The specificity of prostaglandin E and prostacyclin 
analogues as agonists at EP- and IP-receptors is shown in Tables 1.5 and 1.6 
^:.awrence et al, 1992). 
DP-receptor agonists and antagonists 
Human platelets are commonly used for evaluation of DP-receptor agonists and 
antagonists, but the results obtained from these experiments should be 
interpreted with caution since the preparation also contains IP- and TP-
receptors. PGD2 itself has only moderate selectivity for the DP-receptor; it 
possesses significant potency at FP- and TP-receptors. However, a dehydration 
product of PGD2, 9-deoxy-A9-PGD2, has been reported to be equipotent with 
PGD2 at inhibiting platelet aggregation and producing vasodilatation, but is 
more specific, possessing relatively less activity on EP- and FP-receptors. The 
hydantoin analogue, BW245C, is a potent inhibitor of aggregation of human 
platelets, but unlike PGI2, it is inactive on rat platelets. BW245C displaces 
[3H]PGD2 but not [3H]PGh or [^Hjiloprost from bovine and human platelets 
respectively (Coleman et al” 1990). BW245C has been widely used as DP-
receptor agonist, but its disadvantage is that it is converted into a 1:1 mixture 
with its much less biologically active epimer in an aqueous solution. A 
chemically stable PGE analogue, ZK110841, has been reported to be a 
selective DP-receptor agonist by Thierauch et al (1988). This designation has 
also been confirmed in a fibroblastic cell line from bovine embryonic trachea 
(Ito et al” 1990), which specifically responds to PGD2 among the various 
prostaglandins. 
The first compound shown to possess DP-receptor blocking activity is the 
phloretin derivative, N-0164, which weakly, but selectively, antagonises the 
inhibitory activity 0fPGD2 on human platelets (MacIntyre and Gordon,1977). 
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Table 1.3 Selective prostanoid receptor agonists 
Potency Order 
Agonist (at corresponding receptors) References 
DP agonists 
BW245C BW245C > ZK110841 « PGD2 Town et al., 1983; 
ZK110841 Thierauch et al., 1988 
EPj agonists 
17-Phenyl PGE2 PGE2« 17-phenyl-o>trinor- Coleman et al” 1987; 
Sulprostone PGE2 > sulprostone Lawrence et al, 1992 
EP2 agonists 
Butaprost PGE2 > misoprostol > butaprost Gardiner, 1986; 
Misoprostol > AH13205 Coleman et al” 1994b; 
AH13205 
EP3 agonists 
SC46275 SC46275 > sulprostone > Bunce et al., 1990; 
Sulprostone misoprostol == PGE2 « GR63799 Lawrence et al, 1992 
GR63799 Savage et al” 1993; 
Misoprostol 
FP agonists 
Fluprostenol Cloprostenol > fluprostenol > Dong & Jones, 1982; 
Cloprostenol PGF20c Coleman et al” 1990 
IP agonists 
Cicaprost Cicaprost > PGI2 > BMY45778 Dong et al.，1986; 
BMY45778 > octimibate Menitt et al., 1991a;b; 
Octimibate Meanwell et al, 1994; 
TP agonists 
U46619 EP171 > U 4 6 6 1 9 » P G E 2 Maknsten, 1976 
EP171 Jones etaL,l9S9 
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Table 1.4 Selective prostanoid receptor antagonists 
Antagonists pA2 References 
DP antagonists 
BW A8685C 9.26 GUes et aL, 1989 
ZK138357 7.5-7.7 Thierauch et aL, 1994 
EPj antagonists 
SC19220 5.2 - 5.6 Sanner, 1969 
Coleman et al, 1985 
AH6809* 6.4 - 7.4 Coleman et al” 1985; 
Lawrence et aL, 1992 
EP4 antagonists 
AH22921** 5.3 Coleman et aL, 1994a 
AH23848** 5.4 Coleman et al” 1994a 
TP antagonists 
GR32191 8.2 - 8.8 Lumley etal, 1989 
EP045 5.9 - 7.1 Jones et al” 1981 
EP092 7.2 - 8.4 Armstrong et al； 1985 
EP169 8.3 - 8.8 Tymkewycz et aL, 1991 
B A Y u3405 8.1 - 8.9 McKenniff et al” 1991 
*It also has DP-receptor antagonist activity at higher concentrations. **They 
are also TP-receptor antagonists. 
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However, the antagonist of choice is BW A868C, a selective and potent 
competitive DP-receptor antagonist with a pA2 value of 9.26 in human platelets 
(Giles et a/” 1989). It antag0nises PGD2-induced inhibition of human washed 
platelet aggregation through blocking DP-receptor-mediated activation of 
human platelet adenylate cyclase (Trist et al, 1989). Its blocking effects at DP-
receptors have also been observed in preparations of rabbitjugular vein, where 
the relaxation by BW 245C and PGD2 is antagonised with a similar potency to 
that in human platelets (Giles et aL, 1989), and in the rat in vivo, where PGD2 
vasodepressor responses are antagonised (Hamid-Bloomfield & Whitde, 1989). 
Furthermore, its affinities at other prostanoid receptors are 1000 times lower 
than at DP-receptors. However, it has also been demonstrated that BW 245C is 
a partial agonist in elevating cAMP levels in Chinese hamster ovary cells 
expressing DP receptors (Hirata et al” 1994). Another compound ZK138357, 
synthesised from L-(+)-isopropyliden-threitol and having the attachment of the 
side chains to the ring opposite to that of natural prostaglandins, has been 
recendy reported to be a selective DP-receptor antagonist (Thierauch et al, 
1994). It attenuates the inhibition by PGD2 of platelet activation with a pA2 of 
7.7 and antagonises PGD2-induced elevation of cAMP with a pA2 of 7.5; in 
Wv6> it concentration-dependently reduces rat skin blood flow elevated by 
topical application of the DP-receptor agonist, ZK110841. 
EPi -receptor agonists andantagonists 
Many PGE analogues have EPi-receptor agonist activity, but none are highly 
selective (Table 1.5). 17-Phenyl-co-trinor PGE2 has proven useful. Its potency 
at EPi-receptors is approximately one and two orders of magnitude higher than 
at EP3- and EP2-recept0rs respectively. ICI 80205 is more potent than 17-
phenyl-co-trinor PGE2, and also has some selectivity for EPi- as opposed to 
EP3- and EP2-recept0rs, but 17-phenyl-co-trinor PGE2 would have a potential 
advantage over ICI 80205 in studies to characterise EPi-receptors owing to its 
43 
very low TP agonist potency (see Lawrence et al” 1992 for further discussion). 
Iloprost，a PGI2 analogue, has also been recommended as a selective EPi 
receptor agonist (Coleman et al” 1994b)，but it is a partial EPi agonist on some 
tissues and a highly potent IP-receptor agonist. Furthermore, it also shows 
some EP3 agonist potency. 
The first specific EPi-receptor antagonist to be identified was the 
dibenzoxazepine SC19220, but its usefulness is limited by its low potency and 
poor aqueous solubility. Subsequently, another compound, AH6809, has been 
shown to possess a similar profile of action. It is more potent and more water-
soluble than SC19220, but unlike this compound, it also possesses blocking 
activity at DP-receptors and TP-receptors. Furthermore, AH6809 has only 
limited usefulness in vivo since in the presence of 4% bovine serum albumen, it 
is approximately 97% protein bound (Coleman et al, 1990). 
EP2 -receptor agonists 
Two selective EP2 receptor agonists have been reported: butaprost (TR4979, 
Gardiner, 1986) and AH13205 (Coleman et al, 1994b). Despite their low 
potencies, they have proven useful in characterising EP2-recept0rs, particularly 
when compared with other EP-receptor agonists having potent activity at EP2-
receptors, such as misoprostol and PGE2 itself. Misoprostol alone may not 
show an accurate EP2-recept0r agonist potency if EP2- and EP3-recept0rs c o 
exist in the preparation since it is also a potent EP3 receptor agonist. However, 
not all EP2 preparations, such as rabbit jugular vein, sensitively respond to 
butaprost, which suggests the presence of atypical EP2-recept0r subtypes 
(Lawrence & Jones, 1992). To date, no compound has been reported to have 
EP2-recept0r blocking activity. 
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Table 1»5 Specificity of prostaglandin E analogues as agonists at EP receptors 
OLawrence et al, 1992) 
PGE analogues EPi EP2 EP3 
ICI80205 ++++ + +++ 
16,16-Dimethyl PGE2 ++++ ++(+) ++++ 
PGE2 +++ +++ +++ 
17-Phenyl-co-trinor PGE2 +++ + ++ 
Sulprostone ++ 0 ++++ 
MB 28767 (+) (+) +++ 
Oxoprostol (+) 0 ++ 
Misoprostol + ++(+) +++ 
Enisoprost + +(+) +++ 
11 -Deoxy PGE2-1 -alcohol (+) ++ ++ 
11-Deoxy PGEi + ++(+) ++ 
Butaprost (+) ++ 0 
One + corresponds to a potency difference of approximately one order of 
magnitude. 
EP3 -receptor agonists 
Many potent EP3-recept0r agonists have been developed, but most of them also 
possess agonist activity at other EP-receptors and even at other prostanoid 
receptors. However, sulprostone, enprostil and GR63799 show a moderate 
degree 0fEP3-recept0r selectivity (Bunce et al” 1990); enprostil does however 
show considerable TP agonist potency. Recently, SC46275 has been described 
as a potent and highly selective agonist at EP3-recept0rs (Savage et al” 1993). 
Its potency, with an EC50 of 0.04 nM, is four times higher than that of 
sulprostone in inhibiting electrically induced twitch responses of the isolated 
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guinea pig vas deferens (EP3 preparation). It is completely inactive in the 
preparation of the circular muscle layer of guinea pig ileum (EP2) and it is 
extremely weak in the preparation of the longitudinal muscle layer of guinea 
pig ileum, producing only 33% of the maximal PGE2 effect at 30 i^M. The 
direct contractile actions of prostaglandins E are associated with the activation 
of both EPi- and EP3-like receptors on the longitudinal muscle of guinea pig 
ileum (Lawrence et al, 1992), thus the weak contractile effect induced by 
SC46275 on this preparation may not necessarily be mediated via E P ” 
receptors. There are no reports of any compounds with EP3-recept0r-bl0cking 
activity. 
EP4 -receptor antagonists 
The EP4-recept0r has not yet been well characterised. The identification of this 
receptor is mainly based on weak blockade of the PGE2 relaxant response by 
two TP-receptor-blockers, AH22921 and AH23848, with the latter having no 
antagonist activity at EPi-, EP2- and EP3-recept0rs (Coleman et aL, 1994a). 
While these two agents are tentatively listed as EP4-recept0r antagonists, there 
are no selective agonists for this receptor. 
FP-receptor agonists 
PGF20t itself is a potent FP-receptor agonist and also has some agonist activity 
at EP- and TP-receptors. A series of substituted 16-phenoxy analogues of 
PGF2a have been synthesised and evaluated; of them, fluprostenol and 
cloprostenol are very potent and particularly fluprostenol is also highly 
selective, being essentially inactive at DP-，EP-, IP- and TP-receptors (Welbum 
and Jones, 1978). Several compounds have been reported to antagonise 
PGF2a, but many such actions are mediated by prostanoid receptors other than 
the FP type. However, three compounds are believed to inhibit PGF2a effects 
on the preparations containing FP-receptors. K10136 (13,14-didehydro-20-
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methyl PGF2a) inhibits contractions of rat isolated uterine smooth muscle to 
PGF2a but not PGE2, acetylcholine, histamine or 5-HT (Coleman et al” 1990); 
both N,N-dimethylamino PGF2a and N,N-dimethylamido PGF2a exhibit 
specific prostanoid antagonist activity on gerbil colon (Maddox et al., 1978)， 
on which PGF2a and fluprostenol both exhibit high agonist potency. 
Controversially, aU three compounds appear to be agonists on dog and cat iris 
sphincter preparations (Coleman et al” 1990). Their antagonism to PGF2a may 
just indicate that the compounds can induce FP-receptor desensitisationAlown-
regulation, or alternatively it may reflect the existence of FP-receptor subtypes. 
IP-receptor agonists 
PGI2 itself is a very potent IP-receptor agonist and its selectivity for IP 
receptors is reasonable despite the fact that it also has some agonist activity at 
EPi- and TP-receptors. The major problem with this natural compound is that 
it is chemically and metabolically unstable. The chemical instability of PGI2 is 
due to hydration of the enol ether structure, with "internal catalysis" occurring 
due to the close proximity to its own carboxylic group. Carbacyclin, in which 
the enol ether oxygen in PGI2 is substituted with a methylene group, is more 
chemically stable but less potent than its parent compound PGI2. Iloprost 
(Buchmann et al” 1993), which is synthesised by further introduction of a 
single methyl group at C16 and an alkynic group at C18, is the first stable 
analogue of PGI2 with the same potency as the parent compound at inhibiting 
platelet aggregation and relaxing vascular smooth muscle. However, in 
addition to its potent H^-receptor agonist activity, iloprost also possesses potent, 
albeit partial, agonist activity at EPi-receptors, thereby mediating contraction 
of the guinea pig trachea, rat stomach fundus and bovine iris sphincter (Dong et 
aZ., 1986). Furthermore, the metabolic stability of iloprost is not high due to 
the rapid degradation of the upper side chain by P-oxidation; iloprost shows 
only about 20% bioavailability on oral application (Buchmann et al” 1993). 
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This metabolic pathway is completely blocked by the exchange of the P_ 
methylene group of the upper side chain by an oxygen atom. Cicaprost is the 
result of such exchange (Sturzebecher et al., 1986). Interestingly, this 
compound has little or no activity on EPi-receptors while it is slightly more 
potent than iloprost as an IP-receptor agonist (Dong et al” 1986). It is the most 
selective IP-receptor agonist to date (Table 1.6). 
One important factor in the development of PGI analogues has been the 
attempt to produce a compound that is able to distinguish platelet and vascular 
EP receptors. In particular, a compound that retains the platelet inhibitory effect 
but not the peripheral vasodilator activity has been sought. The powerful 
vascular effects of some analogues (flushing, hypotension, headache) have 
limited their clinical use as antithrombotics. However, the outcome of these 
studies has been disappointing. The only compound reported to discriminate 
between IP-receptors in platelets and vascular smooth muscle is (5Z)-
carbacyclin (Corsini et al； 1987), but it is not clear whether the difference 
reflects a true tissue variation or only a species variation in the IP receptor 
since the comparison was made between human platelets and rabbit mesenteric 
artery. Species variation in platelet IP-receptors (Armstrong et al.，1989) has 
been described in the Section on the distribution of ff-receptors; preparations 
from the same species are recommended to be used for the evaluation of IP-
receptor agonists (Merritt et al.’ 1991a;b). Recently, the behaviour of (5Z)-
carbacyclin as a partial agonist activating adenylate cyclase in the membranes 
of myocytes from rabbit mesenteric artery has been interpreted as an 
interaction of a full agonist with two receptors that mediate opposite effects 
(Rovati and Nicosia, 1994). 
Literestingly, some compounds having agonist activity at IP-receptors are 
structurally simple and very different to PGI2 and its close analogues. The first 
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Table 1.6 Specificity of prostacyclin analogues as agonists at IP- and EP-
receptors (Lawrence et al, 1992) 
PGI analogues IP EPi EP2 EP3 
Iloprost ++++ +++ (+) + 
CarbacycUn ++ ++ + 
PGI2 +++(+) + + + 
Cicaprost ++++ (+) (+) 0 
One + corresponds to a potency difference of approximately one order of 
magnitude. 
agent to be described was EP157 (Armstrong et al” 1986); it is a prostaglandin 
endoperoxide analogue and evolved from a programme to synthesise TP-
receptor antagonists. Other agents followed, including octimibate (Merritt et 
al, 1991a;b), BMY42393 (Seiler et al, 1994a;b) and BMY45778 (Meanwell et 
aZ, 1994) as representatives. These compounds do not possess a typical 
prostanoid ring system and have thus been named as non-prostanoid 
prostacyclin mimetics (Meanwell et al, 1994). BMY45778 is the most potent 
of the non-prostanoid PGI2 mimetics (Meanwell et al, 1994); its IC50 for 
inhibition of ADP-induced aggregation of human platelets in platelet-rich 
plasma is 27 nM and it binds to the human platelet IP-receptor with an IC50 for 
displacement of pH]iloprost binding of 7 nM; it has been suggested that 
BMY45778 is a partial agonist at the platelet receptor as it is unable to 
stimulate adenylate cyclase and GTPase to the same extent as iloprost. 
Octimibate also behaves as a partial agonist in activating adenylate cyclase in 
human lung membranes (Merritt et al” 1991b); its potencies for inhibition of 
platelet aggregation vary remarkably in different species, with the highest 
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potency in primates. Even with octimibate there is no indication of any 
difference between vascular and platelet IP-receptors within a species (Merritt 
et al” 1991a;b). Beyond these partial agonists, no IP-receptor antagonist has 
yet been identified. However, the partial agonists may be used as a starting 
point to develop a "pure" IP-receptor antagonist. 
TP-receptor agonists and antagonists 
The natural compound TXA2 is very labile with a half-Ufe in aqueous solution 
at 37 oC and pH 7.4 of approximately 32 seconds. Consequently it is thus 
virtually unusable for quantitative pharmacological studies. It has been well 
documented that PGH2 acts at TP-receptors, but it can spontaneously degrade 
or be enzymatically converted to other prostaglandins and its use as a TP 
agonist is therefore limited. However, some stable PGH2 analogues have been 
successfully synthesised. Of these, U46619 (1 la,9a-epoxymethano-PGH2) and 
U44069 (9a,l la-ep0xymethan0-PGH2) are well characterised; U46619 is 
more useful than U44069 since the latter is often a partial agonist (Jones et al” 
1982); it is widely used as a TP-receptor "standard agonist". U46619 has been 
shown to closely mimic the contractile actions of TXA2, being a potent and full 
contractile agonist on a wide range of TP-preparations, but is weak on 
preparations containing only other prostanoid receptor types (Jones et al” 
1982; Wilson and Jones, 1985; Coleman et aL, 1990). 
In 1982 Jones et al. examined a wide range of TP-receptor agonists and 
classified them into three groups based on their speed of onset and offset of 
action on vascular smooth muscle. The first group is rapid in onset and offset 
of action, more than one concentration-response curve being obtainable on a 
single preparation. The second group has slightly slower onset than the first 
one’ but only one cumulative concentration-response curve can be completed 
because of slow offset. The third group is characterised by very slow onset and 
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offset, and a complete concentration-response curve can not be established on a 
single preparation. U46619 is a representative for the first group; 9,11-azo 
PGH2 for the second group; EP011 for the third group. EP171, a \6-p-
fluorophenoxy-co-tetranor derivative of 9,11-endoxy-lOa-homo PGH2, is the 
most potent TP-receptor agonist reported to date, with a higher specificity than 
U46619 (Jones et al” 1989). Its action is not only slow in onset and offset, but 
is also slowly reversed by TP-receptor antagonists; these properties limit its 
usefuhiess for quantitative studies of TP-receptors. 
In the light of the potential clinical application of TP-receptor antagonists in 
diseases where TXA2 exerts a pathological action, many TP-receptor 
antagonists have been developed. They are a structurally diverse group, some 
more or less closely related to TXA2, some loosely prostanoid in nature, and 
others that are of quite different structural origin. While some TXA2 analogues, 
such as PTA2 and CTA2, are TP-receptor partial agonists, some prostanoid 
analogues such as EP 045 and EP092, which are less related to TXA2, behave 
as selective and competitive antagonists on both platelet and vascular smooth 
muscle TP-receptors (Armstrong et a/.,1985). GR32191 is another prostanoid 
analogue with a potent and specific TP receptor blocking activity (Lumley et 
a/., 1989). Its antagonism of U46619-induced contraction of vascular smooth 
muscle is competitive and surmountable, but it antagonises U46619-induced 
platelet aggregation in an non-competitive manner, with the slope of the Schild 
plot being significantly greater than unity. When the concentration is 10 - 30 
times higher than the estimated pA2 value, its antagonism of U46619-induced 
platelet aggregation is insurmountable. With pH]GR32191, however, it has 
been demonstrated that the interaction of this compound with human intact 
platelets is consistent with an action at a single class of binding site although 
the process is not simple (Armstrong et al” 1993). The dissociation of 
GR32191 from human platelet TP-receptors is slow, which might contribute to 
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its long lasting action and the apparent insurmountable property. In addition to 
such prostanoid TP-receptor antagonists, several interesting compounds which 
are structurally unrelated to prostaglandins have also been reported to possess 
TP-receptor blocking activity. Of them, B A Y u3405 has been well 






To characterise and classify a receptor, several interactive approaches 
including pharmacological, biochemical and molecular biological techniques 
may be adopted. The main criteria for qualification for the operational term 
"receptor" are the processes of recognition and transduction; a receptor must 
recognise a distinct chemical entity and translate information from that entity 
into a form which the cell can read; the readable signal generated can be a 
change in membrane permeability, activation of a guanine nucleotide 
regulatory protein, or an alteration in the transcription of DNA. Both 
recognition and transduction can be investigated by different pharmacological 
approaches. However, each method has its advantages and disadvantages. In 
general, multicellular systems such as isolated tissues have the advantages 
resulting from stimulus amplification mechanisms, because these allow the 
quantification of agonist efficacy. Also, they are better predictors of drug 
response in humans. However, the responses observed do not necessarily 
reflect the real interactions between receptors and drugs. It is therefore 
necessary to be careful in the choice of test systems and to control 
experimental conditions rigorously. Figure 2.1 shows some theoretical 
advantages of various test systems. 
Isolated tissues have been used as main test systems in our studies on 
prostanoid receptors while whole animal experiments also used as 
supplementary approaches. The test systems for EP-receptors include: 
contraction of guinea pig trachea (for EPi); relaxation of cat trachea and 
decrease in blood pressure (for EP2); inhibition of electrical field stimulation 
(EFS)-induced twitch of guinea pig vas deferens (for EP3). ff-receptor test 
systems include: inhibition of platelet aggregation; relaxation of vascular 
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smooth muscle; potentiation of submaximal EFS-induced twitch of guinea pig 
vas deferens; inhibition of spontaneous contraction of rat colon. 
Membrane Single Cell Isolated LiVivo In Vivo 
Fragments Cells Culture Tissues (tnpaired Reflexes) (Intact) 
Control Drug Concentration No Reflex Observed 
Ovemde Integrated 
i Z Z Z Z Z I Z Z Z Z I ^ Response 







Figure 2.1 Representation of different systems for the 
pharmacological study of drug receptors and some theoretical 
advantages of various test systems (adapted from Kenakin et al.，1992). 
I. Functional test systems 
In addition to details of commonly used bathing solutions, drugs, etc., some 
information on particular experimental protocols is given here in order to keep 
subsequent Methods/Results sections from becoming too long. 
Isolated preparations 
Isolated tissues were suspended in 10 ml organ baths containing either Krebs 
solution or Tyrode solution; the composition for Krebs is: NaCl 118，KC14.7, 
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Figure 2.2 Simplified diagram for the set-up of a vascular ring preparation and 
the measurement of changes in tension. 
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Tyrode consists of: NaCl 136, KC1 2.7，CaCl2 1.4, Mg Cl2 0.49, NaH2PO4 
0.32, NaHCO3 12 and glucose 5 mM ； the choice depended on the tissue used. 
The bathing solution was gassed with 95% 0^5% CO2, maintained at 37 ^C, 
and contained 1 pM indomethacin for all isolated preparations but guinea-pig 
vas deferens. Muscle tension was measured with Grass FT03 isometric 
transducers connected to a MacLab data acquisition system (ADInstruments 
Pty Ltd, AustraUa); data sampling rate depended on which type of activity was 
recorded: 40 per min for the tension of vascular and tracheal smooth muscle, 
240 per min for the spontaneous activity of the rat colon and 2400 per min for 
the EFS-induced twitch of guinea-pig vas deferens. Preparations were allowed 
at least 60 minutes to equilibrate. Washout of the bathing solution was by 
upward displacement and overflow. 
Guinea pig trachea and the measurement ofantagonist affinity constants 
Male guinea-pigs, weighing 400 - 450 g, were killed by cervical dislocation 
and exsanguination. Each preparation of tracheal ring contained two adjacent 
sections of cartilage and was suspended in Krebs solution. The spontaneous 
tone of the guinea pig trachea was abolished by inclusion of 1 ^M 
indomethacin and 20 nM atropine sulphate in the bathing solution; the resting 
tone was 0.5 g. 
On two preparations, contractile responses to two series of cumulative doses of 
17-phenyl-co-trinor PGE2 were obtained with an intervening wash period of 60 
-90 min. On a second two preparations, the antagonist potency of AH6809 was 
estimated by adding it 15 min before the second series of cumulative doses. 
Figure 2.3a shows log concentration-response curves for 17-phenyl-co-trinor 
PGE2 in the absence of and in the presence of 2 |xM AH6809. There was no 
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Figure 2.3 Guinea pig trachea: antagonism of 17-phenyl-o>trinor PGE2 (17-
E2)-induced contraction by AH6809. Upper panel: log concentration-response 
curves for 1 7 ¾ alone ( 0 ) and in the presence of 2 i^M AH6809 ( • ) ; lower 
panel: activation curve for 1 7 ¾ ( 0 ) (lower concentration scale) and 
inhibition curve for AH6809 on the precontraction by 1 7 ¾ ( • ) (upper 
concentration scale). Values are means of 2 experiments. 
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change in the log concentration-response curves to 17-phenyl-co-trinor PGE2 
on the control preparations. The estimation of pA2 value was based on the 
conventional Gaddum equation (Gaddum, 1957): 
log (dose-ratio - 1 ) = log [B] + pA2 
where dose-ratio was calculated by division of the EC50 value for 17-phenyl-o> 
trinor PGE2 in the presence of AH6809 by that in the absence of antagonist, 
and [B] is the molar concentration of antagonist. The dose-ratio was 63, giving 
a pA2 value of 7.4. 
The second and more recent method to estimate pA2 value was based on an 
EC50 for agonist derived from the agonist activation curve and an IC50 for the 
antagonist derived from the antagonist inhibition curve in the presence of a 
fixed agonist concentration [A]. The Cheng-Prusoff equation was then used: 
Kcp = IC50/([A]/EC50+l) 
where Kcp is the antagonist dissociation constant and can be simply converted 
to pA2. The EC50 for 17-phenyl-co-trinor PGE2 was 2.2 nM; 7.9 nM of 17-
phenyl-co-trinor PGE2 was chosed to induce a sustained contraction of the 
preparations; the IC50 for AH6809 was 162 nM (Figure 2.3b). The Kcp 
calculates as 35.8 nM, giving a pA2 value of 7.45. This result indicates that the 
Cheng-Prusoff method appears to be suitable for experiments on prostanoid 
receptor characterisation, although the applicability of this analysis is 
controversial (Lazareno et a/’ 1993). The main advantages of this method are 
that less agonist and less labour are needed. It is particularly useful when a 
higher concentration of agonist cannot be applied, due for example to the high 
cost of the agonist or its limited solubility in water. However, several points 
must be bome in mind: the fixed concentration of agonist should be high 
enough to minimise errors; non-competitive antagonists cannot be evaluated. 
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Figure 2.4 Cat isolated trachea: relaxation action of PGE2 on 
carbachol-induced tone. 
Cat trachea 
Sections of trachea were obtained from cats under pentobarbitone anaesthesia. 
Each preparation, consisting of two rings joined at their cartilaginous sections, 
was suspended under 0.5 g load in Krebs solution. Since the cat trachea 
preparation did not generate inherent tone, a contraction must be initiated in 
order to observe the relaxant effects of prostanoids. 1 - 2 |xM Carbachol could 
induce a stable submaximal contraction and then cumulative doses of 
prostanoids were added. Figure 2.4 shows an experimental record of the 
relaxant effect of PGE2 on the isolated cat trachea. 
The relaxation of the cat trachea is specifically mediated via EP2-recept0rs. It 
has been reported that the cat trachea preparation does not contract to 
prostanoids including thromboxane mimetics (Dong et al.，1986). Thus, cat 
trachea is a better preparation than guinea pig trachea in terms of testing EP2-
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Figure 2.5 Guinea pig vas deferens: maximal electrical field 
stimulation (EFS)-induced twitch response was inhibited by 
sulprostone (•，n = 2); submaximal EFS-induced twitch response was 
potentiated by cicaprost (0, n = 8). 
receptor agonist activity since the latter both relaxes and contracts (due to the 
presence of EPi-receptors) to PGE analogues. 
Guinea pig vas deferens 
Lengths (20 mm) of vas deferens were suspended in Krebs solution 
(indomethacin not included) between stainless steel electrodes. For the 
observation of EP3-recept0r-mediated inhibition of neurotransmission, the 
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Figure 2.6 Rabbit mesenteric artery: relaxation by cicaprost of a 
preparation precontracted with low ( 0 , 1 i^M) and high (•，10 i^M) 
concentrations of phenylephrine. Values are means of 2 experiments. 
parameters of electrical field stimulation were: 60 V’ 1 ms, 10 Hz for 1 s every 
32 s. Prostanoid doses were added cumulatively and the responses were taken 
as the percentage of the maximal twitch (0% corresponds to abolition of the 
twitch induced by electrical field stimulation). For the observation of IP 
receptor mediated potentiation of the twitch, the voltage of the electrical field 
stimulation was adjusted to give a twitch response 20% of the maximal 
twitch, other stimulation parameters were the same as above. Prostanoids were 
added cumulatively and the responses were calculated as a percentage of the 
submaximal twitch (200% corresponds to a twitch response which is double 62 
that of the control). The log concentration-response curves for sulprostone and 
cicaprost are shown in Figure 2.5. 
Vascular preparations 
Blood vessels were cleared of fat and adherent connective tissue and cut into 
rings 3 - 4 mm wide. Each ring was suspended between two Z-shaped hooks in 
Krebs solution under a tension of 1.3 g for artery or a tension of 0.8 g for vein. 
About 20 min after setting up in the organ bath, each preparation was exposed 
to a single dose of KC1 (40 mM); any preparations contracting weakly to KC1 
were abandoned. For investigation of the relaxant actions of prostanoids, the 
TP-receptor antagonist GR32191 (200 nM) or EP 169 (200 nM) was added 10 
min before addition of the contractile agent since some of prostanoids have 
been reported to have agonist activity at TP-receptors (Lawrence and Jones, 
1992; WilUams et al” 1994). Either phenylephrine or U46619 or KC1 can be 
used to precontract the preparation; however, their concentrations should be 
controlled to give responses between 50 and 70% of the maximal contraction. 
Figure 2.6 shows the relaxant effects of cicaprost on the rabbit mesenteric 
artery precontracted with 1 i^M (45%) and 10 i^M (100%) phenylephrine; both 
the sensitivity and the maximal response to cicaprost were reduced when it was 
operating against the higher contractile tone. Thus, 1 - 2 pM phenylephrine 
was generally used for precontraction. Responses were expressed as a 
percentage of the initial (control) contraction. 
For the contractile actions of prostanoids, either the absolute value of 
contractile force (i.e. grams) or percentage of the submaximaI contraction to 
100 nM U46619 was used to plot concentration-response curves. 
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Figure 2.7 Rat colon: measurement of spontaneous activity and 
calculation of responses to drugs 
Rat colon 
Male Sprague-Dawley rats, weighing 250 - 300 g, were fasted ovemight and 
kiUed by stunning and exsanguination. A 4 cm length of the ascending colon 
was removed and cleaned of mesenteric tissue. Two segments were cut and, 
without further dissection, were suspended in Krebs solution. An initial basal 
tension of 0.5 g was applied; on relaxation further tension was repeatedly 
applied until the basal tension remained steady at 0.3 g. Since there was 
apparent variation in the amplitude and the frequency of spontaneous activity 
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Figure 2.8 Spontaneous activity of the rat colon: comparison of two 
quantitative methods for the responses to drugs. Cicaprost (0.3 - 20 
nM) and sulprostone (1 nM) were used to generate the data, r = 
correlation coefficient. 
of colon between rats, a reliable quantitative method of assessing inhibition of 
spontaneous activity was needed. The MacLab data acquisition system can 
provide several measurements, such as single actual value, differentiated value, 
integration of the area under trace and mean value during a certain period. In 
our experiments, the area under trace or average contractile force during 2 
minutes before and after the drug addition was measured (Figure 2.7) and then 
converted into a percentage based on the formula given in Figure 2.7. The 
responses to inhibitors as the percentage change from the resting spontaneous 
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Figure 2.9 Experimental records showing the vasodepressor effects 
of intra-aortic injection of PGE2 and butaprost in cat in vivo. 
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activity were highly reproducible. Both integration of the area under trace and 
average contractile force could be used for this purpose and, actually, there was 
a good agreement between these two quantitative methods (Figure 2.8). 
However, the integration method absolutely depended upon the accuracy of 
area selection (duration) while such requirement for the average method was 
not so strict; time factor in the latter cancels out. For this practical reason, the 
average contractile force was used to quantify the drug responses in 
subsequent studies. 
The IP-receptor agonists, cicaprost and iloprost, could potently inhibit 
spontaneous contractions of the rat colon, but iloprost also increased basal 
tension of the preparation. This was due to the activation of EP-receptors on 
the rat colon since iloprost is also a potent agonist at EPi-receptors (Dong et 
al.’ 1986) and has moderate activity at EP3-recept0rs (Jones, unpublished 
observations). Cicaprost is the most selective IP receptor agonist of all PGI 
analogues evaluated, and thus it was chosen as the standard IP agonist. 
Experiments in vivo 
Cats weighing between 3.0 and 4.0 kg were anaesthetised by an intraperitoneal 
injection of pentobarbitone sodium (40 mg/kg). Subsequently, a constant level 
of anaesthesia was maintained by a continuous infusion of pentobarbitone 
sodium solution (10 mg/ml) into a femoral vein. The trachea was cannulated in 
order to maintain a clear airway. After the animal was heparinized, blood 
pressure was recorded using a pressure transducer attached to a catheter 
inserted into a common carotid artery. An arterial cannula was inserted through 
a femoral artery and the tip of the catheter was advanced to lie in the 
descending thoracic aorta; it was used for the injection of prostanoids. Figure 
2.9 shows an experimental record and the responses to PGE2 and butaprost. 
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Figure 2.10 Experimental records showing the inhibition by cicaprost 
of U46619-induced aggregation of human platelets in platelet-rich 
plasma (PRP). The three individual records have been superimposed. 
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Since the cardiovascular effects of an agonist in whole animals are subject to 
many factors such as activation of reflex nervous pathways and metabolism, 
and experimental conditions are sometimes difficult to optimise, whole animal 
preparations are less used than isolated tissues in receptor classification studies 
although the former can yield valuable information. 
Platelet-rich plasma preparations 
20 ml of blood was collected from a forearm vein of human volunteers who 
had not taken non-steroidal anti-inflammatory drugs for at least 7 days 
previously and mixed with 4 ml of acid-citrate-dextrose solution (ACD, 
containing disodium hydrogen citrate 2.0 g, and glucose 3.0 g, in 120 ml of 
water) to prevent clotting. The blood was centrifuged at 230 g for 15 min to 
sediment the red blood cells only. The platelet-rich plasma (PRP) was carefully 
aspirated into a second centrifuge tube. Human platelet aggregation was 
measured with a Chrono-log platelet aggregometer set at 37 ^C and 900 rpm. 
250 ,^1 of PRP was incubated with Krebs solution (200 i^l) and saline/drug 
solution (50 i^l) in siliconized cuvettes for 2 min. The aggregation was initiated 
by the addition of one of aggregating agents such as ADP, PAF or the TP-
receptor agonist U46619; the concentrations of aggregation inducers were 
chosen to give an aggregation response between 70 - 80% of the maximum for 
each agent. Cicaprost was used as the standard IP agonist and its typical 
inhibitory effects on the aggregation in PRP are shown in Figure 2.10. The 
potencies of all other agonists were compared with that of cicaprost. However, 
the results for lipophilic analogues should be interpreted with caution since 
their binding to plasma protein may obscure their true potencies. 
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n. Application of agonists and antagonists 
General concepts 
To characterise EP-receptors or to evaluate the potency of an agonist at an EP-
receptor, the natural product PGE2 and selective EP subtype receptor agonists 
such as 17-phenyl-co-trinor PGE2 for EPi, butaprost for EP2, and sulprostone 
for EP3 are used. Since PGI2 is unstable, only its stable analogues such as 
cicaprost have been used for characterisation of IP-receptors. 
Normally, a series of agonists are used and agonist potency ratios are 
calculated. The premise is that the potency of an agonist depends upon the drug 
factors of affinity and intrinsic efficacy and, also, the tissue factors of receptor 
density and the efficiency with which the receptors are coupled to effector 
mechanisms. In a given tissue in which two agonists are compared directly, the 
tissue factors cancel out, and the relative potency of agonists depends only 
upon the drug parameters efficacy and affinity. Under these circumstances, the 
relative potency of agonists becomes a receptor "fingerprint" which can be 
utilised in receptor classification. If a similarity of relative potencies for a 
series of agonists is found in two different test systems, it is suggested that both 
test systems contain the same type of receptor; conversely, dissimilar relative 
potencies suggest that the test systems contain different receptors. The activity 
of an agonist is affected by the density of receptors and the efficiency of 
stimulus-response coupling. The larger the number of receptors, and or the 
more efficient the coupling, the more agonist response should be produced. A 
low-efficacy agonist may produce direct responses only in highly efficiently 
coupled tissues and act as a "pure" antagonist in other systems. Therefore, a 
series of agonists must be used to factor out these tissue effects. Not all of these 
agonists will be selective (see Chapter 1 for the section of agonists), and 
therefore the identification of tissue preparations containing only one or two 
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types of prostanoid receptors becomes important. In fact，vascular EP-receptors 
were characterised by the use of a series of EP-receptor agonists in our studies. 
However, antagonists are normally more useful in receptor characterisation 
since antagonist potency is theoretically not tissue-dependent, or at least it is 
less susceptible to distortion by tissue-related factors than agonist potency. 
Furthermore, such distortions are more readily detected with antagonists than 
with agonists. This is because they are often reflected in deviations from the 
predicted behaviour for competitive antagonists, i.e. nonparallel shifts of the 
log concentration-response curves for agonists and Schild regressions which 
are not linear or not of unit slope. Such intemal checks on the validity of 
agonist potency ratios are not generally possible. A suggested standard for the 
proposal of a novel receptor subtype is for the pA2 of an antagonist (or ideally 
two compounds with chemicaUy diverse structures) to exhibit a difference of 1 
log unit or greater from its value(s) at known receptors (Kenakin et al., 1992). 
The subdivision of EP-receptors by the use of the antagonist, SC19220, is a 
good example. PGE2 contracts guinea pig trachea; but it also relaxes it，or both, 
depending on the conditions of experiments. SC19220 can specifically block 
the contractions induced by PGE2 but does not affect the relaxations, which 
clearly indicates that the contractions and relaxations are mediated via two 
different EP-receptors. It is now clear that they are EPi- and EP2-recept0rs 
respectively. As confirmed by the present experiments on guinea-pig trachea, 
17-phenyl-co-trinor PGE2 is a potent EPi agonist and AH6809 is a apparently 
competitive EPi antagonist since it shifts the agonist log dose-response curves 
in a parallel manner. However, the general picture of the development of 
prostanoid antagonists is not good, with the exception that a variety of potent 
antagonists are available for TP-receptors. The absence of the antagonists for 
FP-，ff-, EP2- and EP3-recept0rs has slowed down progress in characterisation 
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of these receptors. In spite of this, attempts have always been made to use 
antagonists in this study when applicable. 
Prostanoid agonists and antagonists used in this study 
Figures 2.11, 2.12 and 2.13 show some of the prostanoid agonists and 
antagonists used in this study. The following compounds were gifts: 
sulprostone, cicaprost and iloprost (Schering AG, Berlin, Germany); 
misoprostol (G.D. Searle, U.S.A.)； gemeprost (0N0 802; 16,16-dimethyl-
tranS'A^ PGEi methyl ester) (Rhone-Poulenc, UK); butaprost (Bayer, UK); 
TEI-9063 (17a,20-dimethyl-A6.6a.6a-carba PGIi) (Teijin, Japan); GR 32191 
(9a-(biphenylyl)methoxy-11 p-hydroxy-12P-(N-piperidinyl)-0>octanor-prost-
4Z-enoic acid); GR 63799X (13-oxa-13,14-dihydro-16-phenoxy-co-tetranor 
PGE2-4-(benzoylamino)phenyl ester); SC46275 (methyl 7-[2P-[6-(l-
cyclopenten-l-yl)-4i^-hydroxy-4-methyl-lE,5E-hexadienyl]-3a-hydroxy-5-
oxo-lR, la-cyclopentyl]-4Z-heptenoate)(Neurological Diseases Research, 
Searle Research and Development, Skokie, USA); AH 6809 (6-isopropoxy-9-
oxoxanthene-2-carboxylic acid) (Glaxo Group Research, U.K.). EP 169 (rac 
4a, 1 Oa-dihomo-9a, 11 a-ethano-C0-heptanor-3-oxa-13 -
phenylthiocarbamoylhydrazino prostanoic acid) was synthesised by Dr N.H. 
Wilson of the Department of Pharmacology, University of Edinburgh. PGE2, 
17-phenyl-co-trinor PGE2, PGF2a, fluprostenol (ICI 81008), 11-deoxy PGEi 
and U-46619 were purchased from Cayman Chemicals, U.S.A. 
Ethanolic stock solutions of the prostanoids (10_2 - 3 x 10_2 M) were stored at 
-2QoC and diluted with 0.9 w/v NaCl (saline) solution for use. All the agents 
are chemically stable in neutral or slightly acidic aqueous solution, and 
aqueous stock solutions were used over several weeks with storage at -20®C 
between daily use. Concentrated aqueous stock solutions ofU46619, AH6809 
and EP169 were prepared by addition of NaHCO3; these compounds show low 
i I 
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water solubility and it is essential to form the sodium salts. However, this was 
never done with PGE analogues since dehydration is rapid above pH 8 (Figure 
2.14). 
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Characterisation of vascular EP-receptors 
i 7 6 
Part 1: EP-receptors on the human isolated pulmonary artery 
Prostaglandins are produced by all uterine and intra-uterine tissues. PGE2 and 
PGF2a are thought to be the most important prostaglandins involved in uterine 
contractions. They are potent stimulants of the human uterus in vivo at any 
stage of pregnancy and are extensively used clinically for termination of 
pregnancy and induction of labour (Bygdeman, 1990). The main disadvantages 
of the natural compounds are a short half-life in vivo and the occurrence of 
gastrointestinal side-effects. PGE2 is rapidly metabolised in the body. The 
initial steps in the enzymatic degradation are the oxidation of the 15-hydroxy 
group to a keto group and the reduction of the 13,14-double bond (see the 
section on prostanoid metabolism in Chapter 1). The resulting 15-keto-13,14-
dihydro compound is essentially biologically inactive. A number of PGE 
analogues, which are not substrates for 15-hydroxy prostaglandin 
dehydrogenase and have a more specific effect towards uterine rather than 
gastrointestinal muscle, have been developed and some of them are in routine 
clinical use. They include sulprostone and gemeprost. Gemeprost can be 
administered vaginally and sulprostone can be used intramuscularly and 
intravenously. 
Human myometrial smooth muscle contracts or relaxes to prostanoids, 
depending on the type of prostanoid. It has been proposed that a heterogeneous 
population of prostanoid receptors are present in this tissue, with contraction 
being EP3-, FP- and TP-receptor-mediated and inhibition being EP2-, DP- and 
IP-receptor-mediated (Senior et al” 1993). The termination of pregnancy and 
induction of labour by PGE analogues appear to be due to the activation of 
I 
I EP3-recept0rs. The routinely used PGE analogues, sulprostone and gemeprost, 
! are EP3-recept0r agonists, with the former being particularly potent at this type 
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of receptor but having no activity at EP2-recept0rs (see the section of selective 
agonists in Chapter 1). 
Sulprostone has been recommended for arrest of atonic postpartum 
haemorrhage due to its excellent tolerance (see Hoppe, 1986). However the 
current study originates from observations made at the Prince of Wales 
Hospital, Shatin of severe cardiovascular side effects in two patients receiving 
intravenous sulprostone for postpartum haemorrhage. Systemic hypotension 
occurred in the first patient; this is unlikely to be due to peripheral 
vasodilatation since sulprostone is abnost devoid of EP2 relaxant activity on 
vascular smooth muscle (Coleman etal.，1987a,b; Lawrence and Jones, 1992). 
In the second patient a chest X-ray showed puhnonary congestion (Stock et al” 
1995). In this context, the advice sheet on sulprostone (trade name NaIador) 
contains the warning: "Do not inject as a bolus (the rapid occurrence of a high 
plasma level may lead to a critical increase of pressure in the pulmonary 
circulation)". The mechanism of the puhnonary hypertension is not known, but 
it could be due to constriction of puhnonary vessels by the sulprostone. We 
therefore decided in the first instance to determine whether sulprostone and 
other PGE analogues have constrictor actions on human isolated puhnonary 
vessels, and if so, to identify the prostanoid receptor involved. 
Methods and Materials 
Isolated pulmonary artery preparations 
Lung tissue was obtained from 15 Chinese patients undergoing resection of the 
lung at the Prince of Wales Hospital, Shatin. The patient data are shown in 
Table3.1.1. 
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Table 3.1.1 Patient data and the responses of the isolated pubnonary artery to a 
priming dose of PGE2 
Jatie^t Sex Age Disease State ^？： ^ ! ^ ^ 
Number ^ PGE2** 
1 F 43 haemoangioma 脊 
2 F 62 lung cancer f 
3 M 17 lung cancer • 
4 F 15 tuberculosis • 
5 M 74 lung cancer 舍 
6 M 66 lung cancer • 
7 M 76 lung cancer 舍 
8 M 65 lung cancer • 
9 M 13 lung cancer* • 
10 M 66 lung cancer 舍 
11 M 53 tuberculosis • 
12 F 46 lung cancer* 舍 
13 M 53 lung cancer 舍 
14 M 54 lung cancer • 
15 M 58 tuberculosis 舍 
* indicates metastatic to lung; **priming concentration = 50 nM,舍 indicates 




Within 10 - 20 min of lung removal, dissection of sections of puknonary lobar 
artery (3 - 5 mm in diameter) from macroscopically healthy areas of a lung 
lobe was commenced. The tissue Was placed in Krebs-Henseleit solution at 4 
- 1 0 oC for transport to the laboratory. Adherent tissue, especially that 
containing tar deposits, was carefully removed. Vessel rings (3 - 4 mm wide) 
were cut and suspended in 10 ml organ baths containing the Krebs-Henseleit 
solution aerated with 95% O2 / 5% CO2 and maintained at 37 ^C; indomethacin 
(1 ^lM) was present throughout the experiments. A description of the set-up of 
preparations and the recording system is given in Chapter 2. 
Experimental protocols 
Usually two pairs of matched preparations (i.e. from adjacent portions of an 
artery) were studied. About 20 min after setting up in the organ bath, each 
preparation was exposed to a single dose of KC1 (40 mM); about 5% of 
preparations gave weak contractions to KC1 and were abandoned. About 1 h 
after set-up a single priming dose of PGE2 (50 nM) was applied for 10 - 15 
min. 
Agonist potencies Initial experiments showed that sensitivity to the 
contractile actions of the PGE analogues decayed with time. However it was 
not certain that sensitivity would decay in all experiments. Consequently a 
cross-over design was used in which a cumulative dose-response curve for 
either PGE2 or sulprostone was obtained on one preparation concurrently with 
a cumulative dose-response curve for the test analogue on the matched 
preparation; these measurements took place between 1.5 and 3 h of setting up 
the preparations. Responses greater than 80% of the predicted maximum were 
not obtained in an attempt to reduce tachyphylaxis. After washout each 
analogue was then retested on the other preparation. 
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Relaxant effects A stable increase in tone of about 0.7 g was induced by 
phenylephrine (0.4 - 2 ^lM), U46619 (5 - 10 nM) or KC1 (40 mM). Responses 
to cumulative doses of prostanoids were then obtained 
Antagonist affinities In the first protocol, one of the matched preparations was 
treated with the antagonist and the other with vehicle for 15 min. Cumulative 
dose-response curves to the same agonist were then obtained on both 
preparations. In the second protocol stable submaximal responses to a 
particular agonist were obtained on two matched preparations. The antagonist 
was then added to one preparation and the vehicle to the other; the effects were 
observed for at least 15 min. All these measurements took place 1.5 - 3 h after 
setting up the preparations. 
Drugs 
The sources, chemical structures and solution preparation of prostanoid 
agonists and antagonists are given in Chapter 2. L-phenylephrine hydrochloride 
and indomethacin were purchased from Sigma Chemical Co., U.S.A. 
Results 
Initial observations on the human pulmonary artery 
The first three experiments showed that human puknonary artery preparations 
were contracted by both PGE2 and sulprostone (Figure 3.1.1a,b). Sensitivity 
was high initially with threshold effects observed at 1 - 5 and 0.2 - 0.5 nM 
respectively. However there was a variable loss of sensitivity to the two PGE 
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analogues throughout the experimental period (6 - 8 h). This took the form of 
both an increase in the EC50 value and a reduction in the maximum response. 
The phenomenon is iUustrated for the whole series of experiments in Figure 
3.1.2. Contractile responses to KC1, phenylephrine and the specific TP-
receptor agonist U46619 did not decay over the experimental period (data not 
shown). 
Contractile potencies ofPGE and PGF analogues 
Log concentration-response curves for PGE2 and six of its analogues, 
SC46275, sulprostone, misoprostol, gemeprost, GR63799X and 17-phenyl-0> 
trinor PGE2 are shown in Figure 3.1.3. Relative potencies, expressed as equi-
effective molar ratios (PGE2 = 1.0), are given in Table 3.1.2. The data derive 
only from the first cumulative sequence of doses on each preparation, since the 
variable loss of sensitivity meant that 'within preparations' estimates of relative 
potency (see Methods) were potentially subject to considerable error. 
SC46275 and sulprostone were the most potent prostanoids and their rates of 
onset and retum to resting tension on washout were always slower than those 
of the other prostanoids. 
PGF2a was only a weak agonist (Figure 3.1.3a) and the specific FP-receptor 




In a single experiment, the TP-receptor antagonist EP169 (200 nM) added 
before U46619 blocked its contractile response, with parallel displacement of 
the log concentration-response curve to the right, (dose ratio = 41) (Figure 
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Figure 3.1.1 Experimental records showing the contractile actions of PGE 
analogues on the human isolated puknonary artery where the priming dose of 
PGE2 (50 nM) induced contraction. Records (a) and (b) are from two different 
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Figure 3.1.2 Changes in sensitivity to the contractile actions of 
sulprostone ( • ) and PGE2(O) with time on the human isolated 
puknonary artery. The ordinate is the concentration of prostanoid required 
to increase the tension in the preparation by 200 mg, expressed on a log 
scale. The abscissa is the time period during which the log concentration-
response curve was obtained. 
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Figure 3.1.3 Log concentration-response curves for contractile effects of 
prostanoids on the human isolated pulmonary artery. Data were obtained 
between 1.5 and 3 h in experiments where the priming dose of PGE2 produced 
contraction. Vertical bars show s.e.mean. (a) sulprostone (•，n = 8), 
misoprostol (0 , n = 4)，GR63799X (•，n = 6), 17-phenyl-co-trinor PGE2 ( •， 
mean curve, n = 2), PGF2a (A, n = 3). (b) SC46275 (A, mean curve, n = 2), 
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Figure 3.1.4 Human pulmonary artery: effects of EP169 and AH6809 on 
contractile activity of U46619 or sulprostone. (a) Paired preparations were 
used, one for sulprostone ( 0 ) and U46619 ( • ) ’ and the other for these two 
prostanoids in the presence of EP169 (200 nM) (filled symbols) in a single 
experiment, (b) Sulprostone alone (0) and in the presence of AH6809 (5 |jM) 
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Figure 3.1.5 Experimental records showing that the TP-receptor antagonist, EP 
169，blocks the contractile action of U46619, but not that of sulprostone, on the 
human puhnonary artery. Records (a) and (b) are from matched preparations. Sul 
=sulprostone, W = wash. Concentrations are in nanomolar. 
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3.1.4a). Assuming reversible, competitive antagonism (Gaddum, 1957), a pA2 
value of 8.3 is obtained (single dose ratio estimate). The log concentration-
response curve to sulprostone was unaffected by this treatment (Figure 3.1.4a). 
Similarly in two experiments, a second TP antagonist GR32191 at 200 nM 
failed to affect sulprostone, but blocked U46619 contractions with dose ratios 
of 32 and 55，giving a mean pA2 value of 8.3. 
hi three separate experiments, EP169 (200 and 500 nM) and GR32191 (200 
nM) were added following establishment of submaximal responses to 
sulprostone (10 nM) and U46619 (2 - 10 nM). The antagonists abolished the 
U46619 response but had minimal or no effect on the sulprostone response; 
this is illustrated for EP169 in Figure 3.1.5. 
The interaction of sulprostone and the EPi-receptor antagonist AH6809 was 
investigated in a similar manner to that of the TP antagonists. At 5 p,M, 
AH6809 had no effect on the log concentration-response curve to sulprostone 
(n = 1) OFigure 3.1.4b) and did not relax preparations akeady contracted with a 
submaximal concentration of sulprostone (n = 2). The same stock solutions of 
AH6809 were effective in antagonising the EPi contractile actions of 17-
phenyl-co-trinor PGE2 and gemeprost on the guinea-pig isolated trachea (200 
nM EP169 present); with 2 \iM AH6809 dose ratios of 50 - 60 were obtained 
(n = 3). 
Relaxant actions ofprostanoids 
The two prostacyclin analogues cicaprost and TEI9063 potently inhibited 
agonist-induced tone on the pulmonary artery preparations (Figure 3.1.7a). 
Relaxant potencies against equi-effective concentrations of phenylephrine (1 -
2 l^M) and U46619 (5 - 10 nM) were similar: e.g. cicaprost IC50 = 2.6 士 0.5 
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nM (n = 4) and 2.5 士 0.5 nM (n = 3) respectively. However the maximum 
relaxation achieved against KC1 was only 65 - 85%; this is shown for TEI9063 
in an experiment in which the prostacyclin mimetics were particularly potent 
(Figure 3.1.7a). 
There was no evidence from the first 8 experiments that any of the PGE 
analogues examined were exerting a relaxant EP2 action. However we felt it 
was possible that a strong contractile EP action could mask a weak relaxant 
action. We therefore addressed this situation in the next 5 experiments by 
determining the effects of butaprost and 11-deoxy PGEi (both of which show 
moderate potency and selectivity for EP2-recept0rs) on phenylephrine-induced 
tone. In three of the experiments, PGE2 (50 nM priming dose) increased 
tension by about 0.5 g, as found previously. Butaprost had no effect on basal 
tone at 25 nM but gave slight relaxations (0.05 - 0.15 g) at 125 - 375 nM. 11-
Deoxy PGEi (30 - 450 nM) induced contraction, but its effects were variable 
(Figure 3.1.3b). After production of tone with phenylephrine, PGE2 gave 
additional contractions (Figure 3.1.1b). Butaprost inhibited tone although the 
sensitivity of this effect was low and varied to some degree. Relaxation was 
not seen at 25 nM; on the most sensitive preparation, the IC50 value was 350 
nM; on the least sensitive preparation 375 nM butaprost induced 20% 
relaxation. 11-Deoxy PGEi (30 - 450 nM) had essentially no effect on 
phenylephrine-induced tone in preparations that were more sensitive to 
butaprost, whereas in butaprost-insensitive preparations additional contractions 
were obtained ^ i^gure 3.1.7a). 
In the other two experiments a quite different picture was seen. PGE2 (50 nM 
priming dose), butaprost (125 nM) and 11-deoxy PGEi (30 and 150 nM) 
reduced the resting tone, an effect which was reversed on washing (Figure 
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Figure 3.1.6 Experimental records showing the relaxation by PGE analogues 
of the human isolated puhnonary artery where the priming dose of PGE2 (50 
nM) induced relaxation. W = wash; Phe = phenylephrine; EP169 is a 
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Figure 3.1.7 Relaxant effects of prostanoids against induced tone on human 
isolated puhnonary artery, (a) All preparations gave a contractile response to 
the PGE2 priming dose. Lower left: cicaprost against phenylephrine (•，n = 
4) and TEI9063 against phenylephrine (A), U46619 ( • ) and KC1 ( • ) in a 
single experiment. Upper right: 11-deoxy PGEi ( • ) and butaprost ( • ) 
against phenylephrine on two preparations (——， )in the same experiment; 
EP169 (200 nM) was present, (b) Single experiment in which the priming 
dose of PGE2 relaxed basal tone. PGE2 (0), 11-deoxy PGEi ( • ) and butaprost 




butaprost and 11-deoxy PGEi (Figures 3.1.6a,b and 3.1.7b). Butaprost was 
3.1 and 4.7 times and 11-deoxy PGEi 2.4 and 1.9 times less potent than PGE2. 
The presence of 200 nM EP169 had no effect on the response profiles. Di both 
these experiments sensitivity to sulprostone was low, with EC200mg values 
ranging from 32 - 130 nM early in the experiments. 
Discussion 
The studies demonstrate that PGE2 can either contract or relax the circular 
smooth muscle of human pubnonary artery preparations. In the majority of 
experiments the activity of the contractile system predominated, with SC46275 
and sulprostone being highly potent contractile agents and butaprost showing 
only weak relaxant activity. However in two experiments the balance was 
reversed; sulprostone was weak and butaprost showed greater relaxant potency. 
It must be emphasised that all our tissue came from patients with severe lung 
disease. Clearly there is a possibility that disease processes could have 
modified the contributions of the opposing receptor systems from those 
operative in normal lung tissue. However there is no obvious association 
between the in vitro profile obtained and the available patient data (Table 
3.1.1). 
The contractile PGE action is unlikely to be mediated by FP-receptors, since 
the potent and specific FP-receptor agonist fluprostenol (Crossley, 1975; 
Welbum and Jones, 1978) was inactive. Although PGF2a contracted the 
preparations, it achieves this by activation of TP-receptors (Norel et al” 1991). 
Activation of TP-receptors also seemed unlikely since sulprostone has only 
weak TP agonist activity on standard TP preparations such as rat aorta 
(Coleman et al.’ 1988). Two direct pieces of evidence support this view. First, 
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two potent and specific TP-receptor antagonists did not block the contractile 
action of sulprostone; EP169 has a pA2 range of 8.3 - 8.8 on standard TP 
preparations (excluding rabbit tissues which are relatively insensitive to TP 
antagonists) (Tymkewycz et al” 1991). GR32191 has been examined 
previously for block of U46619 on the human pulmonary artery (Lumley et al” 
1989); the reported pA2 of 8.2 is in agreement with observations in this study. 
Secondly, cross-tachyphylaxis between sulprostone and the TP-receptor 
agonist U46619 was not found. Indeed responses to KC1 and phenylephrine 
were also well maintained throughout the experimental period, thus indicating 
that the preparations were not generally deteriorating. In general, the agonist 
actions of PGE analogues are not prone to tachyphylaxis, and this applies to 
inhibitory (EP3) actions on the guinea-pig vas deferens (see later). However, it 
has been reported that two isoforms of the EP3-recept0r expressed in COS-1 
show different degrees of agonist-induced desensitisation; the EP3a-recept0r 
system undergoes short and long term desensitisation whereas the EP3p-
receptor is not readily desensitised (Sugimoto et al” 1993). 
The most probable mechanism underlying the potent contractile actions of 
PGE2 and its analogues is activation of EPi- and/or EP3-recept0rs. The EPi-
receptor can be excluded since the EPi antagonist AH6809 at 5 ^lM did not 
block the contractile action of sulprostone. The solution of AH6809 used in the 
studies showed the expected activity on the guinea-pig trachea. A dose ratio of 
55 at a concentration of 2 |iJM corresponds to a pA2 of 7.43. This is in good 
agreement with earlier estimates of the affinity of AH6809 on the guinea-pig 
trachea (pA2 = 7.35, Lawrence et al” 1992) and on the guinea-pig ileum (pA2 
=6.8, PGE2 as agonist, Coleman et al” 1985). 
Support for the presence of an EP3-recept0r subtype in the puhnonary artery 
derives from the measurements of the agonist potencies of the nine PGE 
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analogues examined (Table 3.1.2, Figure 3.1.8). In particular, sulprostone was 
found to be more potent than 17-phenyl-co-trinor PGE2. This is the situation 
on the guinea-pig vas deferens, the archetypal EP3 preparation, whereas the 17-
phenyl analogue is more potent on EPi preparations such as the guinea-pig 
trachea and ileum (Lawrence et al” 1992). Furthermore, SC46275, a highly 
potent and selective EP3-recept0r agonist (Savage et al” 1993)，was more 
potent than sulprostone, which is also consistent with its relative potency in the 
guinea-pig vas deferens. However it is necessary to emphasise that there is 
some discrepancy between relative agonist potencies obtained on the guinea-
pig vas deferens and those obtained on another EP3 system, namely inhibition 
of cyclic AMP accumulation in human washed platelets (Matthews and Jones, 
1993). The latter mechanism appears to be involved in the potentiating action 
of PGE analogues on platelet aggregation induced by ADP, PAF or U46619. 
bi particular GR63799X (Bunce et aL, 1990) was relatively less potent on the 
human platelet compared to the vas deferens. Similarly in the present 
experiments GR63799X is somewhat less potent than sulprostone and it has a 
potency on the puknonary artery which is less than would be predicted from its 
potency on the vas deferens (Figure 3.1.8). The special chemical structure of 
GR63799 (Figure 2.11) may be responsible for its lower potency on these 
preparations. It has a bulky upper side chain due to esterification of the 
carboxyl group by ;7-benzamid0phen0l. The big chain may interact with a 
binding point outside the normal agonist binding domain, which is present in 
one receptor not in the other, thereby causing a difference in binding 
characteristics. The amino acid sequence of an EP3-recept0r can be slightly 
different in different species or tissues and this subtle difference can alter the 
characteristics of the receptor. For example, when the arginine residue in the 
seventh transmembrane domain of EP3D-recept0r is mutated to the non-
charged glutamine, this receptor losses the ability to cause cAMP formation or 
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Figure 3.1.8 Correlation of agonist potencies of PGE analogues on the 
guinea-pig vas deferens (GPVD) and the human puknonary artery (HPA). 
Guinea-pig vas deferens data are from Lawrence et aL (1992) and Savage 
et al. (1993). Sul = sulprostone, Miso = misoprostol, Geme = gemeprost, 
17-Phe = 17-phenyl-a>-trinor PGE2,11-Deoxy = 11-deoxy PGEi. The line 
represents a reference for a ratio of 10 between values on the X and Y 
axes. 
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Of the other PGE analogues with potent contractile activity on the pulmonary 
artery, gemeprost (Cervagem) is used for induction of second trimester 
abortion and for cervical softening prior to surgical termination of first 
trimester pregnancy (Crowshaw, 1983; Cameron and Baird, 1984b; see 
Dollery, 1991). Like its close relative 16,16-dimethyl PGE2, it is a potent 
EP3-ag0nist on the guinea-pig vas deferens (Table 3.1.2) and a potent EPi-
receptor agonist on the guinea-pig trachea (EC50 = 3.8 nM, 200 nM EP169 
present, Chan, unpublished observations). Due to its unavailabiUty at the time, 
gemeprost was not tested on the human platelet cyclic AMP system. 
With respect to prostanoid-induced relaxation of the puhnonary artery, we have 
confirmed earlier reports (Hadhazy et al” 1985; Haye-Legrand et al” 1987) of 
the potent action of prostacyclin analogue cicaprost (see the section of IP-
receptor agonists in chapter 1). TEI9063, an isocarbacyclin analogue with 
potent inhibitory effects on human platelets (Negishi et al., 1991)，was also a 
potent relaxant agent. Since cicaprost is the most specific of the prostacyclin 
mimetics examined to date (Dong et al., 1986; Lawrence et aL, 1992)，we 
presume these agents are acting on IP-receptors in the puhnonary artery. 
On preparations where PGE2 was contractile, butaprost, a selective EP2 agonist 
(Gardiner et al.，1986)，produced relaxation at relatively high concentrations. 
This effect may be due to activation of EP2-recept0rs, but in view of the very 
high sensitivity of the artery preparations to prostacyclin mimetics, a 
contribution from IP-receptor activation cannot be ruled out. Stronger 
evidence for the presence of relaxant EP2-recept0rs was obtained in just two 
experiments. PGE2 inhibited phenylephrine-induced tone at concentrations of 
5 nM and above, and 11-deoxy PGEi and butaprost were only about 2 and 4 
times less potent. The variable activity of 11-deoxy PGEi appears to be due to 
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its ability to activate both contractile EP3 (Table 3.1.2) and relaxant EP2 
systems, coupled with differing sensitivities of the two systems in different 
preparations in the same experiment and in different experiments. In contrast, 
butaprost did not contract preparations which contracted well to PGE2 and 
sulprostone, since it is essentially devoid of EP3 agonist activity (Lawrence et 
al” 1992). 
There have been several reports of cardiovascular coUapse associated with the 
use of PGE2 for obstetric purposes (Cameron and Baird, 1984a; Kilpatrick and 
Thorbum, 1990). There have also been reports of myocardial infarction (Fliers 
et al” 1991) and of several deaths associated with the use of sulprostone, 
usually administered in combination with the progesterone antagonist 
mifepristone (Editorial, 1991). If pulmonary hypertension was a causative 
factor in these incidents, then the balance between EP2 dilator and EP3 
constrictor actions in the pulmonary circulation may have been weighted 
towards the latter. In terms of the receptor selectivity of the prostanoid, 
sulprostone does not have EP2 dilator activity. Misoprostol does however, and 
in combination with the progesterone antagonist mifepristone, is being strongly 
recommended for termination of early pregnancy (Peyron et al., 1993). In 
relation to the relative sensitivity of the contractile/relaxant systems in the lung 
vessels, it would be of great interest to measure this during pregnancy. 
However, from both ethical and logistical standpoints, this is unlikely to be 
possible. 
It is also possible that sulprostone has other cardiovascular actions which could 
accentuate the harmful effects of its direct puknonary vasoconstrictor action. 
Thus in preliminary experiments performed in our laboratory, sulprostone (0.1 
-1 \ig kg-l) induced a sustained rise in arterial blood pressure in the 
anaesthetised cat. An increase in cardiac output secondary to systemic 
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venoconstriction appears a likely mechanism, in view of our observation that 
sulprostone at concentrations of 10 nM and above contracted circular smooth 
muscle of the abdominal vena cava of the cat (see part 2 of this Chapter). 
Finally, it must be bome in mind that EP3-recept0r agonists may have two 
interactive and potentially dangerous actions in man, the pulmonary 
vasoconstrictor action described here and the ability to potentiate platelet 
aggregation investigated previously by Matthews and Jones (1993). 
99 
{ . 
Part 2: EP-receptors on the guinea-pig isolated aorta 
In the first part of this Chapter, the contractile actions of PGE analogues on 
human puhnonary arteries were described. This action, which is mediated 
through EP3-recept0rs, usually outweighed the EP2 relaxant system, but in 
some cases, the reverse was true. It is possible that this variation in the 
sensitivities of the contractile/relaxant systems is due to disease processes. 
Pathological influences can be largely excluded by the use of preparations of 
blood vessels from healthy laboratory animals. In fact, very few studies have 
been made of the vasoconstrictor actions of PGE analogues on such 
preparations. Smith and McGrath (1995) have reported that fetal rabbit ductus 
arterious has at least two contractile prostanoid receptors, a TP-receptor and an 
EP-receptor. However, they did not identify which subtype of EP-receptor is 
involved. On the basis of screening different vascular smooth muscle 
preparations for responsiveness to sulprostone (Table 3.2.1)，guinea pig 
isolated aorta was found to have a contractile EP-receptor. On this preparation, 
sulprostone induced contractions at nanomolar concentrations, which is in 
contrast to the reports by Eglen and Whiting (1988; 1989); they stated that this 
compound was inactive on guinea-pig aorta. My further studies indicate that 
the contractile effect of PGE analogues on this preparation is mediated via an 
EP3-recept0r, as is it on human pulmonary artery. However, guinea-pig aorta 
did not show the slow tachyphylaxis to PGE analogues typical of human 
pulmonary artery. It has been suggested that two isofomis of EP3-recept0r 
subtypes exist: one is desensitisation-resistant and the other is not (Sugimoto et 
al.’ 1993). There might be some subtle differences between the EP3-recept0r 
in human pulmonary artery and that in guinea-pig aorta. Furthermore, little 
information is available on the signal transducing mechanism for EP3-recept0rs 
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in vascular smooth muscle. This section will describe the characterisation of 
EP-receptors on guinea-pig aorta and the investigation of the possible 
mechanisms underlying the vasoconstrictor action. 
Table 3.2.1 Responsiveness of vascular smooth muscle preparations to 
sulprostone. 
Vascular preparation Contractile response to sulprostone 
Human puknonary artery +++ 
Pig puknonary artery •* 
Pig coronary artery -
Rabbit mesenteric artery _ 
Rat aorta -
Rat mesenteric artery • 
Rat puknonary artery _ 
Cat vena cava + 
Cat hepatic portal vein + 
Guinea-pig aorta +++ 
+++ : Threshold concentration of sulprostone is 0.3 - 1 nM; + : threshold 
concentration is 10 nM; - : no contraction was seen at 300 nM sulprostone. 
* Pig puknonary artery relaxed to sulprostone. 
Methods and Materials 
Male guinea-pigs, weighing 400 - 450 g, were killed by cervical dislocation 
and exsanguination. The caudal section of thoracic aorta was removed and 
cleared of fat and adherent connective tissue and cut into rings 3 mm wide. The 
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set-up of preparations and measurement of tension change were the same as 
described in Chapter 2 and the first part of this chapter. 
Drugs 
Cyclopiazonic acid (CPA), nifedipine and cadmium chloride (subsequently 
refered to as Cd2+) were purchased from Sigma Chemical Company; CPA was 
dissolved in DMSO (3.4 mg/ml), and nifedipine in ethanol (10 mM, stored in 
dark), and both were diluted with saline. Verapamil hydrochloride was 
obtained from Knoll AG, Germany; it was an injection solution (2.5 mg/ml) for 
human use and was diluted with saline. The chemical structures, sources and 
solution preparation of other agents are given in the preceding section and in 
Chapter 2. 
Results 
Responsiveness of different vascular smooth muscle preparations to 
sulprostone 
Table 3.2.1 shows the contractile responses of different vascular smooth 
muscle preparations to sulprostone; the concentrations of sulprostone ranged 
from 0.1 nM to 300 nM. The guinea-pig aorta was the most sensitive of all 
preparations tested, it was therefore chosen to do a detailed study (see below). 
The cat vena cava and hepatic portal vein also contracted to sulprostone (10 
nM and above). In two anaesthetised cats, sulprostone (0.1 - 1 \Jig kg]) induced 
a sustained rise in arterial blood pressure by 20 - 40 mmHg. This effect could 




Contractile responses ofthe guinea-pig aorta to U46619 
U46619 contracted preparations of guinea-pig aorta in a concentration-
dependent fashion with an EC50 of 8.6 土 0.9 nM (n = 6) (Figure 3.2.1a). The 
TP-receptor antagonist, GR32191 (5，20, 100 nM) caused concentration-
dependent rightward shifts of the dose-response curves for U46619 (Figure 
3.2.2a). By constructing a conventional Schild plot, a mean pA2 of 9.15 and 
slope of 1.06 (95% confidence limits = 0.76 - 1.36) were determined (Figure 
3.2.2b). An estimation of pA2 value for GR32191 was also made using the 
Cheng-Prusoff equation (see Chapter 2 for the equation and its applications). 
The EC50 for U46619 derived from the agonist activation curve was 8.3 nM 
and the IC50 for GR32191 derived from the antagonist inhibition curve against 
100 nM U46619 was 8.9 nM (Figure 3.2.3). The appropriate calculation gives a 
pA2 of 9.17，which is very close to that determined by Schild analysis. 
Contractile responses ofthe guinea-pig aorta to PGE analogues 
At a concentration of 100 nM, U46619 produced about 90% of maximal 
contraction (3 - 5 g), which quickly reversed to baseline on washout of the 
organ bath. A single dose of 100 nM U46619 was applied before testing of 
PGE analogues and the increase in contractile force used as a reference (i.e. 
100% contractile response). GR32191 (200 nM) was then present in all 
subsequent tests to block TP-receptor mediated contractions. As revealed in 
Figure 3.2.1c, 1 - 14 [iM acetylcholine did not relax a preparation denuded of 
endothelium, but this preparation still contracted well to sulprostone. The same 
experiment was repeated twice, with all showing that removal of endothelium 
did not significantly affect the sulprostone response. Subsequently, 
preparations were not deliberately denuded. However the endothelium on some 
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Figure 3.2.1 Guinea-pig aorta: experimental records showing contractile 
effects of prostanoids; (a) Cumulative sequence of U46619 doses, (b) 
Cumulative sequence of sulprostone doses in the presence of GR32191 (200 
nM) and AH6809 (5 |iM), (c) Lack of relaxant effect of acetylcholine (ACh) 
on a preparation denuded of endothelium; however sulprostone was still a 
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Figure 3.2.2a Guinea-pig aorta: log concentration response curves for U46619 
in the presence of 0 (0), 5 (•)，20 ( • ) and 100 (A) nM GR32191. Values are 
mean 土 s.e.mean from 4 preparations. Sigmoids were fitted using the curve 
fitter of SigmaPlot for a four parameter logistic function. Since the slopes of 
four curves fitted individually were not significantly different from one 
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Figure 3.2.2b Schild plot for the antagonism by GR32191 of the contractile 
action ofU46619 on guinea-pig aorta. Broken lines represent 95% confidence 
Hmits for the regression. 
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Figure 3.2.3 Log concentration-response curves for U46619 ( 0 ) as a 
constrictor of guinea-pig aorta and for GR32191 (參）as an inhibitor of 
100 nM U46619-induced contraction of guinea-pig aorta. Each point is 
the mean of 2 experiments. 
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Figure 3.2.5 Log concentration-response curves for contractile effects of 
sulprostone and gemeprost on guinea-pig aorta, (a) gemeprost, first sequence 
( 0 ) and second sequence ( • ) of doses; sulprostone (A) after gemeprost first 
sequence; phenylephrine ( • ) after two sequences of gemeprost (all single 
experiments), (b) sulprostone in the absence ( • ) and presence ( • ) of AH6809 
(5 i^M) (n = 3). GR32191 (200 nM) was present in both (a) and (b). 
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since on some preparations 1 i^M acetylcholine caused 70% relaxation, 
whereas on some it only relaxed by 15 - 20%. 
Each preparation was exposed to single cumulative sequences of doses of two 
different PGE analogues. Figure 3.2.4 shows the log concentration-response 
curves for the contractile effects of seven PGE analogues. SC46275, 
sulprostone, 17-phenyl-co-trinor PGE2 and GR63799 could each elicit a 
contractile response some 50% of the U46619 standard response. Jn contrast, 
log concentration-response curves for PGE2, misoprostol and gemeprost were 
shallower and tended to reach a plateau of 20 - 30% of the U46619 response. 
As will be seen later, this is almost certainly due to the occurrence of 
simultaneous relaxant actions. The testing of a second compound did not 
appear to be affected by the previous testing of any one of the PGE analogues, 
except in the case of gemeprost. Thus the contractile effect of sulprostone was 
markedly attenuated after the first cumulative exposure to gemeprost and 
washout (Figure 3.2.5a; compare to Figure 3.2.4). In addition, there was 
aknost no response to a second exposure to gemeprost, but phenylephrine (0.3 -
0.8 ^M) still contracted the preparation (Figure 3.2.5a). As a consequence of 
this, only the first exposures to gemeprost were used to construct its log 
concentration-response curve. 
Sulprostone was used for further subsequent experiments since it had no 
obvious relaxant activity. The EPi-receptor antagonist, AH6809, at 5 [iM did 
not attenuate sulprostone responses (Figure 3.2.5b). The slight increase in 
sensitivity to sulprostone in the presence of AH6809 was very similar to that of 
sulprostone alone used in the second series of doses. In Figure 3.2.5b, the 
concentration-response curve for sulprostone without AH6809 was obtained 
from the first sequence of doses while the curve for sulprostone in the presence 
of AH6809 was derived from the second sequence of additions. Thus, 5 iiM 
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AH6809 neither antagonised nor potentiated sulprostone responses on the 
preparations of guinea pig isolated aorta. 
Relaxant responses 
As mentioned above, the log concentration-response curves for PGE2, 
misoprostol and gemeprost were shallow and sometimes bell-shaped; it 
appeared that the actual contractile effects were attenuated by opposing effects. 
The selective EP2-recept0r agonist, butaprost, consistently relaxed preparations 
precontracted with phenylephrine (1 i^M) in a concentration-dependent manner 
(Figure 3.2.6a)，with an IC50 of 170 nM. Other PGE analogues with EP2 
agonist activity, such as PGE2 and misoprostol were also tested for relaxant 
activity. These prostanoids only induced a further contraction on the 
preparations akeady contracted with phenylephrine. Against sulprostone (300 
nM)-induced contraction they produced variable relaxation (Figures 3.2.6a and 
b). Thus, it was impossible to compare their relaxant potencies with that of 
butaprost. 
Preparations precontracted with phenylephrine (1 - 2 ^M) also relaxed to the 
ff-receptor agonists, cicaprost and iloprost (Figure 3.2.7); the IC50 values for 
cicaprost and iloprost were 2.6 and 6 nM respectively. The removal of 
endothelium or pretreatment with glibenclamide (200 nM) did not affect the 
responses to cicaprost or to butaprost. 
111 
a 1 2 5 ^ 
100 < ^ 
I ” - ^ ^ 
1 s � - 5 ¾ 
# 2 5 - \ 
� - ^ 
- 2 5 -
I 1 1 1 1 1 
- 1 0 - 9 - 8 -7 - 6 - 5 
log [prostanoid] (M) 
b 125^ A 
i : — f — 
I 50- \ \ 
^ 2 5 - \ ^ \ 
0 -
- 2 5 -
I 1 1 1 1 1 
- 1 0 - 9 - 8 -7 - 6 - 5 
log [prostanoid] (M) 
Figure 3.2.6 Guinea-pig aorta: log concentration-response curves for relaxant 
effects of PGE analogues, (a) Butaprost ( • ) , precontracted with 1 |xM 
phenylephrine (n = 5); misoprostol ( • , • ) ’ precontracted with 300 nM 
sulprostone (two separate experiments), (b) PGE2 ( • ’ 0 , •)，precontracted 
with 300 nM sulprostone (three separate experiments). 
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Figure 3.2.7 Log concentration-response curves for relaxation of the 
phenylephrine-contracted guinea-pig aorta by cicaprost ( • ) and iloprost (•) . 
GR32191 (200 nM) was present. Each point is the mean of 4 experiments; 
vertical bars show s.e.mean. 
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Dependence of the vasoconstrictor actions of sulprostone and U46619 on 
extracellular Cci2+ 
In two initial experiments, the contractile effect of sulprostone (10 nM) was 
abolished by removal of extracellular Ca^+ (Ca2+-free Krebs plus 20 mM 
EDTA) while 10% of the response to U46619 (20 nM) remained under the 
same conditions; the depressed responses were recovered when the bath 
solution was changed back to normal Krebs. Cumulative log concentration-
response curves for sulprostone and U46619 in this Ca2+-free condition were 
constructed in another three experiments and are shown in Figures 3.2.9a and 
b; no contraction to sulprostone could be observed, and the basal tone drifted 
down with time. Single high concentrations of sulprostone (300 nM) and 
phenylephrine (10 i^M) were also tested under the same condition; only 
minimal tonic contractions (< 5%) were induced by these two agents. The 
inability of phenylephrine to elicit an appropriately sized phasic contraction 
implied that 20 mM EDTA might non-specifically depress the contractile 
system. Indeed, when the concentration of EDTA was reduced to 2 mM, a 
phasic contraction to phenylephrine was seen. However, neither sulprostone 
(300 nM) nor U46619 (300 nM) produced an obvious phasic contraction, rather 
a tonic contraction of small size. During the Ca2+-free period, addition of 2.5 
mM CaCl2 into the bath rapidly restored responses to sulprostone and U46619. 
In another two experiments the Ca2+-free medium was prepared with Ca2+-free 
Krebs plus 50 \iM EGTA, as described by Low et a/.(1991). A profile similar 
to that obtained in the 2 mM EDTA experiments was observed, and again 
addition of 2.5 mM CaCl2 into the bath restored the responses (Figure 3.2.12) 
The inorganic Ca^+ channel blocker, Cd2+，at 500 i^M significantly attenuated 
the responses to sulprostone and U46619 (Figures 3.2.8 and 3.2.9). The block 
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was more pronounced for sulprostone (90%) than for U46619 (30%). 
Nifedipine, an L-type Ca2+ channel blocker of the dihydropyridine class, 
consistently inhibited the tone induced by KC1 (40 mM) with an IC50 of 15 
nM. However, its effects on sulprostone contractions were complex. When the 
contraction induced by 10 nM sulprostone was less than 1.2 g, nifedipine did 
not produce any relaxation; but when the contraction was biphasic and larger 
than 1.2 g, this blocker could relax the tone by about 60% (Figure 3.2.10a). 
Verapamil, an L-type Ca2+ channel blocker of the benzothiazepine class, was 
also tested. As expected, verapamil inhibited KC1 (40 mM) contraction (IC50 = 
400 nM). Three of four preparations precontracted with 10 nM sulprostone did 
not relax to this blocker (Figure 3.2.10b); on a fourth preparation a partial 
relaxation was observed (Figure 3.2.10b). 
The effects of cyclopiazonic acid (CPA), a sarcoplasmic reticulum Ca2+ pump 
inhibitor, were also investigated. After removal of extracellular Ca2+, the first 
response to a maximal concentration (10 [iM) of phenylephrine was reduced by 
60% compared to control. Following washout and maintenance of Ca2+-free 
conditions, the second response to phenylephrine was further depressed and 
lacked the initial phasic component (Figure 3.2.11a). In the presence of CPA 
(10 ^iM), the first and second responses to phenylephrine in Ca2+-free medium 
were both minimal (Figure 3.2.11b). Interestingly, when the same 
concentration of CPA was applied after the intemaI Ca2+ had been released by 
maximal phenylephrine (10 i^M), it did not reduce but potentiated contractions 
induced by sulprostone or U46619 (Figures 3.2.8c and 3.2.9); the potentiation 
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Figure 3.2.8 Experimental records showing the contractile effects of (a) 
sulprostone and (b) U46619 alone and in the presence of 500 i^M cadmium 
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Figure 3.2.9 Guinea pig aorta: log concentration-response curves for (a) 
sulprostone and (b) U46619 acting alone in normal Krebs ( 0 , n = 6); in the 
presence of 500 [iM cadmium (•，n = 3); or in the presence of 10 ^iM 
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Figure 3.2.10 Guinea-pig aorta: log concentration-response curves for 
relaxant effects ofL-type Ca2+ channel blockers, (a) Nifedipine on contractions 
to 40 mM KC1 (•，n = 6), 1 \ iM phenylephrine (A, n = 3), and 10 nM 
sulprostone in preparations having normal sensitivity ( 0 , n = 3) and high 
sensitivity to sulprostone (參，n = 3). (b) Verapamil on contractions to 40 mM 
KC1 ( • , n = 4), and 10 nM sulprostone in preparations having normal 
sensitivity ( 0 , n = 3) and high sensitivity to sulprostone (參，n = 1). 
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Figure 3.2.11 Experimental records showing the inhibition by cyclopiazonic acid 
(CPA) of the repletion of a phenylephrine (PE)-sensitive intemal Ca】+ store in the 
guinea pig aorta. 10 [ iM PE maximally contracted the preparations by inducing Ca〗+ 
influx and intemal Ca〗+ release. In Ca^^-free Krebs (plus EGTA 50 p,M), PE could 
only cause intemal Ca〗+ release (upper tracing), which was markedly attenuated by 
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Figure 3.2.12 Guinea-pig aorta: experimental record showing the dependence of the 
vasoconstrictor action on extracellular Ca〗+. The experiment was performed in 
Ca2+-free Krebs (plus EGTA 50 H.M); the preparation was the same as that in Figure 
3.2.11b; the depletion of phenylephrine-sensitive internal Ca〗+ store was done by 
treatment with cyclopiazonic acid 10 | jM and phenylephrine 10 | iM (see Figure 
3.2.11b) before the tests. Phe = phenylephrine; Sul = sulprostone; W = wash. 
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Discussion 
The previous report by Eglen and Whiting (1988) that TP-receptors mediate 
contraction of the guinea-pig aorta has been confirmed in this study. The 
conclusive evidence came from the antagonism by GR32191, a potent and 
specific TP-receptor blocking drug. The GR32191 block was surmountable and 
the slope of the Schild regression was not significantly different from 1. This is 
consistent with competitive antagonism and is in agreement with the reports by 
Lumley et a/.(1989) and Tymkemycz et aL{\99\). It has been reported that the 
potencies of TP-receptor antagonists vary between different TP preparations 
(Tymkemycz et al” 1991). For example, the pA2 for GR32191 in most smooth 
muscle preparations ranges from 8.4 to 9.4. However on rabbit aorta, which in 
common with other rabbit tissues is relatively insensitive to TP antagonists, it 
is 7.2. I t was necessary to determine the pA2 value in order to choose an 
appropriate concentration for blocking TP-receptors. The pA2 value of 9.17 
obtained for guinea-pig aorta obviously falls within the higher affinity range. 
200 nM of GR32191 was used in our experiments, at which a dose ratio of 280 
would be expected. This should be sufficient to remove all potential TP 
receptor agonist activity for PGE and PGI compounds tested in this study. 
Some PGE analogues, for example 16,16-dimethyl PGE2, show moderate TP 
agonist potency (Jones et al., 1982); the use of these agents was deliberately 
avoided in this study. 
hi contrast to the observations of Eglen and Whiting (1988; 1989), PGE2 and a 
number of EP3-recept0r agonists can potently contract guinea pig aortic rings. 
It is felt that this vasoconstrictor action of PGE analogues is mediated via EP3-
receptors for the following reasons. Firstly, both SC46275 and sulprostone are 
very potent contractile agents; the former, a highly potent and selective EP3-
receptor agonist (Savage et al” 1993), is the most potent of seven PGE 
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analogues tested. Both analogues slowly reach a stable level of contraction and 
slowly retum to resting tension on washout. This may reflect their high 
affinities for the EP3-recept0r rather than their lipid solubiUties. Indeed, being 
PGE analogues they are relatively water soluble compounds. In a study of a 
large number of TP-receptor agonists, some of which were highly Upid soluble, 
slow onset/offset on smooth muscle was associated more with potency than 
with Upid solubiUty (Jones et al” 1982). Colquhoun (1973) has demonstrated 
how specific receptor binding of a high affinity ligand in a closely-packed 
cellular system can restrict diffusion of agonist through the extraceUular space, 
such that receptors in the centre of the tissue only "see" the agonist after 
prolonged contact of the agonist with the tissue. The slowing effect wi l l be 
greater as the density of receptors on the cell surface increases. 
Other PGE analogues such as PGE2, misoprostol and gemeprost are also potent 
contractile agents, but since the preparation also contains a relaxant EP-
receptor, their contractile effects are almost certainly attenuated by their 
simultaneous relaxant actions, and this co-existence of two EP-receptor 
subtypes may affect the agonist potency ranking. However an estimation of 
agonist potencies at the level of 10% of the 100 nM U46619 response may 
minimise the influence from the relaxant system. A comparison of IC50 values 
for PGE analogues on the guinea-pig vas deferens, a standard EP3-recept0r 
preparation, with EC(io%) values on the aorta from the present study is shown 
in Figure 3.2.13a. Generally, the correlation between them is good, except in 
the case of GR63799 and 17-phenyl-co-trinor PGE2. On the aorta GR63799 is 
relatively less potent compared to the vas deferens, which was also observed 
on the human pulmonary artery. Thus，the profiles of GR63799 on these two 
vascular preparations are similar (Figure 3.2.13b). In contrast, 17-phenyl-co-
txinor PGE2 is somewhat more potent on the aorta compared to the vas 
deferens and the human pulmonary artery (Figures 3.2.13a and b). It was 
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Figure 3.2.13 Correlation of potencies of PGE analogues on the guinea-pig 
aorta (GPA) and vas deferens (GPVD) and the human pulmonary artery 
(HPA). Sul = sulprostone, Miso = misoprostol, Geme = gemeprost, 17-Phe E = 
17-phenyl-co-trinor PGE2. The lines represent references for a ratio of 10 
(upper panel) and 1 (lower panel) between values on axes X and Y. 
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necessary to investigate the possible involvement of EPi-receptors since 17-
phenyl-co-trinor PGE2 has potent agonist activity at EPi-receptors. This 
possibility is minor since the EPi antagonist, AH6809, at 5 p M did not block 
the contractile action of sulprostone, whereas at 2 ^ M of the same stock 
solution a dose ratio of 63 was obtained against 17-phenyl-co-trinor PGE2 
contractions on the guinea-pig trachea, an EPi preparation. Both sulprostone 
and 17-phenyl-co-trinor PGE2 have been documented to be potent EPi and EP3 
agonists; either of them should selectively act at EP3-recept0rs when combined 
with an EPi antagonist. 
Although PGE2, misoprostol and gemeprost contracted the guinea-pig aorta 
with similar profiles, gemeprost differed from the other EP3 agonists in that its 
retum to baseline tension was slow and first exposure (and washout) depressed 
subsequent respones to itself and the other EP3 agonists. Several explanations 
are possible. Firstly gemeprost may desensitise the EP3-recept0r system. 
However, there was no obvious fade of gemeprost contractions, which might 
be expected i f this mechanism was operating. Secondly gemeprost may exert a 
long lasting relaxant effect through the EP2-recept0r system. Preliminary 
experiments have shown that gemeprost does have a vasodepressor action in 
the cat and relaxes isolated cat trachea (IC50 « 70 nM), both consistent with an 
EP2 agonist action. However, at a time when sulprostone contractions are 
depressed, responses to the cci adrenoceptor agonist phenylephrine are still 
present. 
Returning to a desensitizing action at the EP3-recept0r, some preliminary 
experiments were conducted on human platelets, which contain an EP3-
receptor that induces enhancement of aggregation. It was observed that 
gemeprost at 135 nM did not enhance the aggregation of human platelets, but 
significantly attenuated sulprostone-induced potentiation of aggregation. 
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However’ at this concentration it also showed a moderate inhibition of 
aggregation induced by PAF or U46619. Thus it is difficult to judge i f the 
antagonism of sulprostone-enhanced aggregation is at EP3 receptor level orjust 
due to its functional inhibition through other receptors. 
Two types of relaxant prostanoid receptors are present on the guinea pig aorta: 
EP2 and IP. The EP2-recept0r specific agonist, butaprost, relaxes the 
preparation precontracted by phenylephrine; its potency (IC50 = 170 nM) is 
within the range for EP2-recept0rs. The simultaneous activation of EP2- and 
EP3-recept0rs by PGE2 and misoprostol makes it impossible to compare their 
relaxant potencies; but these two compounds did relax some of preparations 
precontracted with sulprostone. Support for the presence of IP-receptors 
comes from the high potencies of cicaprost and iloprost; cicaprost is the most 
specific of the IP-receptor agonists. The relative potency order of these two 
compounds on guinea pig aorta is also close to that on other IP preparations, 
for example human platelets (Armstrong et al” 1989). 
Thus, generally, the picture of prostanoid receptors on guinea pig aorta is 
similar to that on human puhnonary artery; that is, TP-, EP3-, EP2-, and IP-
receptors are present on these two vascular preparations. However, some 
differences do exist. Firstly, the balance between EP3- and EP2-recept0r 
mediated effects on guinea pig aorta is relatively more constant than that on 
human pulmonary artery; in the former case EP3-recept0rs are always 
predominant whereas in the latter about 15% of preparations can show a 
reversed pattem. It is possible that the disease processes in patients alter the 
balance. On this basis，guinea pig aorta is a better preparation than human 
pulmonary artery in characterising vascular EP3-recept0rs and in evaluation of 
PGE analogues. Secondly, the preparations of guinea pig aorta are 
desensitisation-resistant to EP3-recept0r agonists whereas human puhnonary 
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artery is not. It has been reported that two isoforais of the EP3-recept0r behave 
differently in respect of agonist-induced desensitisation; EP3a undergoes short 
and long term desensitisation whereas EP3p is not desensitised either in the 
short or long term (Sugimoto et aL, 1993). Thus, there might be a subtle 
difference between these two vascular EP3-recept0rs. It is too early to say that 
the human pulmonary artery EP3-recept0r is EP3a and guinea pig aorta EP3-
receptor is EP3p, but i t would be interesting to look at them by molecular 
biological approaches. 
As far as signal transduction for the EP3-recept0r is concerned, it has been 
generally thought that this receptor may cause either inhibition of adenylate 
cyclase or stimulation of phosphoinositide metabolism. In the experiments 
described here, it appears that the activation of EP3-recept0rs causes Ca2+ 
influx; two pieces of evidence support this supposition. Firstly, sulprostone-
induced contraction is highly dependent on the presence of extracellular Ca2+, 
and secondly, the non-specific Ca2+ channel blocker, Cd2+, markedly inhibits 
sulprostone contractions. However, the contribution of L-type (voltage-
dependent) Ca2+ channels to sulprostone contractions appeared to vary 
between preparations. In most preparations nifedipine had no inhibitory effect; 
in those where it did, a secondary contractile phase to sulprostone was seen, 
associated with an enhanced response to a fixed concentration of sulprostone. 
The most likely explanation for this difference is that Ca^+ mainly enters the 
cell through a nifedipine-insensitive Ca2+ channel, and in some cases this is 
accompanied by sufficient membrane depolarisation to cause opening of 
voltage-dependent, nifedipine-sensitive Ca2+ channels. The nifedipine-
insensitive channels may be non-specific cation channels, which have been 
found to be activated by noradrenaline and ATP in the rabbit ear artery and 
portal vein (see Kuriyama et al” 1995 for review). 
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At the beginning of these experiments, it was imagined that, by measuring the 
degree of suppression of sulprostone contractions by cyclopiazonic acid, an 
estimation of the contribution of Ca2+ release from intracellular stores to the 
contractile action of sulprostone would be obtained. However, the situation is 
more complex than this. CPA certainly appeared to deplete the sarcoplasmic 
reticulum Ca2+ store in the aorta as shown by its suppression of the contractile 
response, particularly the initial transient component, to phenylephrine in Ca-
free Krebs solution. In contrast, sulprostone responses were enhanced by CPA; 
a number of explanations for this finding may be advanced. Firstly, Ca2+ 
leaking from the internal stores after the inhibition of sarcoplasmic reticulum 
Ca2+ pump by CPA is probably removed from the cell by a plasma membrane 
pump. Sulprostone may inhibit this process. Secondly, according to the 
capacitative model proposed by Putney (1986)，refilling of internal Ca2+ stores 
is achieved by Ca2+ influx through the plasma membrane. It is possible that in 
some way sulprostone interacts with this Ca^+ influx to enhance its contractile 
activity. Thirdly, the increase in cytoplasmic Ca2+ by sulprostone in normal 
organ bath conditions is buffered by uptake of Ca2+ into sarcoplasmic 
reticulum; after CPA treatment, this Ca2+-buffering is lost and therefore the 
response to sulprostone is enhanced. This Ca2+-buffering mechanism has been 
used to interpret CPA potentiation of responses to 5-HT and KC1 in rat aorta 
and small mesenteric artery (Shima and Blaustein, 1992). Clearly, the only 
situation where the use of CPA would give an unequivocal answer would be i f 
the agonist acted entirely through the release of internal Ca2+; CPA should then 
abolish the contraction. 
Although the lack of contractile activity by sulprostone in Ca-free bathing fluid 
would appear to indicate that the PLC/interaal Ca2+ release system is not 
involved, this may not be so. Lum Min and Tabrizchi (1995) have shown that 
in the rat caudal artery phenylephrine failed to induce phosphatidylinositol (PI) 
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hydrolysis and contraction when Ca2+ was omitted from the bathing fluid. 
Whether extracellular Ca2+ is required to enter the cell is not clear. It is 
possible that the plasma membrane receptor/G-protein/PLC system only 
operates i f a contiguous extemal site is occupied by Ca2+. In this case the 
inhibitory action of Cd2+ may involve competition for Ca2+ binding rather than 
block of a Ca2+ channel. 
Activation of TP-receptors on guinea-pig aorta also appears to mediate Ca2+ 
influx, but the dependence upon extracellular Ca2+ is less than that of 
sulprostone; the TP-receptor-mediated contraction is not abolished either by 
removal of extracellular Ca2+ or by Cd2+, suggesting that both Csfl+ influx and 
intemal calcium mobilisation are involved. This is in agreement with the 
observation on the isolated rabbit aorta, where U44069, a TP-receptor agonist 
similar to U46619, activates a Ca2+ influx pathway, and simultaneously 
releases a fraction of the intracellular Ca2+ pool that is sensitive to 
noradrenaline (Loutzenhiser, etal” 1981). 
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Chapter 4 
Neuronal IP-receptors in the rat colon 
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Prostacyclin inhibits the spontaneous contractile activity and relaxes the tone of 
the rat colon; other products of prostaglandin H2 (PGH2) metabolism, such as 
PGE2 and PGF2a, are contractile. This distinction was particularly useful in the 
early identification of prostacyclin by superfusion bioassay (Gryglewski et al.’ 
1976). The rat colon preparation was also useful in the investigations of the 
agonist specificity of some of the first stable analogues of prostacyclin (Dong 
et al” 1986). Jones' group in Edinburgh showed that iloprost and 
isocarbacyclin activate both IP- and EP-receptors to produce a combination of 
inhibitory and excitatory actions on the colon. On the other hand, cicaprost 
(Sturzebecher et al.’ 1986) invariably inhibited the spontaneous activity of the 
colon and, using data from other smooth muscle preparations, they proposed it 
to be a highly specific IP-receptor agonist (Dong et al., 1986; Lawrence et aL, 
1992). 
However, at the start of my doctoral study, the mechanism of the inhibitory 
effects of prostacyclin on the rat colon was not known; was it through a direct 
interaction with IP-receptors on the smooth muscle cell membrane or through a 
neuronal mechanism? The impetus to investigate its mechanism came from 
my observation that cicaprost did not relax colon preparations contracted 
submaximally with KC1 whereas the P-adrenoceptor agonist isoprenaline did. 
Further experiments showed that the Na+ channel blocker, tetrodotoxin (TTX), 
could abolish the inhibitory action of cicaprost but not that of isoprenaline. A 
neuronal site of action for cicaprost within the colon seemed possible; this 
Chapter describes experiments to define the nature of this action. 
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Methods and Materials 
IsoUited colon preparations 
A description is given in Chapter 2. 
Experimental protocols 
In aU experiments, proximal and distal sections of colon from the same rat 
were used as matched preparations. After about 60 min equilibration, with 
frequent washing, several submaximal doses of the appropriate inhibitory 
agonist were tested on each preparation to ensure that a stable and acceptable 
level of sensitivity had been reached before the following experimental 
procedures were begun. Agonist doses were allowed 3 - 4 min contact with the 
preparation; blockers/inhibitors were added 10 or 15 min before the agonist 
dose(s). 
Effects of cicaprost and isoprenaline on spontaneous activity and KCl- and 
sulprostone-induced tone Spontaneous activity: non-cumulative dose-response 
relationships for cicaprost and isoprenaline were obtained on proximal and 
distal preparations respectively from 3 rats, and also on distal and proximal 
preparations respectively from 3 different rats (data combined and quoted as n 
= 6 in Results); this procedure was repeated with cumulative dosing for 
cicaprost and isoprenaline on KCl-induced tone (6 different rats), and for 
cicaprost on sulprostone- and KCVsulprostone-induced tone (6 different rats). 
Effects of blockers/inhibitors on responses to single doses of inhibitory 
agonists Responses to single doses of both cicaprost and isoprenaline were 
obtained on both proximal and distal preparations from 3 rats, before and after 
treatment(s) with blocker/inhibitor (sequentially increasing concentrations) (n 
132 
= 6 in Results). In the case of L-NAME andAn* apamin on nicotine responses, 
either the distal or proximal preparation was always used as a non-treated 
preparation to assess the extent of agonist desensitisation; during the first 
treatment period, either L -NAME or apamin was present (n = 3), and during 
the second period, a combination of L-NAME and apamin (n = 6). 
Effects of blockers/inhibitors on purinoceptor agonists Cumulative dose-
response relationships were obtained for a purinoceptor agonist on both 
proximal and distal preparations from 2 rats. One preparation was used as 
control and the other treated with antagonist/inhibitor/desensitising agent; 
second agonist dose-response relationships were then established. This 
procedure was repeated using 2 different rats with exchange of control and 
treatment on the proximal and distal preparations (n = 4 in Results). 
Data analysis and statistical tests 
Using the MacLab Chart 3.3 program, spontaneous activity was measured as 
the average contractile force over a 2 min period (480 data points) (see Chapter 
2 for details). The baseline tension value was set by eye. The response to an 
inhibitory agonist was taken as the percentage change from the resting 
spontaneous activity (e.g. -100% corresponds to abolition of spontaneous 
activity). Using data from a number of experiments, mean agonist responses 
elicited during control and treatment (receptor antagonist / channel blocker / 
enzyme inhibitor) periods were compared by unpaired Student's t test; 
statistical significance was accepted when P < 0.05. 
Drugs 
Indomethacin, isoprenaline (racemic), phenylephrine, tetrodotoxin (TTX), co-
conotoxin GVIA, co-conotoxin MVIIA, vasoactive intestinal peptide (VIP), [D-
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p-chloro-Phe6jLeui7]-VIP, n^ysl’Pro2’5，Arg3,4, Tyi^]-Vip, N^-nitro-L-arginine 
methyl ester (L-NAME), D-NAME, ATP, ADP, AMP, UTP and adenosine 
were purchased from the Sigma Chemical Company, U.S.A.; saxitoxin (STX) 
from Calbiochem-Novabiochem Corp., U.S.A.; 2-methylthio ATP, 8-
cyclopentyl-1,3-dipropylxanthine (DPCPX)，and apamin from Research 
Biochemicals International, U.S.A, and suramin from Biomol Research 
Laboratories, U.S.A; pituitary adenylate cyclase-activating peptides 
(PACAP)38 and PACAP(6-38) from Bachem CaUfomia, U.S.A. Etorphine 
was kindly supplied by Dr. T.M. Wong, Department of Physiology, Hong 
Kong University. A stock solution of TTX (500 ^iM) was prepared in saline 
solution containing 0.01% acetic acid and diluted with saline solution. VIP, 
the VIP analogues, co-conotoxins, PACAP38, PACAP(6 - 38)，apamin, L -
NAME and D-NAME were dissolved in distilled water and diluted with saline 
solution before use. Stock solutions of purines were prepared in distilled water 
each day. 
Results 
Iloprost and TEI9063 simultaneously inhibited the spontaneous activity and 
increased the tone of the rat colon, which was particularly pronounced in the 
distal sections, whereas cicaprost always produced inhibitory effects in both 
sections (Figure 4.1). Cicaprost was therefore used in the subsequent 
investigations on the mechanism of the inhibitory effects of IP-receptor 
agonists on the colon. In virtually all cases, responses of the proximal and 
distal sections of the colon to either cicaprost or isoprenaline were similar in 
magnitude, and it was decided to combine the data for graphical and statistical 
analyses. 
Log concentration-response curves for inhibition of the spontaneous activity of 
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the rat colon by cicaprost (IC50 = 3.8 nM) and isoprenaline (12.5 nM) are 
shown in Figure 4.2. In subsequent experiments, the effects of antagonists and 
inhibitors were assessed against submaximaI responses elicited by standard 
concentrations of 10 nM cicaprost and 20 nM isoprenaline; these responses 
remained constant or in the case of cicaprost sometimes sUghtly increased in 
size (5 - 10%) over a period of 2 - 3h. Nicotine also inhibited the spontaneous 
activity of the colon (IC50 = 1 - 2 ^iM), but was prone to tachyphylaxis. In 
subsequent studies, the reduction in response to a standard concentration of 3 
p,M nicotine applied every 20 min was small enough to allow the testing of 
inhibitory agents. Deliberate desensitisation to nicotine, using three or four 
10 ^ M challenges at 15 min intervals, had no effect on cicaprost inhibition 
(Figure 4.4c). Some tool agents (inhibitors/blockers) were used to define the 
nature of cicaprost action; a summary of their effects is given in Table 4.1 
while the details are described below. 
Evidence that cicaprost activates NANC enteric neurones 
The Na+ channel blockers saxitoxin (STX, 0.1 and 1 nM) and TTX (0.1 and 1 
^iM) slightly slowed the rate of spontaneous contractions and tended to make 
the contraction pattem more regular. TTX (1 ^iM) abolished all responses 
induced by electrical field stimulation (EFS) on the rat colon; the responses 
included the inhibition of the spontaneous activity during the stimulation and 
the rebound contraction after the stimulation (Figure 4.3b). At the same 
concentration TTX markedly reduced and in some cases abolished cicaprost 
responses OFigures 4.3a and 4.4a), always abolished nicotine responses (not 
shown), but had no effect on isoprenaline responses (Figure 4.4a). Cicaprost 
responses were also markedly inhibited by STX in a concentration-dependent 
manner (0.1 - 1 nM) (Figure 4.4b); basal spontaneous activity was not affected 
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Figure 4.1 Rat isolated colon: experimental records showing the effects of 
(a) cicaprost and TEI9063 and (b) phenylephrine (Phe) alone and in the 
presence of phentolamine (l^iM). Phentolamine did not block the inhibitory 
action of cicaprost. 
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Figure 4.2 Log concentration-inhibition curves on rat isolated colon. 
Cicaprost and isoprenaline on spontaneous activity (•，0) and stable 
tone induced by 40 mM KC1 (•，•), and cicaprost on contractile 
activity induced by 8.6 nM sulprostone ( • ) and 40 mM KC1 / 8.6 nM 
sulprostone ( • ) . Values are means 土 s.e. mean (n = 6). 
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Figure 4.3 Rat isolated colon: experimental records showing the effect of 
treatment with tetrodotoxin (TTX, 1 p,M) on (a) inhibitory responses to 10 nM 
cicaprost and (b) responses to electrical field stimulation (EFS, 0.1 ms pulses at 
60 V and 10 Hz). 
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Figure 4.4 Spontaneous activity of rat isolated colon. Effects of 
treatment with (a) tetrodotoxin (TTX) or (b) saxitoxin (STX) on 
inhibitory responses to cicaprost (10 nM, hatched columns) and 
isoprenaline (20 nM, open columns) (n = 5 - 6). Concentrations are nM. 
(c) Effects of desensitisation with 3 - 4 applications of 10 \ iM nicotine 
(Nic desens) on inhibitory responses to cicaprost (10 nM, hatched 
columns) and nicotine (10 ^M, solid columns) (n = 4). Values are 
means 士 s.e.mean. * P < 0.05, ** P < 0.01, * * * P < 0.001 as compared 
to appropriate control (Con). 
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Figure 4.5 Spontaneous activity of rat isolated colon. Effects of 
treatment with phentolamine (Phen), propranolol (Prop) or atropine 
(Atrop) on inhibitory responses to cicaprost (10 nM, hatched columns) 
and isoprenaline (20 nM, open columns). Concentrations are nM. 
Values are means 土 s.e.mean (n = 6). * P < 0.05, ** P < 0.01, * * * P < 
0.001 as compared to appropriate control (Con). 
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inhibited spontaneous activity (about -40%); this concentration was therefore 
not tested against cicaprost responses. 
Phentolamine at 1 \ iM did not significantly affect the spontaneous activity of 
the colon, although in some preparations the basal tension was slightly 
decreased. Phenylephrine (3 \ iM) inhibited the spontaneous activity (-70 to 
-80%) but also slightly increased the basal tone. The inhibitory component of 
phenylephrine responses was abolished by 1 ^ M phentolamine, whereas 
cicaprost and isoprenaline responses were unaffected (Figures 4.1b and 4.5). 
Propranolol at a concentration of 1 |iiM ( which had no significant effect on 
spontaneous activity or basal tone) markedly inhibited isoprenaline responses, 
but had no effect on cicaprost responses (Figure 4.5). The response of the 
colon preparation to atropine was complex. Following exposure to 50 nM 
atropine, there was a small reduction in basal tension and spontaneous activity 
was reduced by about 20%. Subsequent doses of atropine (0.1 - 1 |xM) 
produced no further effects. I f however a preparation was initially exposed to 
1 ^iM atropine, resting tension was markedly reduced and spontaneous activity 
abolished for several minutes; these parameters recovered to 60 - 70% of 
control values over a period of 20 min. After washout of 1 [ iM atropine from 
the organ bath, TTX (1 ^M) did not slow the rate, but slightly increased the 
amplitude of spontaneous contractions. The presence of atropine (1 |xM) did 
not significantly affect either cicaprost or isoprenaline responses CFigure 4.5). 
At this stage it was apparent that cicaprost (and nicotine) activated enteric 
neurones to release an inhibitory transmitter. This transmitter was not 
noradrenaline, and since atropine did not affect the inhibitory responses, 
activation of a NANC enteric nervous system was likely. The next part of the 
chapter deals with attempts to identify the inhibitory transmitter by 
pharmacological means. 
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Effects ofnitric oxide synthase inhibition 
Sodium nitroprusside, a NO donor, inhibited the spontaneous activity of the 
colon preparation (IC50 = 0.15 pM) (Figure 4.6), and this action was unaffected 
by TTX (1 nM). The nitric oxide synthase (NOS) inhibitor L-NAME (10 - 500 
^iM) produced transient small contractions of the colon preparations. Cicaprost 
and nicotine responses were partially inhibited by L-NAME, whereas the 
actions of isoprenaline and nitroprusside were unaffected (Figures 4.7a and 
4.8). The enantiomeric D-NAME, which is inactive as a NOS inhibitor, did 
not affect the action of cicaprost QFigure 4.8b). 
Interference with postsynaptic purinergic systems 
The effects of several treatments intended to inhibit postsynaptic purinergic 
systems were investigated on inhibitory responses to cicaprost, nicotine and 
several purinoceptor agonists. Log concentration-response curves for ATP, 2-
methylthio-ATP, ADP, AMP, adenosine and UTP are shown in Figures 4.9, 
4.10 and 4.11. The order of potency was 2-methylthio-ATP (IC25 = 0.17 ^iM) 
> ATP (2.1 _ > ADP (3.4 _ > UTP (18 _ > adenosine (33 _ > 
AMP (300 ^iM). 2-Methylthio-ATP appeared to have two inhibitory 
components; the maximum response of the first component was reached at 4 
pM (Figure 4.9a). 
Log concentration-response curves for ATP derived from two cumulative 
sequences of doses 80 min apart were identical (Figure 4.9a). However, 
desensitisation to ATP could be partially achieved by challenging with three 
doses of ATP (500 ^iM) added at 15 min intervals in between the first and 
second series of ATP doses. Examination of the second ATP curve shows that 
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this procedure was most effective against 10 and 100 ^ M as opposed to 500 
HM ATP (Figure 4.9a); cicaprost responses were unaffected by this treatment 
0^igure4.12). 
At 300 ^iM, the P2x-/P2Y-receptor antagonist suramin produced a rightward 
shift of the ATP curve for responses within the 0 - 50% inhibition range (dose 
ratio = 10 - 20) (Figure 4.9b). However no inhibition was seen when the ATP 
concentration was raised to 500 ^iM. Suramin did not inhibit responses to 
AMP (Figure 4.10b) and adenosine (Figure 4.11a) and produced a small 
rightward shift of the UTP curve (Figure 4.11b). The effect of reactive blue 2, 
a weak antagonist at P2Y-recept0rs, was also investigated. However it was less 
satisfactory than suramin, since at a concentration of 100 ^ M it produced a 
50% inhibition of spontaneous activity. It antagonised ATP responses in a 
similar manner to suramin; its activity against the other purinergic agonists was 
not investigated. DPCPX, a potent antagonist at adenosine Ai-receptors, was 
used at the high concentration of 5 ^iM in an attempt to block adenosine A2-
receptors in the colon. The success of this strategy is evidenced by marked 
inhibition of adenosine responses without significant inhibition of ATP, ADP, 
AMP and UTP responses (Figures 4.9b, 4.10 and 4.11). Neither suramin (300 
M-M), nor reactive blue 2 (100 p^M) nor DPCPX (5 ^iM) had any effect on 
cicaprost responses (Figure 4.12). 
Apamin (25 nM) markedly inhibited responses to ATP, ADP, adenosine and 
UTP (Figures 4.9 - 4.11)，and partially inhibited both cicaprost and nicotine 
responses, while not affecting isoprenaline responses (Figure 4.13a). Cicaprost 
and nicotine induced no obvious change in spontaneous activity (<±5% and 
<±10% respectively) or basal tension in the presence of 100 ^iM L-NAME and 
25 nM apamin; isoprenaline inhibition was unaffected by this combination 
CFigures 4.7b and 4.14). The effect of tubocurarine, a blocker of both high and 
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low conductance Ca2+-activated K+ channels, was also investigated. It 
markedly inhibited the responses to cicaprost, but not those to isoprenaline 
(Figure 4.13b). Its activity against other agonists was not tested. 
Effect ofblocking ofPACAP receptors 
PACAP38, a recendy defined apamin-sensitive inhibitory neurotransmitter in 
the gut (Jin et al” 1994), inhibited the spontaneous activity of the rat colon 
with an IC50 value of about 7 nM (Figure 4.6). PACAP(6-38), a putative 
PACAP receptor antagonist, at 3 ^iM blocked the responses to 6 nM PACAP38 
by 97%, but did not affect cicaprost action (Figure 4.15a). 
Interference with the action ofvasoactive intestinal peptide 
VTP inhibited the spontaneous activity of the colon with an IC50 value of about 
50 nM (Figure 4.6). On five preparations, 100 nM WJP produced 92 土 2 % 
inhibition, which was reduced to 33 土 4 % in the presence of 1 ^ M TTX (P < 
0.01). 
Two VIP analogues, [Lysi，Pro2’5,Arg3,4’Tyr6]-VIP and [D-p-chloro-
Phe6,Leul7]-VIP were examined as potential antagonists of VIP action. The 
former at 1 ^ M transiently contracted the colon; subsequent submaximal 
responses to either VIP (100 nM) or cicaprost were unaffected. The latter 
analogue at 1 and 5 ^iM also had no effect on V f f responses; it was not tested 
against cicaprost. 
Prolonged exposure to VIP as a means of desensitisation was attempted on 
three colon preparations (which tumed out to be somewhat more sensitive to 
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Figure 4.6 Spontaneous activity of rat isolated colon: log 
concentration-inhibition curves for pituitary adenylate cyclase-
activating peptide (PACAP38, 0 ) , vasoactive intestinal peptide (VIP, 
• )，sodium nitroprusside ( • ) and ATP (A). Values are means 土 
s.e.mean (n = 4 - 6). 
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Figure 4.7 Rat isolated colon: experimental records showing the effects of 
treatment with (a) N®-nitro-L-arginine methyl ester (L-NAME, 100 |xM) and 
D-NAME (100 ^iM) and (b) a combination ofL-NAME (100 n<M) and apamin 
(25 nM) on inhibitory responses to 10 nM cicaprost and 20 nM isoprenaline. 
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Figure 4.8 Spontaneous activity of rat isolated colon, (a) Effects of 
treatment with N^-nitro-L-arginine methyl ester (L-NAME, 10 - 500 
l iM) on inhibitory responses to cicaprost (10 nM, hatched columns) and 
isoprenaline (20 nM, open columns), (b) Effects of treatment with D-
NAME (100 \ iM) on responses to cicaprost (10 nM, hatched columns), 
and treatment with L -NAME (100 |xM) on responses to sodium 
nitroprusside (1 ^iM, dotted columns). Values are means 土 s.e.mean of 6 
experiments. * P < 0.05，** P < 0.01，*** P < 0.001 as compared to 
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Figure 4.9 Inhibition of spontaneous activity of rat isolated colon; log 
concentration-response curves for second cumulative sequences (all n = 4). 
(a) ATP acting alone (〇）and corresponding ATP first sequence (拳）； 
ATP after desensitisation by 3 x 500 ^iM ATP ( • ) ; 2-methylthio-ATP (A). 
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Figure 4.10 Inhibition of spontaneous activity of rat isolated colon; log 
concentration-response curves for second cumulative sequences (all n = 
4). (a) ADP acting alone (control curve for apamin, 0 ) and in the 
presence of DPCPX (5 ^iM, • ) and apamin (25 nM，•). (b) AMP 
acting alone (control curve for suramin, 0 ) and in the presence of 
suramin (300 ^iM,參），DPCPX (5 ^iM, • ) and apamin (25 nM, • ) . 
Values are means 士 s.e.mean. 
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Figure 4.11 Inhibition of spontaneous activity of rat isolated colon; log 
concentration-response curves for second cumulative sequences (all n = 
4). Adenosine (a) and UTP (b) acting alone (control curve for suramin, 
0 ) and in the presence of suramin (300 ^iM, • ) , DPCPX (5 ^iM, • ) and 
apamin (25 nM, • ) . Values are means 土 s.e.mean. 
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Figure 4.12 Spontaneous activity of rat isolated colon; effects of ATP 
(3 X 500 ^M) desensitisation, suramin (300 ^iM), reactive blue 2 (RB2) 
(100 ^iM) and DPCPX (5 ^iM) on inhibitory responses to cicaprost (10 
nM). C = control, T = treatment. Values are means 土 s.e.mean (n = 4). 
152 
a 妥 20. 
一 Apamin 
^ Q Con 2.5 25 100 
I ： | |||1| I . I 7 
i - 8 0 . i J y ^ u 
C9 pC 
。 - i o o J 
b 妥 2 0 ] 
w Tubocurarine 
^ 0 Con 20 100 500 
i .0： I I im I 
i - 墨 章 
& -60- m W ** 
•！ I T 
I -80- W ^ 丄 
« 丄 ^ H 
。 . i o o J ^ 
Figure 4.13 Spontaneous activity of rat isolated colon. Effects of 
treatment with (a) apamin (2.5 - 100 nM) and (b) tubocurarine (20 - 500 
^iM) on inhibitory responses to cicaprost (10 nM, hatched columns) and 
isoprenaUne (20 nM, open columns). Values are means 土 s.e.mean (n = 
6). * P < 0.05, * * P < 0.01，*** P < 0.001 as compared to appropriate 
control (Con). 20 ^ M Tubocurarine was not tested against isoprenaHne. 
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Figure 4.14 Spontaneous activity of rat isolated colon. Effects of 
treatment with a combination of N®-nitro-L-arginine methyl ester (L-
NAME, 100 nM) and apamin (25 nM) on inhibitory responses to (a) 
cicaprost (10 nM, hatched columns) (n = 6) and isoprenaline (20 nM, 
open columns) (n = 2) and (b) nicotine (3 ^iM, solid columns). In (b): 
control and combination treatment, n = 6; treatment with L -NAME or 
apamin alone, n = 3. * P < 0.05, * * P < 0.01，*** P < 0.001 as 
compared to appropriate control (Con). 
154 
a 
S 2 0 ] 
•安 PACAP38 Cicaprost 
1 » M ’ I _ 
I ；：; ^ L| § 
g - i o o J 
b 
5 2 0 . 
^ VIP Cicaprost 






6 -60 - ^ M 
^ ^ ^ " H 
& -80- ^ ^ n F c 
03 
6 -100 
Figure 4.15 Spontaneous activity of rat isolated colon, (a) Effects of 
treatment with PACAP(6-38) (3 ^iM, hatched columns) on inhibitory 
responses to PACAP38 (6 nM) and cicaprost (10 nM). (b) Effects of 
treatment with a-chymotrypsin (2 u ml-l, solid columns) on inhibitory 
responses to VIP (100 nM) and cicaprost (10 nM). * P < 0.05, ** P < 
0.01，*** P < 0.001 as compared to appropriate control (open columns). 
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the colon, but after about 5 min contact, spontaneous activity resumed and had 
returned to the control level after 20 min. Although this appeared to indicate 
substantial desensitisation, a second 100 nM VLP challenge (without washout 
of the first dose) resulted in total inhibition, which returned to control level 
slightly quicker than the first response. Similarly, a third 100 nM VIP 
challenge produced about 95% inhibition, foUowed by complete recovery; at 
this time, addition of cicaprost induced a response identical to the pre-VIP 
control. 
Inhibitory responses to 100 nM VIP were almost abolished when a -
chymotrypsin (2 u m H ) was present in the organ bath (Figure 4.15b). In 
contrast, cicaprost responses were not inhibited by this treatment (Figure 
4.15b). 
Effects ofother 'presynaptic agents' 
co-Conotoxin-GVIA (CTX-G) (10 - 400 nM) produced a partial inhibition of 
the cicaprost response, whereas co-conotoxin-MVIIC (CTX-M) (40 - 100 nM) 
was without effect, either alone (Figure 4.16b) or in combination with CTX-G 
(both 100 nM). Attempts to examine the effects of the L-type calcium channel 
blocker verapamil on the action of cicaprost were abandoned since the agent 
itself markedly reduced the spontaneous activity of the colon (IC50 = 10 nM; 
total inhibition at 315 nM). 
Two opioid receptor agonists, etorphine (0.3 - 10 nM) and morphine (100 -
1000 nM), also partially inhibited cicaprost responses (Figure 4.16a). 
Combination of etorphine with maximally-effective concentrations of either L-
NAME or CTX-G produced greater inhibition, but did not abolish cicaprost 
responses (Figure 4.17). 
156 
Relaxation ofKCUinduced tone 
Addition of 40 m M KC1 to the organ bath resulted in the generation of a stable 
level of tone, some 30 to 50% of that obtained with a near maximal KC1 
concentration of 120 mM; spontaneous activity was completely or almost 
completely lost Subsequent addition of cicaprost (10 - 310 nM) was without 
effect, whereas isoprenaline could stiU elicit complete relaxation (IC50 = 50 
nM) OFigures 4.2 and 4.19a,b). Both SNP (0.1 - 5 ^iM) and ATP (100 ^iM) also 
inhibited KC1 tone (not shown). 
The PGE analogue sulprostone at 8.6 nM induced contractions of the colon 
preparation equivalent to the 40 m M KC1 response; there was some 
enhancement of spontaneous activity. The contractile responses, which were 
more pronounced in distal segments, were not blocked by pretreatment with 
phentolamine, propranolol, atropine or TTX (all at 1 p,M). Cicaprost reduced 
both the tone and the rhythmic contractions in sulprostone-treated preparations 
(Figure 4.18a); its EC50 value was 4.5 nM and 90% inhibition was achieved at 
20 nM OFigure 4.2). TTX at 1 ^ iM abolished these cicaprost responses (Figure 
4.18b). Jn the presence of 40 mM KC1, sulprostone (8.6 nM) elicited a further 
increase in tension but spontaneous activity remained absent; cicaprost (10 -
310 nM) produced only minimal relaxation (Figures 4.2 and 4.19c). 
In two experiments, iloprost (10 - 500 nM) contracted the colon preparation in 
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Figure 4.16 Inhibition of the spontaneous activity of rat isolated colon 
by cicaprost (10 nM): effects of treatment with morphine (Mor), 
etorphine (Etor), co-conotoxin MVIIC (CTX-M) and co-conotoxin GVIA 
(CTX-G). Concentrations are nM; values are means 土 s.e.mean of 4 - 6 
experiments. * P < 0.05, ** P < 0.01, * * * P < 0.001 as compared to 
appropriate control (C). 
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Figure 4.17 Inhibition of the spontaneous activity of rat isolated colon 
by cicaprost (10 nM): effects of treatment with etorphine (3 nM) alone 
and in combination with (a) 0)-conotoxin GVL\ (CTX-G, 100 nM) and 
(b) N®-nitro-L-arginine methyl ester (NAME, 100 ^M). Values are 
means 土 s.e.mean of 4 - 6 experiments. * P < 0.05, * * F < 0.01，*** P < 
0.001 as compared to appropriate control (C). 
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Figure 4.18 Rat isolated colon: experimental records showing the effects 
of cicaprost (10 nM) (a) alone and (b) in the presence of tetrodotoxin (1 
^iM) on the tone and enhancement of spontaneous activity induced by 
sulprostone (8.6 nM). 
160 
a b 
Cicaprost (nM) Isoprenaline (nM) 
10 30 70 150 310 W “ , • 參 ^^  35 ^^ 
{ i ^ • ‘ • • .• ‘ • � l f ~ ^ ^ j l 
0 KCl(40mM) > ~ ' KC1 (40 mM) 
5 min 
c d _^_^ _ 
Cicaprost (nM) .__><^ >***^  • 
10 30 70 150 310 W ^ ^ ^ ^ > * " ^ ^ ^ ^ 500 ^ 
• • • • • • _ " - “ ^ 10« 250 
1厂 Z 一 ^ • • 2*5 50 100 
g j u ^ ‘ 10 Doprost (nM) 
oL • KC1 (40 mM) added 
KC1 (40 mM) 15 min earlier 
Figure 4.19 Rat isolated colon: experimental records showing the effects of (a) 
cicaprost, (b) isoprenaline and (d) iloprost in the presence of tone generated by 
40 mM KC1, and (c) cicaprost on tone generated by a combination of 40 mM 
KC1 and 8.6 nM sulprostone. Cumulative concentrations. W = wash. 
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Discussion 
Anatomical and electrophysiological investigations of the contractility of rat 
and dog colon preparations have shown that three tissue components are 
involved: smooth muscle cells, a network of pacemaker ceUs (interstitial cells 
of Cajal, ICC) linked to each other and to smooth muscle cells by gap 
junctions, and a largely inhibitory innervation which is concentrated on the 
ICC (Huizinga et al” 1990; Faussone-Pellegrini, 1992, ref. therein). The 
experiments with the neuronal Na+ channel blockers STX and TTX strongly 
suggest that cicaprost activates the inhibitory innervation of the rat colon. The 
selectivity of these channel blockers at the concentrations used is evidenced by 
their lack of effect on the pacemaker function of the colon. However STX at 10 
nM did depress the spontaneous activity of the colon. Numerous experiments 
have shown that these two channel blockers have minimal direct effects on 
smooth muscle function, whereas TTX blocks cardiac Na+ channels at high 
concentrations (IC50 = 10 ^iM; Honeijager et al, 1986) and skeletal muscle 
Na+ channels at relatively low concentrations (IC50 = 1 ^M; Frelin et al” 
1983). The inhibitory action of nicotine on the colon is also abolished by TTX. 
However, nicotine inhibition is more difficult to study because of its tendency 
to desensitisation, a well-known property of nicotinic receptor systems. 
Deliberate desensitisation with nicotine did not affect cicaprost inhibition, 
implying that the action of cicaprost is not dependent on the integrity of 
nicotinic cholinergic synapses. 
High concentrations of atropine (1 [iM) cause relaxation of the rat colon and 
this may not be due to its potent antimuscarinic activity. Atropine also has 
relaxant effects on blood vessels, which are due to more than one mechanism; 
release of nitric oxide is a contributory action (Haghighi and Pollock, 1994). 
There is a possibility that cicaprost acts pre-synaptically to suppress the tonic 
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Figure 4.20 Schematic diagram of the three tissue components in the 
rat colon. The bold arrows indicate release of inhibitory transmitter(s) 
from the NANC nerve. 
activity of an excitatory nerve supply. The experiments conducted in this study 
do not rule out this mechanism, but the lack of effect of atropine on cicaprost 
inhibition would indicate that the tonic system is not a cholinergic innervation 
acting through post-synaptic muscarinic receptors. 
Inhibitory P3-adren0cept0rs are present in the rat colon (Bianchetti and 
Manara, 1990; McLaughlin and MacDonald, 1990). This receptor subtype is 
somewhat resistant to blockade by classical P-blockers (Harms et aL, 1977; 
McLaughlin and MacDonald, 1990); the pA2 value for propranolol at P3-
receptors mediating relaxation of rat colon is given as 6.5，at Pi-receptors 
mediating atrial stimulation as 8.2 - 8.8, and at P2-r^ept0rs mediating tracheal 
relaxation as 8.3 - 8.6 CWllson et aL, 1984). This would explain the incomplete 
block of isoprenaline action by 1 ^ iM propranolol in my studies. The inability 
of phentolamine and propranolol to inhibit the action of cicaprost suggests that 
cicaprost does not release noradrenaline from postganglionic sympathetic 
neurones. I t appears therefore that cicaprost activates non-adrenergic, non-
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Figure 4.21 Inhibition of nitric oxide synthase (NOS) by L-NAME; the 
asterisk indicates the asymmetric carbon. 
nicotine), the inhibitory action of isoprenaline is unaffected by TTX and 
appears to be non-neuronal in nature. NANC neurotransmission (Bumstock, 
1986) to gut structures appears to be common and the main transmitter 
candidates are ATP (Bumstock et al” 1970), VIP (Goyal and Rattan, 1980)， 
nitric oxide (Bult et al.，1990) and pituitary adenylate cyclase activating 
peptide (Jin et a/” 1994). In general, two or more NANC transmitters may 
operate simultaneously to elicit a relaxant effect (Manzini et al” 1986; Maggi 
and Giuliani, 1993), although one of them may play a dominant role in 
particular segments of the intestine of some species. 
Involvement ofNO generation in action ofcicaprost 
There is good agreement that NO makes a major contribution to inhibition of 
colonic activity elicited by activation of enteric neurones. Hata et al (1990) 
showed that relaxation of the circular muscle of the rat proximal colon due to 
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local distension was abolished by L-NOARG, a NOS inhibitor; L-arginine, the 
precursor of NO (Pakner et al, 1988a), but not D-arginine, largely reversed the 
effect of L-NOARG. Similarly in rat colon, relaxations of circular muscle to 
distension and longitudinal muscle to EFS were essentially abolished by L -
NOARG (Suthamnatpong et a/., 1993; 1994). Jn the guinea-pig colon, L -
NOARG almost abolished the relaxation induced by EFS (Zagorodnyuk and 
Maggi, 1994). In the present experiments, inhibitory responses to both 
cicaprost and nicotine were partially (50 - 60%) blocked by L -NAME at 
concentration of 100 yiM. This concentration could be expected to block NOS 
(Rees et al” 1990). D-NAME however did not affect cicaprost action, 
compatible with stereospecific inhibition of NOS by arginine analogues (see 
Palmer et al” 1988b). Thus it appears that cicaprost- and nicotine-induced 
inhibitions of spontaneous activity in the rat colon are mediated in part by NO. 
Constitutive NOS has been found in enteric nerves (Bredt et al., 1990)，but 
there has been some discussion in the literature (see Zagorodnyuk and Maggi, 
1994) as to whether colonic relaxation is produced by NO generated within 
nerves or by another transmitter, for example VIP (Grider et al., 1992)， 
inducing NO generation in smooth muscle. The present experiments do not 
distinguish between these two possibilities. 
The involvement ofpurinergic nerve transmission in the action ofcicaprost 
The nature of the component of cicaprost inhibition resistant to NOS inhibition 
was first investigated with respect to purinergic transmission. Bailey and 
Hourani (1992) have shown that ATP and adenosine relax the carbachol-
contracted rat colon (IC25 = 35 and 80 p,M) through activation of P2Y-
purinoceptors and adenosine A2-recept0rs respectively. From my experiments, 
these two receptors also appear to mediate inhibition of spontaneous activity, 
although both ATP and adenosine show somewhat greater potency (IC25 = 2.5 
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and 35 |xM respectively). 2-Methylthio-ATP was more potent than ATP, 
consistent with the known properties of this specific P2Y agonist (Gough et al.， 
1973; O'Connor et al” 1991). However the 2-methylthio-ATP log 
concentration-response curve appeared to have two components. A lower 
maximum response for 2-methylthio-ATP relative to ATP has been observed 
previously on piglet aorta endothelial cells (Needham et al” 1987), human 
umbilical vein (Carter et aL，1988) and the mouse submandibular salivary 
gland ceU Une ST885 (Gibb et al., 1994). From scrutiny of all the curves in 
Figures 4.9,4.10 and 4.11，it is possible that the purines could be exerting non-
specific, apamin-insensitive inhibition of colonic contractility above 100 ^iM. 
The studies described here provide no real evidence for a purinergic 
contribution to the inhibitory action of cicaprost. Firstly, desensitisation to 
ATP had no effect on cicaprost responses. Secondly, suramin, a P2x/P2Y-
receptor antagonist (Dunn and Blakely, 1988; Den Hertog et cd.，1989; Hoyle 
et al.，1990; Leff et aL, 1990)，did not affect cicaprost-induced inhibition. 
Although suramin is a weak antagonist (300 |J,M was used), i t did act 
specificaUy, blocking the inhibitory action of ATP but not that of adenosine. 
Higher concentrations of suramin could not be used because of their depressant 
effect on spontaneous activity. Thirdly, the potent adenosine Ai-receptor 
antagonist DPCPX (Collis et al” 1989; Bruns, 1990), used at high 
concentration to block adenosine A2-recept0rs, did not inhibit cicaprost 
responses. 
The bee venom peptide apamin has been shown to block inhibitory responses 
to ATP in guinea-pig taenia coli (Den Hertog et al” 1985)，guinea-pig internal 
anal sphincter OLim and Muir, 1986) and rat gastric fundus (LeFebvre et al” 
1991). In the present study, apamin also markedly inhibited or abolished the 
inhibitory effects of ATP and adenosine. These observations indicate that ATP 
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and adenosine probably inhibit spontaneous activity by opening low 
conductance calcium-activated K+ channels in smooth muscle, since apamin is 
known to specifically block these channels (Banks et al, 1979; Maas and Den 
Hertog, 1979). Apamin partially inhibited and in combination with L -NAME 
aboUshed the inhibitory actions of both cicaprost and nicotine on the colon. 
This suggests that the second transmitter or transmitters released from enteric 
nerves by these two agonists open calcium-activated K+ channels. Although 
the value of this observation in terms of transmitter identification is limited 
(ai-adrenoceptor-mediated inhibition is also apamin-sensitive), i t does provide 
further support against a p3-adrenergic contribution, since isoprenaline 
inhibition was apamin-insensitive. Since cicaprost and nicotine produced no 
excitatory effects in the presence of the L-NAME/apamin combination, it 
would appear that their stimulant actions are limited to inhibitory enteric 
neurones (at least at the concentrations employed). 
Involvement of neuropeptides in the action ofcicaprost 
PACAP and VIP are widely distributed in neurones of the enteric nervous 
system of many species including human, rat and guinea pig (Goyal and 
Rattan, 1980; Arimura et al” 1991; Sundler et al” 1992; Suthamnatpong et al, 
1993). Due to the structural homology between PACAP and VIP, some VIP-
immunoreactive neurones may contain not only VEP but also PACAP (Grider 
and Makhlouf, 1987; Jin et al” 1994). Both agents are inhibitory transmitters in 
various regions of the gut and it has been reported that the release of VIP and 
PACAP produces descending relaxation in the rat colon (Grider et al.’ 1994). 
Two forms of PACAP, PACAP38 and PACAP27, are formed in neurones 
(Arimura et al., 1991; Sundler et al.’ 1992); both have apamin-sensitive 
inhibitory actions (Jin et al, 1994). PACAP(6-38) is a PACAP receptor 
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antagonist, in which the terminal 5 amino acids have been removed from 
PACAP38. I t antagonises the PACAP27-stimulated cAMP production in rat 
pancreatic AR 4-2J cell membranes, with a K i value of 7 nM (Robberecht et 
al” 1992)，and inhibits the relaxation induced by exogenous PACAP27 and 
PACAP38 in dispersed muscle cells of guinea-pig tenia coli (Jin et al” 1994). 
Furthermore, i t blocks the apamin-sensitive neuronal relaxation induced by 
electrical f ield stimulation of guinea-pig tenia coU muscle strips (Jin et al” 
1994). The present study has confirmed the effectiveness of PACAP(6-38) in 
blocking PACAP receptors by showing that at 3 ^iM it virtually abolished the 
inhibition of spontaneous activity of the rat colon induced by 6 nM PACAP38. 
However, k did not affect the responses to cicaprost, which does not support 
PACAP as an inhibitory transmitter released through IP-receptor activation in 
the rat colon. 
Like its homolog PACAP, VIP also inhibited the spontaneous activity of rat 
colon. Its inhibitory effects were partially blocked by TTX, suggesting that 
both prejunctional and postjunctional sites of action are involved. A 
prejunctional action of VIP has also been reported in the dog and cat trachea 
(Hakoda and Ito, 1990); however in these tissues VIP inhibits the release of an 
excitatory transmitter. 
In the studies of Suthamnatpong et aL (1993), the VIP antagonist, VIP 10-28, 
inhibited the EFS response of the distal rat colon to a maximum of 35%; it had 
no effect on EFS responses of the proximal and middle colon. In the present 
experiments, two VIP antagonists, PLysi,Pro2，5，Arg3’4，Tyr^ -VIP (Gozes et al” 
1989) and [ D - p - c h l o r o - P h e 6 , L e u i 7 ] - V I p (Pandol et al” 1986)，did not inhibit 
responses to either VIP or cicaprost. In this context, PD-p-chloro-Phe6,Leui7:-
VIP and another antagonist, [Ac-Tyri,D-Phe2]-GRF( 1 -29)-NH2, were without 
effect on responses to exogenous VIP in the guinea-pig isolated trachea (Ellis 
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and Farmer, 1989). However in the cat trachea, these two antagonists 
abolished the pre-junctional action of VIP to suppress the excitatory junction 
potential (Xie et al” 1991). Clearly these antagonists are useful for blocking 
one subtype of V f f receptor and not for the other(s). 
Lrformation was then sought from VBP desensitisation experiments. However, 
as in the studies of Suthamnatpong et aL (1993), it proved difficult to achieve 
significant desensitisation to YIP. Although inhibitory responses to VJP faded 
with time, subsequent addition of VIP still elicited good inhibitory responses. 
The mechanism underlying this profile of action is not clear. As a last resort, 
evidence of the involvement of VIP as a transmitter was sought from the use of 
a-chymotrypsin, an enzyme that cleaves peptide bonds adjacent to tyrosine, 
lysine and arginine residues; all three amino acids are present in VIP. In 
previous studies, evidence has been obtained both for (rat gastric fundus, De 
Beurme and Lefebvre, 1987) and against (guinea-pig teania coli, Mackenzie 
and Bumstock, 1980; rat duodenum, Manzini et al” 1986) a role for VIP in 
NANC relaxation. The finding that a-chymotrypsin treatment did not inhibit 
the relaxation induced by cicaprost appears to exclude a transmitter role for not 
only YJP but also PACAP and other susceptible peptides such as calcitonin 
gene-related peptide (CGRP). The statement of "appears to exclude" should be 
emphasised, since, as suggested by others, there is no evidence that a 
neuropeptide released from neurones within the tissue is subject to the same 
degree of inactivation as exogenous peptide in the bathing fluid. 
Interaction ofcicaprost with other presynaptic agents 
Further evidence for a neuronal action of cicaprost was sought using other 
agents which act pre-synapticaUy to reduce transmitter release. co-Conotoxin 
GVIA potently inhibited cicaprost action, but only to a maximum of about 
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40%. The ability of this specific N-type Ca2+ channel blocker to inhibit 
cholinergic, noradrenergic and NANC neurotransmission has been investigated 
in detail in a number of preparations by de Luca et al (1990). Functional 
responses to nerve stimulation were usually only partiaUy inhibited, especially 
at high stimulation frequencies or high extemal Ca2+ concentrations. Similar 
effects were observed on the inhibitory response of rabbit urethral muscle to 
EFS (Zygmunt et aL, 1993) and on the i.j.p. of the guinea-pig colon to EFS 
(Zagorodnyuk and Maggi, 1994). These authors have mainly argued for two 
possible causes of this profile: part of the neurotransmitter release process 
either does not require Ca2+ influx or is dependent on influx of Ca2+ through 
ion channels other than the N-type. It is known that L-type (nifedipine-
sensitive) Ca2+ channels are involved in acetylcholine release in guinea-pig 
colon (Marino et aL, 1993). However, in my experiments it was difficult to 
investigate the effects of L-type blockers (e.g. verapamil) since they depressed 
the spontaneous activity of the colon (presumably through block of L-type 
channels on the ICC-smooth muscle cells). A second peptide toxin from 
Conus geographus, co-conotoxin MVIIC, did not affect the action of cicaprost. 
I t has been shown to block both N- and P-type neuronal Ca2+ channels 
(Hillyard et aL, 1992). However, in contrast to the established role for P type 
Ca2+ channels in the central nervous system, they may not be important in 
supplying the Ca2+ necessary for neurotransmitter release in the peripheral 
autonomic nervous system G-undy and Frew, 1994). 
There are many reports in the literature on the depression of transmitter release 
by opioid receptor agonists. The situation in the rat colon is complicated by 
the ability of a range of opioid agonists to cause transient contractions 
(Huidobro-Toro and Leong, 1981). These effects were blocked by naloxone 
and appear to be due to the neuronal release of 5-HT. The transient 
contractions with etorphine and morphine were also observed in this study, but 
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at the time of addition of cicaprost there was no elevation of tone and 
spontaneous activity was very similar to that of the control period. In my 
experiments, cicaprost responses were only partly inhibited by etorphine, a 
highly potent agonist at [i-, 6- and K-receptors, and morphine, a much weaker 
agonist with some selectivity for ^i-receptors (see Hayes et al” 1985, for 
actions on EFS responses of guinea-pig ileum). In the presence of etorphine 
and L-NAME, cicaprost was still able to elicit a small inhibitory response. 
This is complementary to the work of Zagorodnyuk and Maggi (1994), who 
demonstrated that the selective 5-opioid receptor agonist DPDPE, in the 
presence of L-NOARG, only partially inhibited the apamin-sensitive i.j.p. 
induced by EFS in guinea-pig colon. 
Effects ofagonists when tone is raised with K+ 
Raising the extemal K+ concentration to produce submaximal contraction of 
the colon preparation was accompanied by loss of spontaneous activity. Under 
these conditions, isoprenaline, sodium nitroprusside and ATP induced 
relaxation, whereas cicaprost was completely inactive. Use of the EP1yGEP3-
receptor agonist sulprostone to raise the tone of the preparation did not result in 
loss of spontaneous activity; in this case cicaprost still induced a TTX-sensitive 
relaxation. However i f sulprostone was combined with high K+，spontaneous 
activity was lost and cicaprost was again inactive. Two mechanisms may be 
relevant to the lack of effect of cicaprost in the presence of high K+. Firstly, 
cicaprost may still release inhibitory transmitters, but they are ineffective since 
their action on the pacemaker is abrogated by high K+. Secondly, the high K+ 
may prevent the transmitter-releasing action of cicaprost. This is an interesting 
concept, since it raises the possibility that activation of IP-receptors on enteric 
neurones leads to closing of K+ channels and membrane depolarisation. This 
action may not proceed through the Gs-adenylate cyclase pathway typical of 
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the inhibitory actions of prostacyclin on platelet function. An analogous 
situation is the pre-synaptic inhibitory actions of opioid agonists, where 
mediation through cyclic AMP is being abandoned in favour of direct G-
protein links with K+ and>^ or Ca++ channels in the plasma membrane (see Di 
Chiara and North, 1992). 
The loss of IP-receptor-mediated inhibition in the presence of high K+ exposes 
the true contractile action of iloprost on the rat colon. Doprost is known to be a 
potent agonist at EPi-receptors ff)ong et al” 1986) and a moderate agonist at 
EP3-recept0rs (Jones, unpublished observations). However, preliminary 
observations in this laboratory suggest that the nature of the EP-receptor 
mediating contraction of the rat colon is more likely to be an EP3- as opposed 
to an EPi-receptor (Jones, unpublished observations). This has been recently 
confirmed by radioligand binding analysis (Woodward etal” 1995): MB28767, 
sulprostone and PGE2 were potent inhibitors of [^H]PGE2 binding in the rat 
colon, whereas PGF2a, PGD2 and 17-phenyl-co-trinor PGE2 were substantially 
less potent. 
In conclusion, the present study demonstrates that the inhibitory actions of IP-
receptor agonists on the contractility of the rat colon are neuronally-mediated 
and that at least two NANC transmitter mechanisms appear to be involved. 
NO is likely to be one of the inhibitory transmitters. The other transmitter 
mechanism is apamin-sensitive. Some evidence has been obtained against a 
transmitter role for ATP, adenosine, VIP and PACAP. Further studies are 
warranted to characterise the "neuronal" IP-receptors involved, in terms of 
molecular structure, G-protein coupling and structure-activity relationships. 
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Chapter 5 
Differential effects of non-prostanoid prostacyclin mimetics 
on human puhnonary artery and rat colon 
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The early development of prostacyclin mimetics was mainly focused on the 
synthesis of PGI analogues since the natural compound is chemically and 
metabolicaIly unstable. Chemical stability is achieved by the replacement of 
the oxygen atom in the enol ether structure with a methylene; the further 
introduction of a single methyl group at Ci6 and an aUcynic group at Cig can 
compensate for the activity lost due to the structural modification of the enol 
ether. Metabolic stability is improved by the exchange of the P-methylene 
group of the upper side chain by an oxygen atom, whereupon the analogue is 
resistant to p-oxidative metabolism (see Chapter 2 for the chemical structures). 
Obviously, all of these PGI2 analogues are synthesised using the natural 
product prostacyclin as a template. 
However, the spectrum of chemical structure for prostacyclin mimetics has 
been extended by the report (Armstrong et aL, 1986) that the inhibitory action 
of prostacyclin on human platelets can be mimicked by analogues of 
prostaglandin H2 having a diphenyhnethoxime co-chain (Figure 5.1). A l l these 
analogues are structurally different from PGI2 and its close compounds. EP157 
is one of the first agents described; it competes for pH]iloprost binding to 
platelets and inhibits platelet aggregation. 
Recently, a number of structurally simpler compounds related to EP157 have 
been reported to have agonist activity at IP receptors; they lack a typical 
prostanoid ring system and have been termed "non-prostanoid prostacyclin 
mimetics" (Meanwell etal” 1994). Reasonably detailed pharmacology was 
first described for octimibate (Merritt et al” 1991a;b), followed by BMY 42393 
(Seiler et al.，1994a;b), then BMY 45778 (Seiler et al.’ 1995). BMY 45778 is 
the most potent agent; its IC50 for inhibition of ADP-induced aggregation of 
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human platelets in platelet-rich plasma is 27 nM and it binds to the human 
platelet IP receptor with an IC50 of 7 nM for displacement of [3H]iloprost 
binding. BMY42393 is related to BMY45778, but less potent. 
In Chapter 4, the neuronal effects of IP-receptor agonists on rat colon have 
been described. In contrast to the classical inhibitory effects on platelets and 
blood vessels, the prostacyclin neuronal action is excitatory, that is, 
prostacyclin stimulates neurones to release neurotransmitters. L i t t le 
information is available on whether there is any difference between neuronal 
IP-receptors and platelet/vascular IP-receptors. It was therefore considered 
interesting to compare the activities of a range of prostacyclin mimetics which 
are structurally different from one another. The compounds we used included 
cicaprost，EP185, BMY42393 and BMY45778; cicaprost is a standard 
prostanoid IP agonist; EP185, which is related to EP157, is a PGH2 analogue', 
BMY42393 and BMY45778, which are devoid of a prostanoid ring, are non-
prostanoid prostacyclin mimetics. In addition, other compounds (WL602, 
WL603, WL605，CHW23 and CHW38) synthesised in the Department of 
Chemistry of this University, and related to octimibate, were evaluated in this 
study. These compounds are derived from a chemical programme aimed at 
developing IP-receptor antagonists. Thus, compounds showing weak IP agonist 
activity were also examined for IP antagonist activity. 
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Figure 5.1 Structures of non-prostanoid prostacyclin mimetics tested in this study. 176 
Methods and Materials 
The set-up of the preparations and the measurements were described under 
"isolated preparations" in Chapter 2. The collection and dissection of human 
puhnonary artery were the same as described in Chapter 3. However, for the 
isolated colon preparations, only proximal sections were used, and two such 
preparations from two rats were run together as matched preparations. 
Test compound 
, ^ z \ 
Inhibition ^ — — ^ 1 Inhibition 
of of 
platelet aggregation ^ ^ rat colon contraction 
\ ^ o N y / 
Against cicaprost 







Figure 5.2 Experimental protocol for screening the IP-receptor 
agonist or antagonist activity of a compound. 
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Experimental protocols 
Each compound was tested on either human platelet-rich plasma or rat colon, 
or both, to screen its agonist or antagonist activity at IP-receptors. More 
attention was paid to a compound showing antagonism. To examine the 
antagonism of a compound at IP-receptors, this agent was added 10 min before 
a single dose of cicaprost (activation of ff-receptor); in control preparations of 
the rat isolated colon, nicotine rather than cicaprost was added 10 min after 
incubation with the test compound. I f the compound antagonised cicaprost 
responses, more detailed investigations were then pursued. 
Functional competition study First, a cumulative dose-response curve for 
cicaprost was established; the preparation was then incubated with the test 
agent or vehicle for 10 min; a second cumulative dose-response curve for 
cicaprost was constructed. 
Time course ofdevelopment ofblocking action In case of slowly developing 
antagonism, matched preparations, one for the test compound, the other for the 
vehicle or a control drug, were used. Compounds were added 10 min before the 
addition of cicaprost; cicaprost was allowed to contact the preparations for 3-4 
min for each test, followed by 10 min washout and re-equilibration. The same 
procedure was then repeated until the maximal antagonism was virtually 
reached. 
To confirm non-neuronal IP effects, some of compounds were evaluated on 
preparations of human pulmonary artery, while further studies on neuronal IP 
effects were extended by other researchers in our group using preparations of 
guinea pig ileum and vas deferens. 
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Drugs 
Some drugs have been mentioned in the preceding chapters. BMY42393 and 
BMY45778 are gifts from Bristol-Myers Squibb, U.S.A. EP185 was 
synthesised by Dr. N.H. Wilson, Department of Pharmacology, University of 
Edinburgh. WL602, WL603, WL605, CHW23 and CHW38 were synthesised 
by Dr. Henry Wong and his colleagues. Department of Chemistry, Chinese 
University of Hong Kong. 
Table 5.1 Potencies of prostacyclin mimetics on human platelets and rat colon 
Compound IC50 (nM) 
Human platelets Rat colon 
Cicaprost 0.1-0.5 6 
WL602 12,500 32,000 
WL603 > 100,000 18,000 
WL605 > 100,000 > 42,000 (n.e.) 
CHW23 1,000 > 16,000 (n.e.) 
CHW38 > 16,000 (n.e.) 
EP185 200« > 10,000 (n.e.) 
BMY42393 1,200^ > 10,000 (n.e.) 
BMY45778 27^ > 10,000 (7 -15%) 
^Data from Jones et aL, 1993; ^Data from Seiler et al, 1994a; cData from 
Meanwell et aU 1994. > indicates the highest concentration tested; at these 
concentrations, no response or less than 15% maximal response was observed; 
n.e. = no effect; data for human platelets, n = 2; data for rat colon, n = 4 - 6. 
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Results 
The results of screening the potencies of prostacyclin mimetics on human 
platelets and rat colon are shown in Table 5.1. Since platelet aggregation was 
measured in platelet-rich plasma, true IC50 values might be less than those 
quoted because of binding of the test compound to plasma protein. This effect 
wi l l be more pronounced for Upophilic compounds; cicaprost is likely to be 
minimally affected since it is water soluble. 
It is clear that all of the non-prostanoid compounds show very weak or no IP-
agonist activity in the rat colon. This is not the case in human platelets, where 
some compounds show moderate potency (BMY45778, EP185) and others are 
inactive (WL603, WL605). Before making any proposal about the existence of 
IP-receptor subtypes, it was considered necessary to examine several of the 
non-prostanoids on the rat colon in more details. It was also considered 
important to determine the IP agonist potencies of the non-prostanoids on a 
second preparation where BMY45778 shows high potency and protein binding 
is not a problem. Preliminary experiments showed that the human pulmonary 
artery was such preparation. 
Rat isolated colon 
Agonist potencies 
CHW23, EP185, BMY42393 and BMY45778 were chosen for further 
examination; cicaprost was used as a standard IP agonist. Figure 5.3 shows 
non-cumulative concentration-response curves. Cicaprost inhibited the 
spontaneous activity with an IC50 of 6 nM. Neither CHW23 nor EP185 nor 
BMY42393 had any effect on colonic activity at 0.1 to 10 ^iM compared to the 
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Figure 5.3 Spontaneous activity of rat isolated colon: non-cumulative 
log concentration-inhibition curves for cicaprost (•)，BMY45778 (0) , 
BMY42393 ( • ) ’ CHW23 (A) and EP185 ( • ) • Each point is the mean 
of 4 - 6 experiments, with s.e.mean shown by vertical bars. 
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Figure 5.4 Spontaneous activity of rat isolated colon. Effects of 
treatment with prostacyclin mimetics on inhibitory responses to 
cicaprost (10 nM) and nicotine (3 ^iM). Mean 土 s.e.mean of 4 
experiments. EP = EP185; B42 = BMY42393; B45 = BMY45778. 
**P < 0.01 as compared to appropriate control (Con). 
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DMSO vehicle curve, whereas BMY45778 produced a small degree of 
inhibition at the two highest concentrations tested. 
Antagonist activities 
The response (-80 土 3%) to a single dose of cicaprost (10 nM) was unaffected 
by either 10 ^ M EP185 (-80 士 6%) or 10 ^iM BMY42393 (-84 土 6%). 16 ^iM 
CHW23 slightly increased the cicaprost response. However, the combination 
of cicaprost (10 nM) and BMY45778 (10 ^iM) produced only -49 土 5% 
inhibition (P < 0.01) (Figure 5.4). In contrast the inhibitory action of 3 ^iM 
nicotine (-87 土 3%) was not inhibited by 10 [ iM BMY45778 (-91士 2%). 
Competition studies Although in most experiments non-cumulative dosing 
was used in order to maximise the sensitivity of the preparations, cumulative 
doses were applied in a set experiments to observe the antagonism produced 
within a short period. After completion of the first cumulative concentration 
curve for cicaprost，the preparations were incubated with 10 ^ M BMY45778 
for 10 min and then a second series of cumulative doses of cicaprost were 
added. Log concentration-response curves for cicaprost are given in Figure 
5.5; dose ratio = 3.8 at the 50% response level. It was suspected that the 
shallower curve to cicaprost in the presence of BMY45778 was due to the 
"antagonism" increasing with increasing time of exposure to the BMY45778. 
Further experiments were carried out to study this. 
Time course of the blocking effect of BMY45778 Using the matched 
preparations, the antagonist effect of BMY45778 was compared with that of 
BMY42393; same amount of vehicle (DMSO, 0.001 - 0.1% v/v) was used for 
dissolving these agents. The first exposure to 1 p,M BMY45778 for 10 min did 
not significantly affect the inhibitory effects induced by cicaprost (10 nM), but 
cicaprost responses were progressively attenuated with time, following the 
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Figure 5.5 Rat colon: cumulative log concentration-response curves 
for cicaprost alone acting ( 0 ) and in the presence of 10 ^iM 
BMY45778 (10 min exposure) ( • ) . Each point is the mean of 4 
experiments, with s.e. mean shown by vertical bars. 
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Figure 5.6 Inhibition of rat colon motility by repeated applications of 
10 nM cicaprost: effect of continuous exposure to 1 | jM BMY45778 
( • ) and 1 \ iM BMY42393 (0) . Values are means 士 s.e. mean, n = 5. 
185 
0 ^ ^ 
|秦\A 
r \ \ ！ ‘ \ \ 
喜• VV 
-100H , , ~ 、 * ^ 1 
- 1 0 -9 -8 -7 - 6 -5 
log [cicaprost] (M) 
Figure 5.7 Spontaneous activity of rat isolated colon: non-cumulative 
log concentration-inhibition curves for cicaprost alone acting ( 0 ) and 
in the presence of 1 \ iM BMY45778 ( • ) (70 min exposure). 
BMY45778 was re-applied after washout of the cicaprost. Each point 
is the mean of 4 experiments, with s.e. mean shown by vertical bars. 
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subsequent additions of the same dose of BMY45778 with the same incubation 
time of 20 min intervals with 10 min washout and re-equilibration between 
drug additions. After 4 such exposures, the cicaprost response was ahnost 
aboUshed (Figure 5.6). The reversal of the antagonism was very slow; 80 min 
after subsequent washout little or no recovery of cicaprost response could be 
observed. Since the spontaneous contractility decreased with time, we were 
not able to observe the recovery process further. On the matched preparations, 
BMY42393 did not show any blocking effect on cicaprost action (Figure 5.6). 
In another set of experiments, after a non-cumulative concentration-response 
curve for cicaprost alone was established, each preparation was exposed to 
BMY45778 (1 ^iM) 4 times with each time 10 min contact and 10 min washout 
(total time: 70 min), and then challenged with non-cumulative doses of 
cicaprost in the presence of 1 [ iM BMY45778. Figure 5.7 shows the log 
concentration-response curves for cicaprost before and after BMY45778 
treatment. The pA2 value for BMY45778 against cicaprost is 6.8. 
Human pulmonary artery 
Preparations precontracted with phenylephrine relaxed to cicaprost in 
concentration-dependent manner (Figure 5.8 and 5.9); its IC50 was 0.7 nM. The 
log concentration-response curves for the relaxation of phenylephrine-induced 
tone by three non-prostanoid prostacyclin mimetics, BMY45778, BMY42393 
and octimibate, are also given in Figure 5.8; their IC50 values were 3, 58 and 
174 nM. respectively. However, as illustrated in Figure 5.9, their actions were 
slow, both in onset and offset; it took 40 - 60 min for a BMY45778 response to 
reach a stable level after a single dosing (Figure 5.9), and 150 - 180 min, with 
frequent wash-outs, for a preparation to recover from the inhibition (Figure 
5.10). 
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Figure 5.8 Log concentration-response curves fpr relaxation of the human 
puhnonary artery by cicaprost ( • ) , BMY45778 (•)，BMY42393 ( 0 ) and 
octimibate (A), (a) Precontracted with phenylephrine, GR32191 (200 nM) was 
present, (b) Precontracted with U46619, nifedipine (200 nM) was present, (c) 
Precontracted with 40 mM KC1, GR32191 (200 nM) was present. A l l 
precontractions were 50 - 70% of maximum. 
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Figure 5.9 Experimental records for the relaxant actions of cicaprost and 

































































































































































































The preparations precontracted with KC1 (40 mM) also relaxed to cicaprost, 
BMY45778, BMY42393 and octimibate, but the maximum responses were 
significantly less (Figure 5.8c). The maximum responses (about 40 - 50% 
relaxation) were reached at the concentrations up to 40 nM and 400 nM for 
cicaprost and BMY45778 respectively. Their IC25 values were estimated as 2 
nM for cicaprost, 10 nM for BMY45778, 112 nM for BMY42393 and 500 
nM for octimibate. In contrast, the KCl-induced tone could be almost totally 
relaxed by nifedipine (200 nM). 
To minimise the involvement of influx of extracellular Ca^+ in the contraction 
induced by U46619, 200 nM nifedipine was used. The log concentration-
response curves for the relaxation ofU46619-tone in the presence of nifedipine 
are given in Figure 5.8b; their IC50 values were 1，2.8, 47 and 141 nM for 
cicaprost, BMY45778，BMY42393 and octimibate respectively. Furthermore, 
cicaprost relaxation of U46619-induced tone was not significantly affected by 
KC1 (40 mM) in the presence of nifedipine, that is，a full relaxation could still 
be reached even in the presence of high K+. 
Discussion 
As discussed in Chapter 3, prostanoid-induced relaxation of the human 
pubnonary artery is mediated through two different prostanoid receptors: EP2 
and IP. The balance between the relaxant EP2 system and the contractile EP3 
system is variable, with the latter being predominant in the most cases. The 
relaxant IP system is more constant, and is very sensitive. 
BMY45778 and BMY42393 are potent in relaxing the human puhnonary artery 
precontracted with phenylephrine; the order of potency of the IP-receptor 
agonists is cicaprost > BMY45778 > BMY42393 > CHW23, with equi-
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effective molar ratios relative to cicaprost of 1, 4.7, 68 and 500 respectively 
(Table 5.2). For the inhibition of human platelet aggregation measured in 
platelet-rich plasma (PRP), the order of potency is cicaprost > BMY45778 > 
CHW23 > BMY42393; equi-effective molar ratios are 1，34’ 1000 and 1500 
respectively (Table 5.1). However such a comparison should be interpreted 
with caution since non-prostanoid prostacyclin mimetics exhibit a high degree 
of protein binding relative to cicaprost or iloprost (Jones et aL, 1993; Meanwell 
et al” 1994). Thus, the actual potencies of BMY45778, BMY42393 and 
CHW23 on human platelets may be higher than those measured in PRP. 
Taking this fact into account，the potency of these non-prostanoid prostacyclin 
mimetics is compatible on human platelets and human puknonary artery. 
hi contrast to the potent effects on human puhnonary artery, only BMY45778 
of the four non-prostanoid prostacyclin mimetics studied had any inhibitory 
effect on rat colon motility. The maximum effect was only about 15% of the 
cicaprost maximum, and in preparations with a lower sensitivity to cicaprost, 
BMY45778 had little effect. The equi-effective molar ratio of BMY45778 
relative to cicaprost on the rat colon is more than 600 times higher than that on 
the human pulmonary artery, which suggests that EP-receptors are different on 
these two tissues. 
However, a comparison of IP agonists between the tissues from two different 
species is not recommended since IP-receptors vary in species (Armstrong et 
al, 1989; Merritt et al., 1991b). Rat neutrophils have been reported to express 
IP-receptors that are similar to those on human platelets (Wise and Jones, 
1994). BMY45778 is a potent agonist for the inhibition of rat neutrophil 
aggregation; the order of potency of the IP-receptor agonists is cicaprost > 
BMY45778 > BMY42393, with equi-effective molar ratios relative to 
cicaprost of 1, 8 and 139 (Wise et al” 1995)，which is close to that on human 
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pulmonary artery. Since the studies on both rat neutrophils and rat colon are 
performed in protein-free solution, the equi-effective molar ratios should 
reflect the agonist affinities of BMY45778 and BMY42393 on the IP-
receptors. Thus again, two different pictures of IP-receptors within-species are 
also revealed. It therefore appears that human pulmonary artery and rat 
neutrophils express similar IP-receptors, but different IP-receptors are 
expressed on rat colon. 
Table 5.2 Equi-effective molar ratios of prostacyclin mimetics on three 
different types of tissues 
Compound Equi-effective molar ratio 
HPA Rat colon Rat neutrophil* 
^^HaMMH^^^^^HBMMMHMMMMIMMMHH^H^H^^^^H^^^^M^^H^^H^^HBM^^MH^a^HBMM^BnMHHWHMMMHMMMHMBMI^^BHMaMHnMMH^H^M^^H^HMHn 
Cicaprost 1 1 i 
BMY45778 4.7 > 1667 8 
BMY42393 68 > 1667 139 
CHW23 500 > 2667 
EP185 >2667 192 
HPA = Human puhnonary artery; * data from Wise et al” 1995. 
This hypothesis was further supported by the finding that BMY45778 could 
block the inhibitory effect of cicaprost on the rat colon. Partial agonist activity 
has been reported previously for octimibate on human coronary and mesenteric 
arteries (Merritt et al” 1991b), and for EP157 in pig platelets (Armstrong et al” 
1986). However, BMY45778 behaves as a full agonist on human pulmonary 
artery and on rat neutrophils while it has partial agonist activity and 
antagonises the inhibitory effect of cicaprost on the rat colon. Together these 
data clearly demonstrate that BMY45778 is able to distinguish rat colon IP-
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from human pulmonary artery IP-receptors. In Chapter four, it has been 
described that the inhibitory effect of cicaprost is a neuronal action. Thus rat 
colon ff-receptor can be termed as neuronal IP-receptor. It is very tempting to 
say that neuronal IP-receptor is different from non-neuronal IP-receptor such as 
those on human puhnonary artery, human platelets and rat neutrophils. 
Guinea pig ileum and vas deferens are neuronal IP preparations, where IP-
receptor agonists induce contractions by the release of ACh and a substance P-
like transmitter (Jones and Lawrence, 1993) and potentiate submaximal EFS-
stimulated twitch response through enhancement of transmitter release (Jones, 
1993) from nerves respectively. The prolonged exposure to BMY45778 (1 p.M) 
also blocks the neuronal stimulant actions of cicaprost on guinea pig ileum 
(Chan, unpublished observations) and guinea pig vas deferens (Tam, 
unpublished observations). As observed on the rat colon, the blocking action of 
BMY45778 is slowly developed on these two preparations. Thus two distinct 
profiles of BMY45778 are shown on neuronal and non-neuronal IP 
preparations, which are summarised in Table 5.3. 
BMY42393 is very similar in structure to BMY45778 and has similar 
pharmacological characteristics on platelets (Seiler et al., 1994a); it competes 
for [3H]iloprost binding to platelet membranes, but has little effect on 
[3H]prostaglandin E2, _ p r o s t a g l a n d i n D2 or [3H]SQ29548 binding. 
BMY42393 is 44 times less potent in inhibiting ADP-induced human platelet 
aggregation in PRP and 24 times less potent in displacing [3H]iloprost binding 
to platelet membranes than BMY45778. On the human pubnonary artery, the 
potency difference between these two compounds can virtually be considered 
to be of the same order as that on platelets, but on neuronal IP preparations 
they show very different profiles. In contrast to BMY45778, a single high dose 
(10 ^iM) of BMY42393 with short time incubation (10 min) does not attenuate 
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Table 5.3 Differential effects of BMY45778 on neuronal and non-neuronal IP-
preparations 
Preparation Neuronal BMY45778 on IP-receptors 
involvement agonist activity blocking activity 
Human platelets - + n.a. 
HPA • + n.a. 
Rat neutrophils - + n.a. 
Rat colon + p.a. + 
Guinea pig ileum + p.a. + 
GPVD + p.a. + 
HPA = human pulmonary artery; GPVD = guinea pig vas deferens; p.a.= 
partial agonist; n.a. = not appropriate, since the compound is a full agonist at 
IP-receptors and so potent that the blocking activity cannot be tested. 
cicaprost response, nor does the prolonged exposure to a lower concentration 
(1 H.M). This again supports the existence of subtypes of IP receptors. 
Octimibate relaxes human subcutaneous resistance vessels with an IC50 of 1.7 
^M, but evokes only weak relaxation of human coronary and mesenteric artery 
(Merritt et al.’ 1991b). The authors described this agent as a partial agonist. 
However, our results suggest that octimibate is a full agonist at IP-receptors on 
human pulmonary artery since it induces full relaxation of the preparation 
precontracted with phenylephrine or U46619. Even on the KCl-induced tone, 
the maximal relaxation achievable with octimibate is similar to that obtained 
with the standard IP-receptor full agonist, cicaprost. Merritt et aL (1991) used 
only KC1 to preconctract the human vascular preparation, where the maximal 
relaxation by iloprost, an IP full agonist similar to cicaprost, is about 60%. This 
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incomplete relaxation, as revealed in our observations on the KCl-induced 
tone, indicates that KC1 is not an appropriate vasoconstrictor for the 
precontraction in the evaluation of the potencies of IP-receptor agonists on 
vascular tissues. 
On the other hand, k ako implies the involvement of potassium channels in the 
vasodilatation by IP-receptor agonists. The K+ channel opening properties of 
prostacyclin and its analogues have been reported by two groups (Siegel et al., 
1992; Jackson et al” 1993). K+ channel opening frequently causes 
hyperpolarization of the cell membrane and the hypeq>olarization consequently 
inhibits the opening of voltage-operated Ca2+ channels and agonist-induced 
Ca2+ mobilisation from stores by interfering with agonist-induced inositol 
1,4,5-trisphosphate (InsP3) (Quast, 1993)，thereby lowering intracellular Ca2+. 
The activity of adrenomedullin (AM), a hypotensive polypeptide from 
pheochromocytoma tissue and an agent elevating intracellular cAMP, is worthy 
of mention at this point. The extent of the tension inhibition by A M was much 
greater than expected based on the extent of reductions of intracellular Ca2+ 
(Kureishi et al., 1995). It was proposed that the relaxation is not only due to a 
decrease in intracellular Ca2+ but also due to a decrease in the Ca2+ sensitivity 
of the contractile apparatus. The relaxation of human pulmonary artery by IP-
receptor agonists in this study may also involve multiple mechanisms. The 
activation of IP-receptors coupled to G-protein Gs causes elevation in cAMP, 
and the increased cAMP then hyperpolarises cell membrane of smooth muscle, 
which may be cancelled out by high extracellular K+ concentration since under 
this condition cAMP does not have any significant effect on the membrane 
potential (Somlyo etaL，1970). The high K+-depolarisation-insensitive relaxant 
component of the puhnonary artery may be related to the intracellular Ca2+ 
levels rather than Ca2+ influx. This possibility is indicated by the finding that 
cicaprost could totally relax U46619-induced tone in the presence of high K+ 
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and L-type Ca2+ channel block with 200 nM nifedipine. This relaxation is not 
due to the inhibition of Ca2+ influx, since nifedipine at 200 nM can apparently 
virtually block Ca2+ influx through L-type Ca2+ channels. However, the precise 
mechanism underlying the interference with intracellular Ca2+ processes is not 
clear; it would be interesting to look at. 
There are reasonable prospects for the potential application of non-prostanoid 
prostacyclin mimetics both in clinical use and in basic prostanoid research. 
Firstly, platelet inhibitory properties are beneficial effects in diseases 
associated with an increased activation of platelets. It is known that 
inadequately controlled platelet activation under pathophysiological conditions 
can result in the development of arterial thrombi, for example, causing unstable 
angina and transient ischemic attacks if platelet aggregates are formed in 
coronary and cerebral arteries. Under extreme circumstances, platelet 
activation can progress to thrombus formation and blood vessel occlusion, 
manifest as myocardial infarction and stroke. As a consequence, platelet 
inhibiting drugs constitute a critical component of clinical antithrombotic 
strategies. However, prostacyclin and its analogues have not proven to be 
effective in the treatment of myocardial infarction and angina in clinical trials 
CWennmahn, 1993). Several possible factors may affect the therapeutic results. 
As to the pharmacology of the drugs themselves, they are not selective between 
antiplatelet action and vasodilation. Thus prostacyclin analogues cannot be 
given in adequate amounts to patients since the patient's systemic blood 
pressure must be controlled at a reasonable level. On the other hand, the 
duration of action is relatively short although the metabolic stability is 
improved in some of the compounds such as cicaprost. For ischaemic 
peripheral vascular disease, prostacyclin analogues have proven effective, but 
the duration of therapeutic benefit remains to be improved (Sinzinger, 1993). 
The non-prostanoid prostacyclin mimetics have shown effectiveness and long 
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duration of action in animal models of arterial thrombosis (Seiler et aL’ 1994b). 
Thus, the novel chemical structures can provide simple templates to develop 
compounds with an acceptable doration of action in man. Furthermore, the 
stable orally active property of these compounds are convenient for the 
patients. 
Secondly, while considered as undesirable side effects when only antiplatelet 
actions are wanted, the vascular actions of prostacyclin and its stable mimetics 
may be useful properties for the treatment of peripheral vascular disease 
(Sinzinger, 1993) and for clinical improvement in patients suffering from 
primary pubnonary hypertension (Butt et al.，1993). Our experiments show the 
potent relaxant action of BMY45778 on human pulmonary artery, thereby 
offering a basis to explore the clinical application to improve survival in 
patients with severe primary pulmonary hypertension before transplantation. 
Since the intravenous use of vasodilatory drugs in the treatment of pulmonary 
hypertension is limited by an attendant drop in systemic vascular resistance and 
intrapuknonary shunting, attempts have been made to administer drugs through 
inhalation. In addition to nitric oxide, prostacyclin by the inhalation has been 
reported to reverse the puhnonary vasoconstriction in hypoxic dogs (Welte et 
aL, 1993). Aerosolised prostacyclin was also used for puhnonary hypertension 
in neonates (Bindl et aL, 1994). Thus, it would be very interesting to look at 
the effects of BMY45778 aerosol in pulmonary hypertension. I f it can produce 
a sustained reduction in pubnonary vascular resistance, it would be particularly 
useful to the patients who need a chronic infusion of prostacyclin since chronic 
infusion is expensive and there is a risk of infection (Bames and Liu, 1995). 
Thirdly, the block of IP-mediated neuronal stimulant actions by BMY45778 
could be a basis for the development of neuronal IP-receptor antagonist into an 
analgesic agent. It has been documented that prostacyclin possesses 
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hyperalgesic activity (Ferreira et al” 1978). While it is not pain-producing in 
its own, it sensitises pain receptors to stimulation by other agents such as 
bradykinin and 5-hydroxytryptamine. In a spinal cord/functionally-attached tail 
preparation from the neonate rat，cicaprost enhances responses of peripheral 
nociceptors to thermal and chemical stimuli (Rueff and Dray, 1993). The 
potential advantage of a prostanoid antagonist is that it only selectively blocks 
the response mediated by the corresponding receptor, unlike nonsteroidal 
antiinflammatory drugs that inhibit the synthesis of all types of prostanoids. 
BMY45778 behaves as an IP partial agonist on neuronal preparations, but it 
can be used as a starting point to develop a pure antagonist. Besides its 
potential clinical applications, an IP antagonist would be very useful in the 
characterisation and further classification of IP-receptors, and it may 
consequently facilitate the development of more selective agonists. 
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Chapter 6 
General Discussion and Perspective 
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In this section I have attempted to put the results of my studies into a broader 
context and to indicate possible directions for future studies. 
EP-receptors mediating vascular smooth muscle contraction 
In general, PGE2 produces a vasodepressor action in vivo. This action is 
mainly due to vasodilatation mediated through either EP2- or EP4-recept0rs 
(Coleman, et aL, 1994b). Contractile effects have been observed in some 
isolated vascular preparations when a high concentration of PGE2 was applied 
(Jones, et al” 1982; Baxter et aL, 1995), but they were mediated via TP-
receptors. The EP3-recept0r agonist sulprostone was inactive on the human 
isolated uterine artery (Baxter et al” 1995). However, in the present study 
sulprostone and other EP3-recept0r agonists were found to potently contract 
human intrapuknonary arteries and guinea-pig aorta, and these effects were not 
antagonised by TP- and EPi-receptor blockers. 
The EP3-recept0r has been generally thought to couple to either inhibition of 
adenylate cyclase or stimulation of phosphoinositide metabolism. However, my 
experiments have demonstrated the involvement of Ca^+ influx in the 
constrictor action of EP3-recept0r agonists on guinea-pig aorta. It is speculated 
that the EP3-recept0r couples, either directly or via a G-protein, to Ca2+ 
channels QFigure 6.1). The channels may not specifically be of the L-type, and 
the cytoplasmic Ca2+ is moderately elevated through this way. When the 
increase in intracellular Ca2+ reaches a certain level in some cases, L-type Ca2+ 
channels are triggered to open through a second mechanism (e.g. Ca2+-
activated Ca^+ influx) and more external Ca2+ flows into the cytosol. The 
depletion of the intemal Ca2+ store by treatment with an internal Ca^ + release 
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Figure 6.1 Some possible mechanisms of tonic and phasic contraction of vascular 
smooth muscle, as illustrated by the agonist action of phenylephrine (Phe) at 
apadrenoceptors and sulprostone (Sul) at EP3-recept0rs. Essentially sulprostone 
induces Ca〗+ influx through non-specific cation channels. When the increased 
Ca2+ reaches a certain level, it can trigger a further Ca】+ influx, either through a 
direct Unk to Ca】+ channels or through releasing a calcium influx factor (CffO. 
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inducer phenylephrine and a sarcoplasmic reticulum Ca2+ pump inhibitor 
cyclopiazonic acid (CPA) produces a calcium influx factor (Cf f , a small and 
soluble messenger, Randriamampita and Tsien, 1993)，which then relieves an 
inhibitory constraint on a direct pathway for Ca2+ to enter the cytosol from the 
extracellular space and consequently promotes Ca2+ influx. 
However, further work remains to be done to confirm the above hypothesis. 
Firstly, simultaneous measurements of intracellular Ca^+, using the Ca^+ 
indicator fura-2, and tension of smooth muscle in the guinea-pig aorta wi l l 
provide information on the correlation of the increase in intracellular Ca2+ and 
the tension developed by EP3-recept0r agonists. I t is documented that 
contraction via the diacyl glycerol - protein kinase C (DAG-PKC) pathway can 
operate at resting levels of intracellular Ca2+. In view of the reports that 
phospholipase C (PLC) activity is dependent on extracellular Ca2+ in some 
vascular tissues (Lum Min and Tabrizchi, 1995), and i f the Ca2+ binding sites 
are located at the outside of the plasma membrane, it is possible that EP3-
receptors couple to production of DAG via activation of PLC and the 
contractile effects are dependent on extracellular Ca^+, although Ca^+ influx is 
not involved. Experiments with 45Ca2+ wi l l also be helpful in understanding 
the source of the increased intracellular Ca^+. 
Secondly, the measurement of phosphatidylinositol (PI) hydrolysis wi l l give an 
answer as to whether PLC activation is involved in the responses to EP3-
receptor agonists. The aorta can be preincubated with pH]inositol, and then 
either total [^HJinositol phosphates ([3H]IPtotai), which assesses total PLC 
activity, or [^HJinositol l,4,5-trisphosphate (InsP3), which quantifies the 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2), can be measured. 
The determination of the mass of InsP3 and PIP2 by radioreceptor assays 
together with the measurement of [3H]IPtotai are recommended for the 
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investigation on PI hydrolysis in order to provide an accurate picture of this 
second messenger pathway (Wojcikiewicz et al” 1993). 
Thirdly, using the patch-clamp technique, Ca2+ currents can be recorded to 
characterise the type and the ionic selectivity of the channels with the help of 
different channel blockers and pipette solutions. Should the opening of 
membrane Ca2+ channels be responsible for contraction induced by EP3-
receptor agonists, it would be necessary to determine whether the channels are 
voltage-dependent or operated through receptor occupation. It is suggested that 
noradrenaline at high concentrations depolarises the cells and opens voltage-
dependent Ca2+ channels, whereas at low concentrations it increases the open-
state probability of Ca2+ channels (Nelson et al” 1988). The patch-clamp 
technique wi l l also help us to understand under what condition the L-type Ca2+ 
current can be elicited by the agonists. This information may provide a basis 
for the treatment of the puhnonary hypertension associated with the side effects 
of EP3-recept0r agonists. 
Neuronal IP-receptors 
Since the rat colon was used in the early identification of prostacyclin by 
superfusion bioassay, it had been thought that prostacyclin or its mimetics 
acted at EP-receptors on the cell membrane of intestinal smooth muscle, as is 
the case in vascular tissues. However, the present study demonstrates that the 
inhibition of rat colon contractility by IP-receptor agonists is neuronal in 
nature. Prostacyclin stimulates enteric neurones to release non-adrenergic non-
cholinergic (NANC) transmitters (Figure 6.2). This indicates that prostacyclin 
may have some physiological effects in the gut. There is no evidence that 
prostacyclin is a transmitter, but it possibly works as a neuro-modulator since it 
can be produced in the rat colon (Phillips and Hoult, 1988). The distribution of 
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Figure 6.2 Possible mechanisms of inhibition of rat colon contractility by ff-receptor 
agonists. EP agonists stimulate an increase in intracellular Ca〗+, via either an adenylate 
cyclase-cAMP system or coupling to a Na+ channel-depolarisation mechanism. 
Ca^^-caknoduUn activates nitric oxide synthase (NOS), which catalysizes the synthesis 
of NO from arginine. NO quickly diffuses into pacemaker/smooth muscle ceUs, thereby 
reducing spontaneous activity. The second transmitter can hyperpolarise the target 
ceUs through opening apamin-sensitive K^ channels. 
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ff-receptors in central neuronal tissues has been recently revealed by Northern 
blotting analysis (Narumiya, 1995), but that in enteric nerves has not been 
examined yet due to the high non-specific reactions in the gut (Narumiya, 
personal communication). 
At least two NANC transmitters are involved in the inhibition of spontaneous 
activity of the rat colon; nitric oxide (NO) was tentatively identified to be one 
of them by classic pharmacological approaches. Techniques for the 
measurement of NO are available, for example NO-sensitive electrodes, and it 
would be worthwhile using them to detect the amount of NO released from 
tissues in the organ bath before and after addition of IP-receptor agonists. 
Together with the isolation of enteric neurones (synaptosomes), the 
measurement of NO wi l l possibly distinguish whether NO is generated within 
nerves or within smooth muscle following stimulation by another transmitter. 
The second transmitter mechanism for prostacyclin action in the rat colon is 
apamin-sensitive; pharmacological evidence obtained in this study does not 
support ATP, adenosine, VIP or PACAP as transmitter candidates. The first 
step in identifying the unknown transmitter could be to see whether its release 
can be detected by one or more tissues in a superfusion bioassay system. This 
technique has already proved its worth in other areas of autacoid research 
(Vane, 1969). 
The different profiles of structurally-different prostacyclin mimetics on 
neuronal and non-neuronaI IP preparations highlights the existence of possible 
subtypes of IP-receptors; BMY45778, a non-prostanoid prostacyclin mimetic, 
is able to distinguish them. It is documented that IP-receptors on platelets and 
vascular smooth muscle (non-neuronal) couple to the production of cAMP via 
the G-protein Gs, which is responsible for the inhibitory effects on these 
tissues. Is this signal transduction pathway also involved in the neuronal 
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stimulant actions of prostacyclin? It is possible. An increase in cAMP in 
neurones generally elevates intracellular Ca^+; it is therefore speculated that in 
the enteric neurones of the rat colon the increased Ca^+ interacts with the 
cahnodulin unit of nitric oxide synthase (NOS) to cause NO production; NO is 
released from the nerves and rapidly diffuses into the target cells (intestinal 
smooth muscle); it acts through activation of soluble guanylate cyclase and 
subsequent formation of cGMP; cGMP activates a protein kinase and this leads 
ultimately to the dephosphorylation of myosin light chains and muscle 
relaxation. It has been reported that IP-receptor agonists activate adenylate 
cyclase on membranes prepared from the NCB-20 neuroblastoma cell line 
(Armstrong et al” 1986). However, it does not necessarily mean that this type 
of coupling occurs in enteric neurones. Theoretically, it should be possible to 
investigate the issue using an adenylate cyclase inhibitor such as SQ 22536 and 
MDL-12330A; the responses to IP-receptor agonists on the colon wi l l be 
blocked by the inhibitor i f cAMP is the second messenger. However, the 
inhibitor should selectively interact with the enzyme in neurones and should 
not interfere the pacemaker/smooth muscle system by any means; it seems that 
such an inhibitor is not available. In this context, the measurement of cAMP in 
neurones cultured from the rat colon may be helpful. 
Alternatively, neuronal IP-receptors in the rat colon are linked with Na+ 
channels, directly or via a second messenger pathway, thereby causing 
depolarisation (Figure 6.2). Extracellular Ca2+ then flows into the cytosol 
through voltage-dependent Ca2+ channels; the channels are at least partially of 
N-type. This can only be proved by patch-clamp experiments on isolated 
neurones from the colon. 
The potential differences between neuronal and non-neuronal BP-receptors can 
be further studied by molecular biological approaches. It would be easier to 
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investigate the signal transduction pathways with the IP-receptors expressed in 
Chinese hamster ovary cells. In particular, a testing system containing 
recombinant neuronal IP-receptors would be very useful in the development of 
an IP-receptor antagonist; the structure of BMY45778 could be used as a 
template to develop a pure antagonist’ and finally the latter could be 
investigated for clinical use as an analgesic agent. 
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